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“Es ist nicht genug zu wissen, man muß auch anwenden.  
Es ist nicht genug zu wollen, man muß auch tun.”  
 
“Knowing is not enough, we must apply.  
Willing is not enough, we must do.” 
 
(Johann Wolfgang von Goethe) 
   
   
Abstract 
 
 
Background 
Elevated blood pressure is an important risk factor for cardiovascular diseases (CVD). 
Modest reductions in blood pressure at the population level, as can be achieved by 
dietary and lifestyle changes, have a large impact on the burden of CVD. Blood pressure 
is regulated by several physiological mechanisms, including vascular endothelial function.  
 
This thesis 
The studies described in this thesis examined the potential effects of various 
micronutrients and other food components on blood pressure and endothelial function. 
The first aim was to assess the importance of selected minerals on population blood 
pressure levels and the second was to investigate the vascular effects of food 
components other than minerals that have recently attracted attention in the field of 
nutrition and blood pressure. 
A review of 21 national surveys showed that current dietary potassium intakes are 
suboptimal (1.7-3.7 gram per day). We estimated that increasing intakes to the 
recommended level of 4.7 gram per day can reduce population systolic blood pressure by 
2-3 mmHg in Western countries, this effect being similar to that which can be achieved 
by reducing current sodium intakes to recommended levels. Our meta-analysis of 40 
randomized controlled intervention studies showed that increasing calcium intake by 
~1200 mg per day significantly lowers systolic blood pressure by 2 mmHg and diastolic 
blood pressure by 1 mmHg. This effect tended to be stronger in populations with lower 
intakes (<800 mg per day). In an 8-week placebo controlled parallel study in 124 
subjects with elevated blood pressure, we found no significant blood pressure lowering 
effects of skimmed milk enriched in potassium (1500 or 750 mg per daily serving) 
combined with calcium, magnesium, selenium, vitamin C and vitamin E. However, this 
study was not designed to detect reductions in systolic blood pressure of 2-3 mmHg, 
which are still relevant at the population level. 
In two 4-week placebo controlled cross-over studies, in 162 subjects with 
untreated elevated blood pressure, we could not demonstrate an antihypertensive effect 
of a yogurt drink with lactotripeptides obtained by enzymatic hydrolysis (study 1: 10.2 
mg per day; study 2: 4.6 mg per day plus 350 mg added potassium). In another 2-week 
placebo controlled cross-over study in 35 healthy males we found no consistent effect on 
   
endothelial function and blood pressure of ~800 mg polyphenols per day from either a 
wine-grape mix or grape seeds. Finally, a meta-analysis of 14 randomized controlled 
intervention studies showed that folic acid at a high dose (≥5000 g per day), which can 
not be attained with a regular diet, significantly improved flow-mediated dilation by 8%. 
 
Conclusion 
Adequate potassium and calcium intakes can play an important role in the prevention of 
hypertension at the population level. Lactotripeptides have no relevant effect on blood 
pressure in Caucasian populations. The potential of grape polyphenols and folic acid to 
improve endothelial function is limited.  
 Multiple actions are needed to lower blood pressure at the population level and 
reduce the burden of CVD. To improve intakes of potassium and calcium, public health 
measures should re-emphasize the intake of fruits, vegetables, and low-fat dairy 
products. Further optimization of mineral intakes, in particular reduction of sodium 
intake, requires collaborative actions of government and food industry. 
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Blood pressure and cardiovascular diseases 
 
Cardiovascular diseases (CVD), including heart disease and stroke, form the world’s 
leading cause of morbidity and mortality. The major risk factors for CVD are age, gender, 
hypertension, smoking, dyslipidemia and diabetes.1 Of the single modifiable risk factors, 
elevated blood pressure poses a greater risk for CVD than elevated serum cholesterol or 
smoking.2 Nowadays, systolic blood pressure is considered a more powerful predictor of 
CVD than diastolic blood pressure, especially after the age of 50 years.3 Hypertension is 
also a major risk factor for renal disease.4 
 CVD risk increases linearly with increasing blood pressure, starting from levels as 
low as 115/75 mmHg.5 Modest reductions in average population blood pressure level can 
result in substantial reductions in CVD risk, i.e. a 2 mmHg lower systolic blood pressure 
on population level is estimated to lower mortality from stroke by ~10% and mortality 
from ischemic heart disease and other vascular causes by ~7%.5 It has been estimated 
that up to 80% of CVD may be preventable by lifestyle changes, including a healthy diet, 
physical exercise and abstinence from smoking.6, 7 
 This thesis has two general aims, namely 1) to assess the importance of a 
selected number of minerals on population blood pressure levels, and 2) to study the 
effect of “emerging” food components on blood pressure and endothelial function. 
 
Elevated blood pressure is an important risk factor for CVD. There is a graded increase in 
risk of CVD across the entire blood pressure range. At the population level small changes 
in blood pressure on the population level have a major impact on CVD incidence. 
 
 
Prevention Strategies 
 
The majority of people with moderately increased risk levels contribute to more cases of 
disease and mortality than the relatively small number of persons with extremely high 
risk levels. In 1981 Geoffrey Rose explained that interventions targeting the general 
population, aimed at shifting the risk curve for major determinants of disease, such as 
blood pressure, to the left (the population-based approach), may be more effective to 
reduce the population burden of disease than interventions targeting high-risk individuals 
(high-risk approach) (Figure 1).8 However, Rose also noted that a population-based 
strategy only, can much improve overall public health, but has less benefit for the 
individual with very high risk. Conversely, focus on individuals with high-risk only brings 
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benefit to an individual, but may have a small impact in the population. This 
phenomenon was called the “Prevention Paradox”8 and explains why it is generally 
recommended that the high-risk approach and the population-based approach should be 
complementary, which is also supported by recent analyses.9, 10 
In addition, it has been observed that subgroups that were formerly at lower 
exposure to risk benefit more from population-based interventions than those who were 
formerly at greater exposure to risk. Thus, for more substantial reductions of CVD 
burden, population-based interventions should ideally also alter the underlying risk 
behaviors and socioeconomic causes of elevated blood pressure levels.10, 11  
 Worldwide just over half the burden of disease attributable to high blood pressure 
occurs in people with mean systolic blood pressure levels less than 145 mmHg.12 Current 
guidelines for the prevention of hypertension recommend a combination of a population-
based strategy and an intensive targeted strategy focused on individuals with high risk 
for hypertension.13, 14 Lifestyle changes at individual level can help prevent the onset of 
hypertension, contribute to control other CVD risk factors, and reduce the number and 
doses of medication in those treated.4 Population-wide improvements of lifestyle factors 
could play a crucial role in preventing a rise in population blood pressure levels. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 The “population-based” and “high-risk” strategy for the prevention of CVD 
illustrated for blood pressure as risk factor for CVD.15 
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The risk of CVD can be reduced by two complementary strategies; the population-based 
approach (interventions aimed at reducing the risk factor across the whole population) 
and the high-risk approach (interventions aimed at reducing risk factors in high-risk 
individuals). Lifestyle interventions are important both at the individual level and the 
population level. 
 
 
Population blood pressure levels 
 
Blood pressure data from the Netherlands show that only 28% of the population (≥12 
years) has blood pressure levels classified as optimal (<120/80 mmHg), 35% has normal 
or high-normal blood pressure levels (120-139/80-89 mmHg) and 37% has blood 
pressure levels classified as hypertensive (≥140/90 mmHg)16, as defined in Table 1. In 
Europe, 20-25% of the population has optimal blood pressure levels17-21, and an average 
of 44% is classified having hypertension, as defined in Table 1.22 It should be noted that 
these figures are probably an overestimation of the prevalence of hypertension, as in 
most population-based surveys blood pressure levels are based on single 
measurements.23 In general, blood pressure levels are somewhat higher in men 
compared to women and tend to increase with age (Table 2).22 
 
Table 1 Definitions and classification of blood pressure levels (mmHg).1 
Category2 Systolic   Diastolic 
Optimal <120 and <80 
Normal 120-129 and/or 80-84 
High-normal 130-139 and/or 85-89 
Hypertension ≥140 and/or ≥90 
1 According to European Society of Hypertension/European Society of Cardiology 2007 guidelines  
2 In case of use of anti-hypertensive medication classified as hypertension. 
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Table 2 Blood pressure distribution (%) in the Netherlands (by gender and 10-year age 
category) based on the REGENBOOG1 project (1998-2001).16 
  10 years age category (years) 
 Category <19 20-29 30-39 40-49 50-59 60-69 ≥70  
Men         
 Optimal 63 30 24 17 11 8 3 
 Normal 20 31 30 25 17 12 5 
 High-normal 11 23 27 24 20 14 10 
 Hypertension 4 15 18 34 52 66 82 
Women         
 Optimal 80 58 57 39 22 11 2 
 Normal 13 23 19 20 19 16 9 
 High-normal 3 11 12 14 13 14 11 
 Hypertension 1 8 11 27 45 60 78 
1 REGENBOOG is the acronym for “Risicofactoren En GezondheidsEvaluatie Nederlandse Bevolking 
een Onderzoek Op GGD-en”. 
 
The majority of people (70-80%) in Western countries have above optimal blood 
pressure levels. 
 
 
Diet and blood pressure 
 
A variety of diet and lifestyle modifications have been established to lower blood pressure 
and reduce the incidence of hypertension.4 These include increased physical activity, 
weight loss, moderation of alcohol intake, increased dietary potassium intake and 
reduced dietary sodium intake.4 Other dietary factors for which effects on blood pressure 
have been suggested by intervention studies are calcium24, magnesium25, fibre26, vitamin 
C27, and fish oil.28 Regarding macronutrients, the Optimal Macronutrient Intake Trial to 
Prevent Heart Disease (Omni-Heart) study, showed that replacing part of the 
carbohydrates with either protein or monounsaturated fat lowers blood pressure.29 For 
most interventions, data show that the absolute blood pressure lowering effect is more 
pronounced in people with higher pre-treatment blood pressure levels.26, 28, 30, 31 
 The Dietary Approaches to Stop Hypertension (DASH) study was a landmark 
intervention study investigating the effects of dietary patterns, rather than individual 
nutrients, on blood pressure. After 8 weeks of intervention, substantial reductions in 
blood pressure were observed among participants assigned to the DASH (combination) 
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diet, a diet rich in fruit, vegetables, and low-fat dairy products and reduced in saturated 
fat, total fat and cholesterol, compared to those assigned to the control diet, 
representing a typical American diet.32 In addition, as part of the same study a diet rich 
in fruit and vegetables, and reduced in snacks and sweet, also significantly reduced blood 
pressure compared to the control diet. This effect was about half the size of that found 
for the DASH diet.32 Compared to the typical American diet, the DASH diet also contained 
substantially higher amounts of the minerals potassium (4415 versus 1752 mg), calcium 
(1265 versus 443 mg) and magnesium (480 versus 176 mg), as well as some other 
nutrients, such as vitamins and fiber.32 The DASH study was not designed to identify the 
contribution of single nutrients to the observed blood pressure effect. Nevertheless, it is 
plausible that the minerals potassium, calcium and magnesium were at least partly 
responsible for blood pressure reduction in this study. Reducing sodium intake in 
combination with the DASH diet was found to be even more effective.33 Blood pressure 
lowering effects of the DASH diet were found in various subgroups of participants, based 
on race, gender, age, family income, physical activity, and hypertension status.30 The 
DASH study showed that blood pressure reductions similar to drug treatment can be 
achieved with dietary intervention.30, 34 Interventions aimed at adoption of the DASH diet 
in free-living populations showed that dietary instructions are effective in increasing 
adherence to this diet35-37, especially when the dietary advice is adjusted to fit national 
food preferences and portion sizes.35 However, compliance to the original DASH diet in 
free-living populations is difficult to attain.36 Greater emphasis on foods that contain high 
levels of the desired nutrients per calorie, would likely help to reach the DASH intake 
goals.36 In this context, it is relevant to investigate which particular nutrients or 
combination of nutrients are primarily responsible for the blood pressure lowering effects 
observed with the DASH diet. 
 
Several lifestyle factors, such as weight loss, increased physical activity, moderation of 
alcohol intake, increased dietary potassium intake and reduced dietary sodium intake 
lower blood pressure levels. The DASH (combination) diet, a diet rich in fruits, 
vegetables, and low-fat dairy products and reduced in saturated fat, total fat and 
cholesterol, is an integrated dietary approach with established blood pressure lowering 
effects.  
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Blood pressure and endothelial function 
 
Blood pressure is regulated by various physiological mechanisms38, which involve 
endothelial function, water-mineral balance regulated by the kidneys, and autonomic 
regulation by the heart and brain.38 Endothelial cells are involved in vasoconstriction and 
vasodilation, blood clotting, atherosclerosis and inflammation.39, 40 A large body of 
evidence supports the fundamental role of nitric oxide as the main endothelium-derived 
relaxing factor.41-43  
 Endothelial function can be measured by flow-mediated dilation, and reduced 
values are considered an early marker for endothelial dysfunction. Flow-mediated dilation 
represents the ability of the brachial artery to dilate in response to ischemia-induced 
hyperemia in the forearm and as such it reflects the bioavailability of the vasodilator 
nitric oxide.44 The application of flow-mediated dilation measurement has grown rapidly 
over the past decade.  
 Endothelial function may predict prognosis of disease progression and 
cardiovascular events in patients with CVD45, but evidence supporting that endothelial 
function predicts CVD in the general population, independently of other CVD risk factors, 
is still limited.46-53 Endothelium-dependent vasodilatation is sometimes portrayed as a 
causal mechanism in the development of hypertension, but endothelial dysfunction is 
also commonly seen together with other CVD risk factors, and thus not specific for 
elevated blood pressure levels.54, 55 The relevance of endothelial dysfunction in 
hypertension needs to be further supported by prospective studies documenting that 
interventions improving endothelial dysfunction also translate into lower blood pressure 
levels and a lower risk of developing hypertension.  
 
Blood pressure regulation is dependent on several underlying physiological functions, 
including endothelial function. Flow-mediated dilation is a technique that measures 
endothelial function. There is growing evidence that endothelial (dys)function is a marker 
for cardiovascular risk.  
 
 
Minerals 
 
Sodium 
A large number of studies provide strong evidence for a causal link between high sodium 
intake, hypertension56-58 and CVD.59, 60 A reduction in salt intake of 4-6 gram per day is 
Chapter 1 
Introduction 
 
18 
estimated to reduce systolic blood pressure by 2-4 mmHg in the general population56, 57, 
with a more pronounced effect in hypertensives compared to normotensives.57 Sodium 
intakes are high in most populations61 and the need to reduce sodium intake for 
decreasing CVD risk is currently being emphasized58 and translated into public health 
measures.62, 63  
 
Potassium 
Potassium has received less attention than sodium. Nevertheless, there is a substantial 
body of data from both epidemiological and clinical studies indicating that an increase in 
potassium intake of 2-3 grams per day reduces systolic blood pressure by 3-4 mmHg31, 
64-66 and is also associated with a decreased risk of CVD.67 Analyses of different 
subgroups indicate a more pronounced blood pressure effect of potassium in 
hypertensives compared to normotensives, in non-Caucasians compared to Caucasians 
and at higher urinary sodium excretion compared to lower sodium excretion levels.66 
Several authoritative bodies acknowledge that increased potassium intake is beneficial to 
health. The adequate intake of potassium for adolescents and adults in the United States 
and Canada was set at 4.7 gram per day, based on a review by the Institute of 
Medicine.68 An adequate potassium intake could blunt the age-related rise in blood 
pressure, reduce the adverse effects of high sodium chloride intake on blood pressure, 
reduce the risk of recurrent kidney stones, and possibly decrease bone loss.68  
Potassium is abundantly available in diets based on natural foods. However, 
current diets based on processed foods are generally high in sodium and low in 
potassium.69 In the United States and United Kingdom reports of national survey data 
have clearly indicated that dietary intakes of potassium are low and of concern for public 
health70, 71, especially in combination with current high sodium intakes. Several reports 
have published potassium intake data72-75, but no recent report has addressed worldwide 
potassium intakes in populations and/or estimated the impact of potassium intakes on 
population blood pressure levels.  
 
Sodium to potassium ratio 
Several studies indicate that potassium and sodium jointly play an important role in 
regulating blood pressure.69, 76 In epidemiological studies, the sodium to potassium 
intake ratio is more strongly linked to blood pressure and CVD risk than sodium alone.56, 
77, 78 Data from the International Study of Salt and Blood Pressure (INTERSALT) showed 
that the relation of the urinary sodium to potassium ratio to blood pressure followed a 
pattern similar to that for sodium, but more strongly and consistently.78 Recent data from 
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the Trials of Hypertension Prevention (TOHP) 10-15-year follow up showed that a greater 
sodium to potassium excretion ratio (mean of multiple 24-hour urinary excretions) was 
associated with increased risk of subsequent CVD, and this effect was stronger than that 
of sodium or potassium alone.67 Several intervention studies found that replacing regular 
sodium salt with potassium-enriched salt reduces blood pressure and lowers CVD event 
rates.79-82 In addition, in societies in which sodium intake is low and potassium intake is 
high, blood pressure does not rise with age, and the incidence of CVD is generally low.69  
 
Calcium 
Several meta-analyses of randomized controlled studies on calcium supplementation and 
blood pressure have been published. Allender et al. found a significant reduction in 
systolic blood pressure of 0.9 mmHg and a non-significant reduction in diastolic blood 
pressure of 0.2 mmHg in a meta-analysis of 26 randomized controlled intervention 
studies.83 Bucher et al. found a significant BP reduction of 1.3/0.2 mmHg when pooling 
33 calcium intervention studies.84 Griffith et al., in 1999, included a total of 42 studies, 
with calcium doses in the range of 500-2000 mg per day.24 The primary aim of this meta-
analysis was to increase precision of the effect estimate and compare the effect of 
dietary calcium with supplemental calcium. Pooled estimates were significant and larger 
than in previous meta-analyses, i.e. -1.4 mmHg for systolic blood pressure and –0.8 
mmHg for diastolic blood pressure.24 Food-based calcium supplementation had a larger 
effect than use of calcium supplements, but this difference was not significant. A 
Cochrane meta-analysis only included 13 studies with a minimum duration of 8 weeks, 
whereas the other meta-analyses also included short-term studies (minimum duration of 
2 weeks).85 This meta-analysis found a significant reduction in systolic blood pressure of 
2.5 mmHg, while diastolic blood pressure was not significantly affected.85  
 Based on findings from these meta-analyses, the overall effect of calcium on 
blood pressure in the population as a whole is probably small, but effects in population 
subgroups may be larger. Substantial heterogeneity was found in all meta-analyses, 
which could reflect differences in effect among specific patient populations, type of 
interventions, or methodological aspects of the studies. Most meta-analyses planned 
subgroup analyses, but due to varying amounts of data available only a few sources of 
heterogeneity could be addressed.24, 84, 85 For example, the hypothesis that a blood 
pressure effect of calcium is stronger with low habitual intakes24, 84, 86  was not addressed 
in these meta-analyses.24, 84  
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Combination of minerals 
Only a few intervention studies addressed the effect of combinations of the minerals 
potassium, calcium and magnesium on blood pressure, without influencing sodium 
intake. Sacks et al. performed 2 randomized controlled studies in a large number of 
participants testing the effect of combinations of these minerals on blood pressure. In the 
first study 125 subjects with untreated mild or borderline hypertension received either 
potassium (2346 mg per day) and calcium (1000 mg per day), potassium and 
magnesium (360 mg per day), calcium and magnesium, or placebo for 6 months.87 In 
this study the changes in blood pressure between the treatment and placebo groups were 
not significant. In the second study, the effect of potassium (1564 mg per day), calcium 
(1200 mg per day), magnesium (336 mg per day) or a combination of these minerals on 
blood pressure during 16 weeks was examined in 321 normotensive women with low 
habitual intakes.88 Compared to placebo the mean differences in the intervention group 
were only significant for potassium, with reductions of 2.0 mmHg in systolic blood 
pressure and 1.7 mmHg in diastolic blood pressure. The administration of calcium and 
magnesium with potassium did not enhance the effect of potassium alone.88  
 The effect of calcium, magnesium, and potassium in a dairy matrix was 
investigated in two smaller placebo controlled intervention studies. In the first 6-week 
intervention study, normal milk treatment (potassium 1650 mg per day, calcium 1180 
mg per day, magnesium 110 mg per day) compared to mineral-poor milk treatment 
(potassium 580 mg per day, calcium 95 mg per day, magnesium 10 mg per day) reduced 
systolic blood pressure by 2.7 mmHg, but not diastolic blood pressure in 53 
normotensive female students on a low calcium diet (<500 mg per day).89 In the second 
intervention study, the effect of 4 weeks consumption of a potassium-enriched high-
calcium skim milk (1585 mg potassium, 1040 mg calcium, and 71 mg magnesium per 
day) and a high-calcium skim milk (855 mg potassium, 1075 mg calcium, and 74 mg 
magnesium per day) on blood pressure was compared to a non-enriched skim milk (885 
mg potassium, 720 mg calcium, 64 mg magnesium per day). In this study in 38 
participants, systolic blood pressure, but not diastolic blood pressure, decreased 
significantly in the potassium-enriched high-calcium milk group compared to placebo (8 
mmHg). Blood pressure on the high-calcium skim milk diet was non-significantly lower 
than on placebo.90 
 To summarize, a limited number of studies have examined the effect of combined 
mineral intake on blood pressure.91 Most of these studies hypothesized that simultaneous 
intake of potassium, calcium and magnesium could lower blood pressure more than 
intervention with individual minerals. This was not confirmed by two large studies 
Chapter 1 
Introduction 
 
21 
investigating the effect of such a combination of minerals as supplements. The results of 
two smaller studies addressing the effect of combinations of these minerals in a dairy 
matrix suggest a possible blood pressure lowering effect of these minerals. However, 
additional data from larger intervention studies are needed to confirm this. The effects of 
potassium, calcium, magnesium on blood pressure have not been investigated in 
combination with other nutrients, such as vitamins. 
 
Meta-analyses of intervention studies showed that increased potassium intake lowers 
blood pressure. The impact of current potassium intakes on population blood pressure 
levels has not yet been addressed. A small blood pressure lowering effect of calcium has 
been found in meta-analyses of intervention studies, but effects in specific population 
subgroups are largely unknown. Few studies examined effects on blood pressure of 
combined intake of potassium, calcium and magnesium.  
 
 
Other food components 
 
Many other food components have been investigated in relation to blood pressure and 
endothelial function. In recent years an increasing number of studies have addressed the 
possible beneficial effects of various types of milk-derived bioactive peptides (mainly 
lactotripeptides), polyphenols (mainly flavonoids), and B-vitamins, in particular folic acid.  
 
Lactotripeptides 
Blood pressure lowering effects of lactotripeptides, specifically Isoleucine-Proline-Proline 
(IPP) and Valine-Proline-Proline (VPP) have been reported in a considerable number of 
human intervention studies.92-100 Two meta-analyses have summarized the studies 
published in this field between 1996 and 2005.101, 102 One included intervention studies 
on lactotripeptides, but also other bioactive peptides derived from food proteins.101 The 
other meta-analysis included lactotripeptides intervention studies only.102 Both meta-
analyses reported significant reductions in systolic blood pressure (5 mmHg) and diastolic 
blood pressure (2 mmHg). Most trials were relatively small studies in Japanese 
populations.92-96 Some Finnish studies also showed blood pressure reductions during 
treatment with lactotripeptides, but the effects were smaller than in Japanese trials.97-100 
Daily doses of lactotripeptides ranged between 3-5 mg in most of these intervention 
studies.103 As reviewed by Geleijnse and Engberink, a number of methodological aspects 
in these intervention studies warrant further consideration.103 In some studies placebo 
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effects were not properly accounted for, and in other studies pretreatment blood 
pressure tended to be higher in the intervention group than in the control group.103  
 Since the publication of these meta-analyses101, 102 additional randomized 
controlled studies in other European populations have been reported. These studies 
found no significant effects of lactotripeptides on blood pressure.103-108 Recent 
publications reviewing data in this field conclude that current evidence for an effect of 
these lactotripeptides on blood pressure is not compelling, and that confirmation of blood 
pressure lowering effects in additional large scale well-designed intervention studies is 
needed.103, 109  
 
Grape polyphenols 
Polyphenols, and especially the subclass of flavonoids, have been examined in many 
studies for their relation with CVD and vascular outcomes, including blood pressure and 
endothelial function.110 Flavonoids occur naturally in plant-based foods and are 
abundantly present in fruits, vegetables, grains, herbs, and beverages. The strength of 
the evidence from randomized controlled studies for effects of flavonoids on blood 
pressure and the CVD risk factors varies among the different flavonoids subclasses.111  
 Several studies indicated that red wine and grape extract consumption might 
lower CVD risk markers, and in particular endothelial function markers111, but this 
evidence is largely based on in vitro findings showing effect on nitric oxide metabolism.112 
In addition, a number of intervention studies investigated the effect of wine on 
endothelial function. Most of these studies focused on acute rather than the chronic 
effects of red wine consumption.112 The studies had conflicting results and it is not clear 
whether the grape polyphenols, ethanol, or other compounds in red wine are responsible 
for the possible benefits.112  
A limited number of small intervention studies addressed the chronic effects (2-8 
weeks) of polyphenolic compounds from grape on endothelial function and/or blood 
pressure.113-116 Two studies investigated the effect of purple grape juice (~832-1664 mg 
polyphenols per day117) on flow-mediated dilation in patients with coronary artery 
disease.113, 114 In these studies improvements in flow-mediated dilation were found, but 
no control groups were included.113, 114 Two other small studies were performed in 
healthy volunteers. Zilkens et al.115 showed that daily consumption of 375 ml of red wine, 
but not daily consumption of 375 ml of de-alcoholized red wine, increased blood pressure 
levels compared to abstention from alcohol. No effects were on flow-mediated dilation in 
this study. Park et al.116 showed that consumption of purple grape juice (885 mg 
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polyphenols per day) reduced both systolic (3.7 mmHg) and diastolic (3.0 mmHg) blood 
pressure compared to placebo intervention.   
Since evidence from well-controlled intervention studies is still very limited, future 
placebo-controlled studies should address the effect of the polyphenolic part of grape 
polyphenols on endothelial function and blood pressure.  
 
Folic acid 
Several randomized controlled interventions studies have addressed the possible 
beneficial effects of folic acid (vitamin B11) on endothelial function and blood pressure.118 
A recent meta-analysis included 12 randomized controlled studies published between 
1999 and 2007 in which folic acid was provided at a minimum dose of 5000 μg/d for at 
least 2 weeks (duration ranged from 2-12 weeks). In 4 of these studies effects on blood 
pressure as well as endothelial function were addressed, 4 other studies addressed 
effects on blood pressure only and the remaining 4 studies addressed the effects on 
endothelial function only. The results of this analysis showed a borderline significant 
reduction in systolic blood pressure of 2 mmHg, no effect on diastolic blood pressure, and 
a 1.61% increase in flow-mediated dilation change after supplementation with folic 
acid.118 The effect of folic acid on endothelial function over a wider dose range, including 
lower doses, has not been systematically reviewed. 
 
A number of intervention studies in Japanese and Finnish populations show blood 
pressure lowering effects of lactotripeptides. Data suggest that grape polyphenols could 
improve endothelial function, but evidence from randomized controlled intervention 
studies is still limited. Folic acid at high doses may have beneficial effects on endothelial 
function and blood pressure; possible effects at lower dose levels have not been 
systematically reviewed. 
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Rationale and aim of this thesis  
 
Blood pressure levels show a graded independent relationship with risk of cardiovascular 
diseases (CVD). The majority of people in Western populations have above optimal blood 
pressure levels. Therefore, small changes in population blood pressure levels can have a 
substantial impact on CVD incidence. For related vascular function markers, including 
endothelial function, it is less clear whether they can independently predict CVD. 
 Minerals have been investigated in many studies for their effects on blood 
pressure. Evidence for the impact of current sodium intakes in populations on blood 
pressure and CVD has clearly been established, which has resulted in several public 
health measures to reduce salt intake. A vast amount of data from meta-analyses of 
intervention studies showed that potassium supplementation significantly lowers blood 
pressure. The potential impact of current potassium intake on population blood pressure, 
however, has not been systematically assessed. For calcium, meta-analyses of 
intervention studies showed a small, but consistent blood pressure lowering effect. 
Whether calcium supplementation could be more effective in specific population 
subgroups has not yet been established. Many blood pressure trials focused on the effect 
of individual minerals (i.e., potassium, calcium and magnesium), but only a few studies 
addressed the effect of combined mineral intake on blood pressure. Two studies suggest 
that a combination of these minerals in their natural dairy matrix could reduce blood 
pressure. The effect of combinations of minerals and vitamins in a dairy matrix has not 
yet been investigated.  
 In more recent years, several other food components have been studied for their 
possible effects on blood pressure, including lactotripeptides, polyphenols and folic acid. 
Intervention studies, mainly in Japanese and Finnish populations showed blood pressure 
lowering effects of lactotripeptides. However, most of these studies were relatively small 
and several had methodological shortcomings. Additional large scale well-designed 
intervention studies are needed to conclude whether lactotripeptides could lower blood 
pressure. Promising effects of grape polyphenols on blood pressure and endothelial 
function have been suggested, but evidence is largely based on in-vitro experiments and 
studies investigating acute effects of red wine on endothelial function. Placebo-controlled 
intervention studies addressing the chronic effect of grape polyphenols on endothelial 
function and blood pressure are lacking. The effect of folic acid on endothelial function 
and blood pressure has been addressed in several intervention studies. A recent meta-
analysis found indications for reductions in endothelial function and blood pressure after 
high-dose supplementation with folic acid. The effects of folic acid over a wider dose 
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range, including levels that can be attained by diet, on endothelial function, have not 
been systematically reviewed. 
 
This thesis had 2 general aims:  
 To assess the importance of selected mineral intakes for population blood pressure 
levels  
 To assess the effects of “emerging” food components on blood pressure and 
endothelial function  
 
More specifically, the following research questions were addressed:  
 What is the impact of increased potassium intake on population blood pressure? 
(Chapter 2) 
 What is the effect of increased calcium intake on blood pressure, overall and in 
population subgroups? (Chapter 3) 
 Does potassium combined with other micronutrients at low doses have beneficial 
effects on blood pressure? (Chapter 4) 
 Do lactotripeptides improve blood pressure in a European population? (Chapter 5) 
 Does the polyphenolic fraction of grape extracts improve endothelial function and 
blood pressure? (Chapter 6) 
 Does folic acid improve endothelial function? (Chapter 7) 
 
The outline of this thesis is depicted in Figure 2. In Chapter 2 the potential impact of 
increased potassium intake on population blood pressure is described. The meta-analysis 
in Chapter 3 focused on calcium supplementation and blood pressure, overall and in 
population subgroups. Chapter 4 describes a randomized controlled blood pressure trial 
of low-dose supplementation of potassium combined with other minerals and vitamins.  
 Chapter 5 presents the results of two randomized controlled studies of 
lactotripeptides (IPP and VPP) and blood pressure in European populations. In Chapter 6 
the results of a randomized controlled intervention study of grape polyphenols and 
changes in endothelial function and blood pressure are presented. Chapter 7 describes a 
meta-analysis of randomized controlled trials of folic acid supplementation and 
endothelial function. In Chapter 8 the main findings are summarized and interpreted, 
followed by a discussion of methodological aspects of the studies, future research 
directions, and the relevance for public health. 
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Figure 2 Schematic overview of the studies described in this thesis. 
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Small reductions in blood pressure (BP) on a population level could have a substantial 
impact on cardiovascular disease risk.1 This is especially relevant considering that the 
majority of the population has suboptimal BP levels. Dietary sodium reduction is a clearly 
established lifestyle change that has great potential to improve public health. Potassium, 
on the contrary, received much less attention. Nevertheless, a substantial body of data 
shows that increasing potassium intake lowers BP.2 We reviewed population data on 
potassium intake and estimated the potential impact of increased potassium intake on 
population BP levels.  
 
 
Methods  
 
We searched PubMed and contacted health authorities worldwide for national population-
based dietary surveys conducted from 1990 to 2009 that included data on potassium 
intake in more than 1,000 adults. We defined the recommended level of potassium intake 
at 4.7 gram per day (g/d), based on the Dietary Reference Intakes from the Institute of 
Medicine.2 The effect of dietary potassium on systolic BP was set at 1.0 mmHg reduction 
per 0.6 g/d increase in intake, based on estimates from the INTERSALT study3 and we 
assumed this relation to be linear. Population BP data were obtained for Finland, the 
United Kingdom and the United States, representing populations with relatively high, 
medium, and low potassium intakes.4-7 For these countries we estimated the potential 
impact of increasing potassium intakes on population systolic BP levels and classification 
in different systolic BP categories, assuming a uniform shift in the population BP 
distribution, independent of initial BP level.  
 
 
Results 
 
In 21 countries spread across North America, Europe, Asia and Oceania, the mean 
potassium intakes ranged from 1.7 (China) to 3.7 g/d (Finland, the Netherlands, and 
Poland) (Figure 1, references and data available at 
http://www.wageningenuniversity.nl/UK/newsagenda/news/). Mean intakes in women 
were generally lower than in men. Based on our assumptions and intake data from 
Finland, United Kingdom and United States, a hypothetical increase in potassium intake 
to 4.7 g/d would shift the population systolic BP distributions to 1.7 to 3.2 mmHg lower 
levels in Western countries. This is in the same order of what can be predicted for a 
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reduction in sodium intake from 9 to 5 g/d. This theoretical increase in potassium intake 
in these countries would increase the percentage (%) of men and women in the optimal 
systolic BP category (<120 mmHg) by approximately 2 to 5% and 4 to 8%, respectively, 
and decrease the percentage of men and women with systolic BP levels in the higher 
range (≥140 mmHg) by approximately 2 to 5% and 4%, respectively. 
 
Figure 1 Current potassium intakes (g/d) and differences from recommended level for 
the 21 countries included in our review.  
 
 
Comment  
 
Increasing current potassium intakes in populations to recommended levels may lower 
population systolic BP in Western countries by 1.7 to 3.2 mmHg, which can be predicted 
to reduce the risk of stroke mortality by 8 to 15%, and the risk of heart disease mortality 
by 6 to 11%.1 This is of similar magnitude as what can be achieved by lowering sodium 
intake, and highlights the importance of dietary strategies focussing on both reducing 
sodium intake and increasing potassium intake. There are various ways to improve 
intakes of minerals in the population. Adherence to dietary guidelines, with ample fruit 
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and vegetables, whole grains, and low-fat dairy products, should be promoted. Food 
companies can help by promoting the availability of healthier foods and also by 
improving the type and content of minerals in their products. 
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Supplemental Material 
 
In this document we present additional information on methodology, secondary results 
and additional comments related to our publication on potassium intakes and population 
blood pressure levels.  
 
 
Methods 
 
Search strategy 
To estimate dietary potassium intakes we searched for published national survey data on 
websites of national health authorities and performed a literature search in PubMed. We 
also contacted researchers to ask for relevant national data through their respective 
networks and used citation lists from retrieved publications to identify other eligible 
studies.  
The initial search delivered 971 publications and reports. Abstracts were screened 
to determine eligibility based on the following criteria 1) Representative national survey 
or observational survey, 2) Sample size > 1,000 subjects, 3) conducted in the time 
period 1990 – September 2009, 4) Adults (>19 years), and 5) potassium intake 
estimated from 24 hour urine collections or from dietary questionnaires. This provided us 
with 83 potential surveys. The full papers were screened by AG and LAJM and 63 surveys 
were excluded for the following reasons, 1) No mean/median potassium intake reported 
(for total population or per gender), 2) Studied sample not representative for general 
population, 3) Surveys estimating potassium intake from food frequency questionnaire 
(FFQ) or from random (“spot”) or overnight urine samples alone, 4) Data included in 
prior reports (in case of duplicate publication most recent data were used). This left us 
with 20 studies (representing 21 countries) to be included in this review.  
 
Recommended potassium intake 
In human intervention trials on potassium and blood pressure (BP), the average 
supplementary dose given in addition to intake from the diet was 2-3 gram per day 
(g/d).1-4 The average pre-treatment intake from the diet based on urinary potassium 
excretion in meta-analyses of these randomized controlled trials was approximately 2.4 
g/d.1, 2 Thus the total potassium intake in the treatment groups was approximately 5 
g/d.1, 2 In the Dietary Approaches to Stop Hypertension (DASH) study the target for 
potassium intake in the intervention group was similar, i.e. 4.7 g/d.5 In the United States 
Chapter 2 
Potassium intakes and population blood pressure 
 
 
41 
and Canada the adequate intake for potassium for adolescents and adults was set at 4.7 
g/d by the Institute of Medicine.6 This daily amount was based on scientific evidence 
showing that this level blunts the age-related rise in BP, reduces the adverse effects of 
high sodium chloride intake on BP, reduces the risk of recurrent kidney stones, and 
possibly decreases bone loss.6 The American Society of Hypertension recently published a 
position paper in which it also recommends a desirable level of potassium intake of 4.7 
g/d.7 
 
Estimating the effect of increasing potassium intake on population blood pressure 
The design and statistical approach employed in the INTERSALT study allowed for an 
accurate estimation of the relationship between potassium and BP.8 In this study of 32 
countries, including over 10,000 people, a mean increase in potassium intake of 0.6 g 
(15 mmol) per day was associated with an estimated mean decrease in systolic BP of 1 
mmHg. Assuming that the relation between potassium intake and BP is linear in the 
normal population ranges of intake, we used this estimate to predict the potential impact 
on population BP of optimizing potassium intake up to a level of 4.7 g/d. 
We selected 3 Western countries (Finland - relatively high intake, United Kingdom 
- average intake, United States - relatively low intake) for which both potassium intake 
and BP data (mean  SD) were available from the same surveys.9-12 For these countries 
we estimated the potential impact of optimizing potassium intakes on population systolic 
BP levels and classification in systolic BP categories (optimal, normal/high-normal, 
hypertensive). We assumed a normal distribution to estimate the effect on BP 
distribution. Effects for men and women are reported separately, because BP distribution 
is different for men and women, and also because combined data were not reported for 
the United Kingdom and Finland. For the United States, mean population BP data and its 
distribution were calculated from NHANES 2005-2006 data.9 We incorporated sample 
weights and the stratification and clustering of the design into the analysis of the 
NHANES data.9  
 
 
Results 
 
Overview of data from national surveys 
Supplemental Table 1 presents characteristics of the dietary surveys from North America, 
Europe, Asia and Oceania selected for this review and corresponding data on potassium 
intakes. The majority of the studies used 24-h dietary recalls to estimate dietary 
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potassium intake, but multiple day food records and weighing methods were also 
employed. Sample size ranged from 1,179 (Hungary) to 53,394 (China) and response 
rates ranged from 27% in Hungary to 86% in Poland.10-22 
The median value of the average potassium intakes in all countries was 3.2 g/d, 
and mean potassium intake in the countries ranged from 1.7 g in China to 3.7 g in 
Finland, the Netherlands and Poland (Supplemental Table 1, Research Letter Figure 1). 
Median potassium intake in women was 2.9 g/d and ranged from 1.6 g in China to 3.4 g 
in the Netherlands and Finland. Potassium intakes in men were higher. Median intake in 
men was 3.5 g/d and ranged from 1.8 g in China to 4.4 g in Poland. 
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Supplemental Table 1 Characteristics of the national surveys reporting potassium intakes 
Intake in g/d (Mean  SD)$ Country  
(survey year) 
Population sample Sample 
size (N) 
Age (y) Dietary assessment method 
Men Women Total 
Australia (1995-
1996)19 
Nationally representative sample, 1995 Australia National Nutrition 
Survey 
10,851 ≥19 24-h dietary recall (mainly) 3.7 (1.9) 2.8 (1.5) 3.3 (1.6) 
Austria (1991-
2008)18  
Nationally representative sample, Austrian Study on Nutritional Status 
(ASNS). 
2,123 19-64 24-h dietary recall 2.7 (1.1) 2.6 (1.0) 2.6 (1.0) 
Canada (2004)14 Multistage stratified cluster, Canadian Community Health Survey, Cycle 
2.2 
18,820 ≥19 24-h dietary recall 3.5 (3.0) 2.8 (2.3) 3.1 (2.7) 
China (2002)45 Nationally representative sample, Chinese National Nutrition and Health 
Status survey 2002 
53,394 18-70+ 3 consecutive 24-h dietary 
recalls and weighing 
methods 
1.8 1.6 1.7 
Denmark (2000-
2002)17 
Nationally representative sample, Dietary habits in Denmark 2000-
2002.  
3,151 18-75 7-d food record 3.8 (1.1) 3.2 (0.9) 3.5 (1.0) 
Estonia (1997)21 Nationally representative samples of each respective population, Baltic 
Nutrition and Health Surveys 1997 
2,108 19-64 24-h dietary recall 3.8 (1.8) 3.1 (1.3) 3.4 (1.6) 
Finland (2007)10 Random sample drawn from the population register, FINDIET 2007 
survey 
2,007 25-74 48-h dietary recall; every 
2nd respondent 3-d food 
record. 
4.1 (1.3) 3.4 (1.0) 3.7 (1.2) 
France (2006-
2007)15 
Nationally representative sample, Afssa, INCA 2 study 2,624 18-79 7-d food record 3.3 (0.9) 2.7 (0.7) 3.0 (0.8) 
Germany (2005-
2006)46 
Nationally representative sample, second German National Nutrition 
Survey (NVS II). 
13,959 19-80 2x24-h dietary recalls and 
2x4-d weighing protocol in 
sub-sample 
3.8 (1.2) 3.3 (1.0) 3.5 (1.2) 
Hungary (2003-
2004)18, 47  
Third Hungarian Nutrition Survey (NHS), national dietary survey of 
adult population 
1,179 ≥18 3-d dietary record 3.0 (0.9) 2.7 (1.1) 2.8 (1.0) 
Israel (1999-2001)48 Random sample drawn from the national population registry (1992 
subjects); Further random sample of 4393 subjects (neighbours of the 
first sample) MABAT First Israeli national health & nutrition survey 
3,242 25-64 Questionnaires and 24-h 
dietary recall 
2.9 (1.3) 2.3 (1.0) 2.6 (1.2) 
Italy (1994-1996)18, 
64 
INN-CA  study (Nationwide Nutritional Survey of Food Behaviour of 
the Italian population) 
1461 19-64 7-d food record 3.4 (0.8) 2.9 (0.8) 3.1 (0.8) 
Latvia (1997)21 Nationally representative samples of each respective population, Baltic 
Nutrition and Health Surveys 1997 
2,308 19-64 24-h dietary recall 4.2 (2.2) 3.1 (1.6) 3.6 (2.0) 
Lithuania (2007)18 National Nutrition survey 2007, national, random sample of inhabitants 1,936 19-64 24-h dietary recall 3.3 (1.4) 2.5 (1.0) 2.9 (1.3) 
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$ For surveys differentiating between potassium intakes including alimentary supplements and excluding supplements we used the data including 
supplements, unless unavailable. For the survey in the United Kingdom we reported intakes of 7-day weighted intake dietary record to keep data 
between countries comparable. For Spain and Austria information is based on data published in the respective 2004 and 2009 European Nutrition and 
Health Report.18, 65 For countries for which SDs were not reported we calculated the SDs based on data available from the report. For countries for which 
the SD could not be calculated based on the data available, no SD is reported. For Australia the SD was calculated based on data provided by the 
Australian Bureau of Statistics. 
 
Netherlands (1997-
1998)13  
Nationally representative panel of households (VCP-3) 4,711 19-75+ 2-d diary method (2 
consecutive days) 
4.0 (1.1) 3.4 (0.9) 3.7 (1.0) 
New Zealand (1996-
1997)20 
Nationally representative sample, 1997 New Zealand National Nutrition 
Survey (NNS97) 
4,390 19-65+ 24 h dietary recall 4.0 (1.8) 3.0 (1.7) 3.4 (1.8) 
Poland (2000)18, 22 Food consumption and anthropometric survey 2000, randomly selected 
individuals reflecting the demographic characteristics of the whole 
population. 
2,440 19-64 24-h dietary recall 4.4  (1.5) 3.1 (1.1) 3.7 (1.5) 
Spain (1990-1998)65 Cross-sectional data from regional population nutrition surveys carried 
out between 1990 and 1998. Eve study 
10,208 25-60 Repeated 24-h dietary 
recalls (mainly), 3-d food 
diaries, FFQ 
3.3 2.9 3.1 
Sweden (1997-
1998)16 
Representative sample of 2000 households, Riksmaten 1997-98. 
Dietary habits and nutrient intake in Sweden. The second national food 
consumption survey 
1,215 18-74 7-d pre-coded record book 3.5 (1.0) 3.1 (0.8) 3.3 (0.9) 
United Kingdom 
(2000-2001)11  
Nationally representative sample, The National Diet & Nutrition Survey: 
Vol. 3. 
1,724  19-64 7-d weighed intake dietary 
record and 24-h urine 
collection 
3.4 (1.0) 2.7 (0.7) 3.0 (0.9) 
United States (2005-
2006)12 
Nationally representative sample, NHANES 2005-2006  4,520 ≥ 20 24-h dietary recall 3.2 (2.0) 2.4 (1.8) 2.8 (2.0) 
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Estimated impact on population blood pressure distribution 
In Supplemental Figure A we illustrate the differences between current and 
recommended potassium intakes for Finland (mean potassium intake of 3.7 g/d), United 
Kingdom (3.0) and United States (2.8) and the estimated reduction in population systolic 
BP in these countries if potassium intakes were increased to a level of 4.7 g/d, assuming 
a 1 mmHg decrease in systolic BP per 0.6 g/d increase in potassium intake as described 
above. In this way, increasing potassium intake can be estimated to reduce average 
systolic BP of the population in Finland by 1.7 mmHg, in the United Kingdom by 2.8 
mmHg and in the United States by 3.2 mmHg. In women expected reductions are 3.4 
mmHg, 2.2 mmHg and 3.9 mmHg, respectively, which is larger than in men (2.2 mmHg, 
1.0 mmHg and 2.5 mmHg, respectively), because of lower habitual potassium intake in 
women. 
With the theoretical optimization of potassium intakes, an estimated 2%, 5% and 
5% of men in respectively Finland, the United Kingdom and United States would shift to 
optimal systolic BP levels (<120 mmHg) and 2%, 5% and 3% less men in respectively, 
Finland, the United Kingdom and United States would have systolic BP in the higher 
range (≥140 mmHg). For women, 4% in Finland, 8% in United Kingdom, and 6% in 
United States would shift to optimal systolic BP levels and 4% less women in these three 
countries would have systolic BP in the higher range (Supplemental Table 2). Similar 
estimations can be performed for other countries and population groups. 
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Supplemental Figure A Potassium intakes (current intakes, g/d and differences from 
recommended level) and illustration of estimated impact on population systolic blood 
pressure after increasing potassium intake in Finland, United Kingdom and United States. 
*Assuming a linear 1 mmHg reduction in population systolic blood pressure per 0.6 g/d 
increase in intake up to a level of 4.7 g/d. 
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Supplemental Table 2 Predicted percentage (%) of Finnish (25-74 years), United 
Kingdom (19-64 years) and United States (≥20 years) men and women in systolic BP 
categories before and after a theoretical increase in potassium intake and the expected 
change in percentage in the different systolic BP categories.  
  Prevalence in systolic BP categories 
 Systolic BP (mmHg) Before increase After increase Change 
Finland 
Men <120 19% 20% +2% 
 120-139 41% 41% +1% 
 ≥140 41% 38% -2% 
Women <120 30% 34% +4% 
 120-139 38% 38% 0% 
 ≥140 32% 28% -4% 
United Kingdom 
Men <120 25% 30% +5% 
 120-139 50% 50% 0% 
 ≥140 25% 20% -5% 
Women <120 45% 53% +8% 
 120-139 42% 37% -4% 
 ≥140 13% 9% -4% 
United States 
Men <120 44% 48% +5% 
 120-139 34% 33% -1% 
 ≥140 22% 19% -3% 
Women <120 49% 55% +6% 
 120-139 28% 26% -2% 
 ≥140 23% 18% -4% 
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Comments 
 
Methodological constraints 
Several methodological considerations of our study warrant further consideration. These 
include the assessment of potassium intakes and assumptions made to predict effects of 
increasing potassium intakes on BP. 
First, it should be mentioned that the quality of the methodology and food 
composition databases used between the different surveys varies which affects accuracy 
and makes direct comparison between countries difficult. Furthermore, within most 
individual surveys potassium intake was only measured via dietary assessment methods. 
These were found to provide reasonable estimates of intake.6, 23-27 However 
measurement of potassium intake by 24-h urinary excretion is the best estimate of 
intake,11, 23 but not always practical on large scale though. Due to the nature of dietary 
questionnaire methods, a systematic error can occur if the entire study population or 
substantial subgroup - such as overweight persons - consistently over- or underreports 
dietary intake. In the case of systematic underreporting, our analysis would overestimate 
the effect on population BP, whereas over-reporting would result in underestimation of 
the BP effect. Because FFQ are known to underestimate potassium intakes, we excluded 
such studies from the present review.24, 25, 27  
For predicting the effect of increasing potassium intake on BP, we set the target 
recommended potassium intake level for adults at 4.7 g/d based on the 
recommendations by authoritative bodies in the United States and expert panels, which 
reviewed all available data on health effects of potassium.6, 7 For our prediction, we also 
assumed that increasing dietary potassium intake has a linear effect on BP of -1 mmHg 
per 0.6 g potassium. This estimate is based on results from the INTERSALT study and 
has been corroborated by data from several other observational studies.28-31 Data from 
meta-analyses of intervention studies in which potassium was supplemented at doses of 
2-3 g/d show a 3-4 mm Hg reduction in systolic BP, which is closely in line with -1 mmHg 
per 0.6 g potassium.1, 2, 4 Three additional intervention studies were published after these 
meta-analyses32-34, including two studies with relatively low doses of potassium (0.9-1.2 
g/d)32, 34, finding similar BP lowering results. Although no formal dose-response 
intervention studies are available data from intervention studies support that the linear 
relation we assumed is a reasonable assumption.  
Another assumption we made is that the effect of increasing dietary potassium 
intake is independent of initial BP level. However, dietary interventions to reduce BP are 
known to be more effective in people with higher initial BP levels.2, 35-37 Therefore, it is 
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plausible that improving diet or lifestyle would have more population impact in countries 
with relatively high BP levels. This also means that with BP lowering interventions, the BP 
distribution would not simply shift to the left while keeping its shape, but would also 
become narrower. Taking this phenomenon into account would result in larger estimated 
effects in countries with higher initial BP levels, such as Finland, and smaller estimated 
effects in countries with lower initial BP levels, such as the United States. Likewise, the 
impact in people having high BP levels would be larger, resulting in a larger reduction of 
the number of people with high blood pressure levels after increasing potassium intake. 
On the contrary impact on BP effect in the lower ranges would be expected to be smaller. 
We found that women have lower potassium intakes (median intake: 2.9 g/d) 
than men (median intake: 3.5 g/d). It should be noted, however, that the optimal level 
of potassium intake might be lower in women due to their smaller body size and lower 
caloric intake. Consequently, we might have overestimated the hypothetical effect of 
suboptimal potassium intakes in women.6, 38 
Comparison of the potassium intake data from the national surveys reviewed here 
with potassium excretion data from the INTERSALT study (1982-1985)39 and INTERMAP 
study (1990-1997)40 suggests that intakes have increased somewhat over the last two 
decades. However, findings between these and our study should be compared with 
caution, because of essential differences in methodology of assessing potassium intake 
and in sampling of participants. A recent paper reported potassium intake data in several 
European countries based on a random sample of the European Prospective Investigation 
into Cancer and Nutrition (EPIC) study. Average potassium intakes were similar to data 
reported here for most countries, except for intakes in Spain and United Kingdom, which 
were much higher by EPIC compared to the survey data we included in our review for 
these countries.41  
 
Comparison with reductions in sodium intake 
The potential of increasing potassium intake levels is considerable. Reducing salt intakes 
from the concurrent approximately 9 to 5 g/d as advised by the World Health 
Organisation42 would reduce systolic BP in the range of 2-4 mmHg, based on 
observational data from the INTERSALT study8 and a Cochrane Systematic Review of 
intervention studies.43 Our estimate of 1.7-3.2 mmHg for increasing potassium intake is 
in the same order of magnitude. Thus, improving potassium intake seems to have as 
much potential for improving BP as reducing sodium intake.  
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Sodium to potassium intake ratio 
Sodium and potassium have opposite effects on BP and other measures of health. 
Several studies suggest that the sodium to potassium intake ratio is more closely linked 
to BP and CVD risk than the effect of sodium or potassium alone.44 In all national surveys 
for which we could obtain data on both sodium and potassium intake from the same 
survey, the molar ratio was >1 (range 1.3 – 6.3).10-18, 45-48 This probably represents an 
underestimation of the true intake ratio, as intakes were assessed using dietary 
assessment methods known to systematically underestimate sodium intake.11, 25, 27, 49 By 
comparison, the INTERSALT39 and INTERMAP40 study found molar ratios >2 (except for 
the few rural populations included) based on more reliable 24-h urinary excretion data. 
The recommendations for sodium of <2.0 g/d (equals 87 mmol per day)50 and for 
potassium of 4.7 g/d (equals 120 mmol per day)6 result in a molar ratio of < 0.7. This 
clearly indicates that current ratios of dietary potassium to sodium intakes are far from 
optimal. 
 
Feasible options for increasing potassium intake 
Potassium is abundantly available in every-day foods that are advised in guidelines for 
healthy diets51, for example intake of 5 portions of fruit and vegetables per day already 
delivers more than 1 g/d.32 In practice this means that adequate potassium intakes can 
easily be achieved by following existing dietary guidelines. For instance, adherence to 
DASH dietary pattern as advised in the Dietary Guidelines for Americans, will result in a 
potassium intake of 4.7 g/d.52 
In the general population, dietary potassium intakes above adequate levels pose 
no potential risk of adverse health effects as excess potassium is readily excreted in the 
urine.52, 53 However, some specific subgroups in the population should be careful with 
increasing potassium intakes. These include specific patients with impaired kidney 
function; especially those with glomerular filtration rate below to 10–20 ml/min/1.73 
m2.54-56 Another group that should beware of increasing dietary potassium intake are 
patients on ACE-inhibitors, angiotensin receptor blockers, and potassium-sparing 
diuretics. However, these patients are typically under medical supervision and follow 
specific guidelines to control potassium and other nutrients intake6, 53, and are aware that 
general population guidelines and campaigns to increase potassium intake do not apply 
to them. 
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Estimated effect on cardiovascular disease risk 
It is estimated that on a global scale about 62% of stroke and 49% of heart disease are 
attributable to suboptimal BP.57 Data from recent national surveys indicate that only 20-
28% of people have optimal BP levels (<120/80 mmHg without use of anti-hypertensive 
medication).58-62 (personal communication Lucie Viet (RIVM/CBS/ Regenboogproject 
1998-2001). This means that a majority of the population can benefit from dietary and 
lifestyle changes positively influencing BP. BP reductions of 1.7-3.2 mmHg by increasing 
potassium intakes in the population as estimated here can be predicted to reduce the risk 
of stroke mortality by 8-15% and heart disease mortality by 6-11%.63  
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Abstract 
 
Background: Calcium plays a role in blood pressure (BP) regulation, but the importance 
of supplemental calcium intake for the prevention of hypertension is still debated. 
Objective: We conducted a meta-analysis of randomized controlled trials to determine 
the effect of calcium supplementation on BP. 
Design: A systematic search for randomized trials of calcium supplementation and BP in 
non-pregnant subjects was performed in Medline from 1966 to June 2003. Seventy-one 
trials were identified, 40 of which met the criteria for meta-analysis (total of 2492 
subjects). Two persons independently extracted data from original publications on 
changes in calcium intake and BP. In addition, data were collected on subjects’ 
characteristics, that is, age, gender, initial BP and initial calcium intake. A random effects 
model was used to obtain the effect of calcium supplementation on BP, overall and in 
predefined population subgroups. 
Results: Calcium supplementation (mean daily dose: 1200 mg) reduced systolic BP by –
1.86 mmHg (95% confidence interval: –2.91 to –0.81) and diastolic BP by –0.99 mmHg 
(–1.61 to –0.37). In people with a relatively low calcium intake (<800 mg per day) 
somewhat larger BP estimates were obtained, that is, –2.63 (–4.03 to –1.24) for systolic 
BP and –1.30 (–2.13 to –0.47) for diastolic BP.  
Conclusion: Our study suggests that an adequate intake of calcium should be 
recommended for the prevention of hypertension. More research on BP in people with 
calcium-deficient diets is warranted. 
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Introduction 
 
High blood pressure (BP) is a well established risk factor for cardiovascular morbidity and 
mortality.1 Calcium is a key factor in the regulation of cardiovascular function and 
alterations in calcium metabolism have been reported in human and experimental 
hypertension.2 Epidemiological studies have shown an association between calcium 
intake and BP, but findings are inconsistent and could be confounded by healthy lifestyle 
and diet.3 Randomized controlled trials (RCTs) that provide stronger evidence for 
causality suggest that supplemental calcium could indeed exert an effect on BP, but 
reductions are generally small.4-6 Because of heterogeneity in BP response among 
subjects, however, it cannot be excluded that an adequate intake of calcium is important 
for the prevention of hypertension in specific populations or population subgroups.7-12 We 
performed an updated meta-analysis of randomized controlled trials of calcium 
supplementation and BP, which had sufficient power to detect small treatment effects 
with high precision. Furthermore, we performed meta-analyses in strata of subject 
characteristics to examine in more detail heterogeneity of BP response to calcium intake. 
 
 
Subjects and Methods 
 
Search strategy 
The MEDLINE database (1966–June 2003) was searched for RCTs of calcium 
supplementation and BP using the terms ‘(calcium NOT calcium antagonis* NOT calcium 
channel NOT calcium entry NOT calcium blocker) AND (blood pressure OR hypertension)’ 
as Medical Subject Headings (MESH terms) or words in title. Searches were limited to 
clinical trials or RCTs in humans. Furthermore we performed a manual search using 
citation lists from retrieved articles, meta-analyses and systematic reviews to identify 
other eligible studies. No language restriction was used.  
 
Selection of trials 
RCTs on the effect of calcium supplementation on BP in non-pregnant normotensive or 
hypertensive subjects were selected. Studies were excluded if they met any of the 
following criteria: data included in prior reports (duplicate publication), lack of 
appropriate BP data, co-intervention (except for co-intervention with vitamin D), study 
population with renal disease or hyperparathyroidism, lack of control group, or study 
duration of less than 2 weeks. Seventy-one RCTs were identified (reference list of all 
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identified studies is available from the authors), of which 40 proved eligible for this meta-
analysis (Figure 1).2, 13-51 
Figure 1 Selection of studies for meta-analysis of randomized controlled trials of calcium 
supplementation and blood pressure.  
 
Validity assessment and data abstraction 
We retrieved original articles for data abstraction, except for two trials for which only an 
abstract was available.33, 47 Two authors (LAJM and JMG) independently extracted the 
data. In case of discrepancies consensus was reached, if necessary with the help of a 
third author (MTS). Studies were scored with regard to blinding towards the type of 
treatment (i.e. open, single-blind, double-blind). 
 
 
 
 
 
 
 
Potentially relevant RCTs 
identified and screened for 
retrieval (n = 84) 
RCTs included in meta-analysis 
(n = 40, with 50 relevant strata) 
Potentially relevant RCTs 
included (n = 71) 
RCTs excluded, with reason 
1. data from the same patients included in prior 
reports (n = 6)  
2. lack of appropriate blood pressure data (n = 3)  
3. co-intervention (n = 13) 
4. study population with renal  disease or 
hyperparathyriodism (n = 2)  
5. non-placebo-control group (n  = 1)  
6. duration < 2 weeks (n = 6)  
RCTs excluded, with reason  
1. no RCT (n = 10)  
2. pregnant study population (n  = 3)  
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Extraction of study characteristics  
Changes in systolic and diastolic BP and accessory variance measures were abstracted 
from articles, as were data on calcium dose and the following trial population 
characteristics: mean age, gender distribution, initial systolic and diastolic BP and initial 
(i.e. habitual) calcium intake. One trial tested different doses of calcium with a single 
control group34 and three trials tested multiple formulations of calcium with a single 
control group.32, 33, 46 For these trials, BP changes in the intervention groups were 
averaged and extracted from BP change in the control group. In trials in which BP was 
measured at several points in time we used the longest follow-up period during which the 
patients were still on randomized treatment. With regard to BP, measurements in sitting 
position were used. If not available, supine BP, standing BP or mean daytime ambulatory 
BP was taken in that order. For one trial we used BP data that were adjusted for 
confounders, because raw data were not given in the original article.28 If different 
publications on identical studies were found, we used all available information for data 
abstraction and cited the most recent publication.34, 52 One trial in which all subjects 
participated in the parallel phase and part of the subjects in a cross-over phase was 
treated as if it had a parallel design.50 Imputations were made for mean age, based on 
the midpoint of the age range, in one trial.24 gender (i.e. 50% males) in three trials.18, 24, 
47 and initial calcium intake in 16 trials. The latter imputation was based on the mean 
calcium intake in the population from which trial participants had been recruited, for 
which data were derived from population-based dietary surveys (overview of surveys and 
mean population calcium intakes is available from the authors). If participants had been 
on a run-in diet for more than 4 weeks before the start of the trial, calcium intake during 
that period was taken as the habitual calcium intake.38, 42 For one trial we contacted the 
authors to obtain additional data.26 For two other trials24, 47, we derived data from a 
meta-analysis6 and a review9, respectively.  
 
Meta-analysis 
For parallel trials, the change in BP from baseline in the intervention group was 
subtracted from the change in BP from baseline in the control group to yield the net 
change in BP due to calcium supplementation. For crossover trials with similar baseline 
BP for intervention and control periods, the net change in BP was calculated as the final 
BP during intervention minus the final BP during control treatment. Otherwise the net 
change in BP was calculated similarly as for parallel trials. Variance measures for net 
changes in systolic and diastolic BP were obtained. If not given, variance measures were 
derived from confidence intervals, P values, or individual variance measures for change 
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in BP in intervention and control groups or intervention and control periods (crossover 
design). For parallel trials in which no variance measures for paired differences were 
given and for crossover trials, the pooled variance was estimated according to the 
method of Follmann et al.53 assuming a correlation of 0.50 between baseline and final BP 
values. If variance measures were only reported at baseline, we assumed similar 
variance at the end of follow-up. The SAS statistical package was used for data-analysis 
[SAS Version eight, SAS Institute, Inc., Cary, NC, USA]. Homogeneity of effect size was 
tested by Q statistics54 and significant heterogeneity was found among trials (P < 
0.0001) both for systolic BP (2 = 308.16) and diastolic BP (2 = 334.12). We chose a 
random-effects model for meta-analysis of continuous outcomes that takes into account 
both within and between study variations, using the SAS PROC MIXED statement.55 For 
each trial the BP effect was weighted by the reciprocal of its variance, that is, 1/SE2. BP 
estimates are reported with 95% confidence intervals. Two-sided P-values <0.05 were 
considered statistically significant. 
  We performed predefined subgroup analyses to study modification of BP response 
to calcium supplementation. Subgroups were based on calcium dose (1000 mg vs 
>1000 mg/day) and trial population characteristics, that is, median age (<45 vs 45 
years), initial BP (<140/90 mmHg vs 140/90 mmHg), gender (50% vs >50% males) 
and initial calcium intake (<800 mg vs 800 mg/day). Analysis by calcium dose, age and 
initial calcium intake were based on the median of the frequency distribution of these 
variables.  
 Analyses in strata of trial population characteristics and calcium dose were 
repeated using a multivariate random effects model adjusting for potential confounders 
(except when used as a stratification variable), that is, mean age (years), gender 
distribution (%males), initial BP (dichotomous variable, i.e. <140/90 mmHg vs 140/90 
mmHg), initial calcium intake (mg/day) and calcium dose (mg/day).  
 Publication bias was visually examined after construction of a funnel plot in which 
weight factors (1/SE2) were plotted against net changes in systolic BP. In addition a non-
parametric ‘trim and fill’ method was used to adjust for publication bias.56 
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Results 
 
Study characteristics 
Table 1 displays characteristics of 40 trials selected for meta-analysis, comprising 50 
different strata and a total of 2492 subjects. Eighteen strata had a cross-over design 
(572 subjects in total) and 32 were double-blind. Trial sample size ranged from 7 to 452 
subjects. Duration of intervention ranged from 3 to 208 weeks (median: 9.5 weeks) and 
daily calcium dose from 355 mg to 2000 mg (mean: 1200 mg, median: 1055 mg). In 
four trials, calcium intake was increased by dietary intervention14,21,22,26 and in one trial 
both by dietary intervention and calcium supplements.33 Trials were mainly conducted in 
white populations (39 strata), and mostly included both men and women (31 strata). 
Mean age of trial populations ranged from 11 to 77 years (43.7  14.3 years (mean  
s.d.)). Based on mean BP at baseline (cut-off: 140/90 mmHg), 27 strata were derived 
from normotensive populations and 23 strata from hypertensive populations. From visual 
examination of the funnel plot it was concluded that small trials with large systolic BP 
reductions are possibly overrepresented (Figure 2). A non-parametric ‘trim and fill’ 
method revealed that two trials might have been missing. After adjustment for putative 
missing data, the overall effect on systolic BP was attenuated to –1.33 mmHg (95% 
confidence interval (CI); -2.66 to 0.00). 
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Table 1 Overview of randomized trials of calcium supplementation and blood pressure included in the meta-analysis.  
Systolic BP (mmHg) Diastolic BP (mmHg)  First author, 
stratum 
Year  Design n1 Duration 
(wks) 
Age 
(years) 
Men 
(%) 
Race2 
Initial Change (SD)3 Initial Change (SD)3 
Calcium 
dose 
(mg/day) 
Intervention 
13a Belizan, men 1983 p,db 23 22 26 100 White 113 –0.80 (5.26) 71 –6.02 (5.96) 1000 Calcium gluconate 
13b Belizan, women 1983 p,db 20 22 24 0 White 102 –2.40 (5.06) 68 –4.50 (5.30) 1000 Calcium gluconate 
14 Bierenbaum 1988 c,o 50 8 43 50 White 119 –4.00 (11.16) 79 –1.00 (7.38) 1150 Dairy products 
15 Bloomfield 1986 p,db 32 4 53 19 White 139 5.30 (15.01) 92 0.00 (5.44) 1500 Calcium carbonate 
16 Bostick 2000 p,db 185 26 59 63 White 130 –2.20 (17.65) 76 –1.30 (10.30) 1500 Calcium carbonate 
17 Cappuccio 1987 c,db 18 4 49 61 White 154 3.50 (11.73) 103 1.10 (8.29) 1600 Calcium gluconate 
18 Davis 1996 p,o 34 4 17 50 Black 125 –1.70 (7.85) 91 –0.50 (5.77) 1500 Calcium gluconate 
19 Dwyer 1998 c,db 99 8 16 44 Black 116 0.74 (13.75) 66 –1.68 (18.39) 1500 Calcium carbonate 
20 Galloe 1993 c,db 20 12 63 66 White 169 2.20 (20.1) 97 3.30 (12.3) 2000 Calcium gluconate 
21 Gillman 1995 p,db 101 12 11 50 Black 102 –1.30 (7.21) 58 –0.20 (5.93) 600 Calcium citrate 
malate enriched juice 
22 Green 2000 c,db 38 4 53 50 White 123 –4.00 (15.72) 77 –1.00 (9.27) 355 Dairy products 
23 Grobbee 1986 p,db 90 12 24 86 White 143 –0.40 (11.34) 83 –2.40 (9.95) 1000 Calcium citrate 
24 Jespersen 1993 c,db 7 8 46 50 White 148 –0.57 (7.2) 93 –0.86 (3.88) 1000 Calcium carbonate 
25a Johnson, ht 1985 p,db 34 208 53 0 White 141 –14.0 (22.31) 86 0.00 (10.21) 1000 Calcium carbonate 
25b Johnson, nt 1985 p,db 81 208 53 0 White 120 1.00 (13.34) 74 2.00 (8.37) 1000 Calcium carbonate 
2 Kawano 1998 c,o 60 8 58 58 Asian 149 –2.00 (13.15) 90 –1.10 (7.67) 1000 Calcium carbonate 
26 Kynast-Gales 1992 c,o 13 4 61 100 White 136 3.62 (10.37) 83 0.15 (7.01) 1109 Dairy products 
27 Lijnen 1996 p,db 32 16 24 100 White 114 –2.00 (6.93) 73 –1.00 (7.09) 2000 Calcium gluconate 
28a Lyle, blacks 1987 p,db 21 12 28 100 Black 114 –6.90 (10.03) 71 1.20 (7.24) 1500 Calcium carbonate 
28b Lyle, whites 1987 p,db 54 12 35 100 White 115 –3.70 (8.65) 75 –1.10 (7.39) 1500 Calcium carbonate 
29 Lyle 1992 p,db 42 8 34 76 White 133 –6.00 (8.53) 87 –7.20 (5.89) 1500 Calcium carbonate 
30 Martinez 1989 p,o 51 8 44 39 White 157 –4.00 (10.75) 99 –2.00 (6.60) 1000 Not given 
31a McCarron, ht 1985 c,db 47 8 52 52 White 152 –3.80 (15.07) 94 0.00 (7.94) 1000 Calcium carbonate 
31b McCarron, nt 1985 c,db 31 8 48 38 White 121 –2.00 (15.57) 75 –3.30 (8.19) 1000 Calcium carbonate 
32 Meese 1987 c,db 26 8 49 38 Black 143 –1.00 (7.94) 96 –3.00 (4.89) 800 Calcium carbonate, 
calcium citrate 
33a Morris, ht men 1988 p,o 46 12 45 100 White 138 –4.35 (6.10) 94 –2.25 (4.07) 1500 Dietary calcium, 
calcium carbonate 
33b Morris, ht women 1988 p,o 36 12 45 0 White 138 –2.90 (5.76) 94 0.05 (4.94) 1500 Dietary calcium,  
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calcium carbonate 
33c Morris, nt men 1988 p,o 26 12 45 100 White 118 –4.70 (4.74) 74 0.50 (4.39) 1500 Dietary calcium, 
calcium carbonate 
33d Morris, nt women 1988 p,o 19 12 45 0 White 118 –1.75 (5.29) 74 –0.10 (2.73) 1500 Dietary calcium, 
calcium carbonate 
34a Nowson, ht 1989 p,db 47 8 60 87 White 155 –1.50 (11.10) 91 0.50 (6.25) 800/1600 Calcium carbonate 
34b Nowson, nt 1989 p,db 48 8 42 58 White 123 0.00 (19.4) 74 0.30 (9.01) 800/1600 Calcium carbonate 
35 Orwoll 1990 p,db 65 156 56 100 White 131 1.88 (14.73) 84 3.75 (10.61) 1000 Calcium carbonate4 
36 Pan 1993 c,db 29 11 74 72 Asian 136 –7.09 (13.05) 72 –0.87 (11.05) 800 Calcium citrate 
37 Sacks 1998 p,db 153 16 39 0 White 116 –0.70 (5.84) 74 –0.90 (4.49) 1200 Calcium carbonate 
38 Sanchez 1997 p,db 20 8 45 60 White 166 1.10 (23.84) 99 –2.10 (13.97) 1500 Calcium gluconate 
39 Siani 1987 c,db 8 3 40 75 White 154 5.10 (13.86) 96 1.30 (2.4) 1000 Calcium gluconate 
40 Siani 1988 c,db 14 4 41 80 White 139 2.20 (12.19) 91 0.70 (9.08) 1000 Calcium gluconate 
41 Strazzullo 1986 c,db 17 15 43 61 White 145 –1.00 (11.78) 91 –1.00 (6.08) 1000 Calcium gluconate 
42 Takagi 1991 c,o 9 8 77 33 Asian 146 –12.1 (13.06) 78 –6.00 (8.89) 1000 AA calcium 
43 Tanji 1991 c,db 19 13 48 33 White 146 –1.00 (16.66) 95 0.00 (7.11) 1200 Calcium carbonate 
44 Thomsen 1987 p,db 28 52 50 0 White 124 –4.10 (16.55) 76 0.20 (10.38) 2000 Calcium gluconate 
45 Van Beresteyn 1986 p,db 58 6 21 0 White 115 –1.70 (9.22) 65 0.40 (6.68) 1500 Calcium carbonate 
46 Vinson 1987 p,o 14 7 21 100 White 116 4.70 (5.22) 75 –2.70 (3.07) 500 Calcium gluconate, 
calcium yeast 
47 Waal-Manning 1987 p,db 52 39 61 50 White 143 –2.00 (28.64) 84 –2.00 (15.91) 1000 Calcium supplement 
48a Weinberger, ht 1993 c,db 17 8 45 41 White 131 –2.00 (15.48) 87 –1.00 (8.28) 1500 Calcium carbonate 
48b Weinberger, nt 1993 c,db 29 8 45 41 White 116 1.00 (12.41) 72 –1.00 (9.59) 1500 Calcium carbonate 
49a Yamamoto, men 1995 p,db 306 26 42 100 White 126 0.50 (3.37) 84 1.00 (2.83) 1000 Calcium carbonate 
49b Yamamoto, women 1995 p,db 146 26 45 0 White 125 –2.10 (3.83) 84 –1.60 (2.77) 1000 Calcium carbonate 
50 Zhou 1994 p,db 56 14 46 51 Asian 157 –18.9 (15.90) 103 –8.56 (9.33) 1000 Calcium carbonate 
51 Zoccali 1988 c,db 21 8 43 70 white 142 2.00 (14.39) 88 2.00 (9.59) 1000 Calcium gluconate 
Abbreviations: c, crossover; db, double-blind; ht, hypertensive; nt, normotensive; o, open; p, parallel 
1 Number of subjects that completed the trial. 2 Predominant race in study population. 3 Values represent net BP effects of calcium supplementation with 
standard deviations (SD) in parentheses. 4 Combined with cholecalciferol treatment (1000 IU/day). 
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Figure 2 Funnel plot of change in systolic blood pressure (BP) (mmHg) against weight 
factor (1/SE2) in randomized controlled trials of calcium supplementation and BP. 
 
Quantitative data analysis 
Forest plots of BP effects in individual trials with 95% CIs are shown in Figure 3. Meta-
analysis of randomized controlled trials yielded a weighted estimate for the overall effect 
of calcium supplementation of –1.86 mmHg (–2.91 to –0.81) on systolic BP and of –0.99 
mmHg (–1.61 to –0.37) on diastolic BP. If only double-blind trials were included, 
reductions were –1.67 mmHg (–2.87 to –0.47) and –0.93 mmHg (–1.64 to –0.22), 
respectively. BP estimates were not significantly different among subgroups (Table 2), 
but there was a tendency towards an increased BP sensitivity to calcium in populations 
with a low initial calcium intake (<800 mg/day) compared to populations with higher 
intakes (≥800 mg/day), both for systolic BP (–2.68 mmHg (–4.07 to –1.28) vs –0.90 
mmHg (–2.41 to 0.61), respectively) and diastolic BP (–1.30 mmHg (–2.15 to –0.46) vs 
–0.63 mmHg (–1.53 to 0.28), respectively). BP responses to calcium supplementation 
Change in SBP during intervention (mmHg) 
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did not differ significantly in strata of mean age (<45 vs 45 years), calcium dose (1000 
mg vs >1000 mg/d), initial BP (<140/90 mmHg vs 140/90 mmHg) and gender (50% 
vs >50% males). Dietary increases in calcium intake (five trials) tended to have a larger 
effect on systolic BP than calcium supplements (–2.56 mmHg (–4.98 to –0.13) vs –1.70 
mmHg (–2.85 to –0.55)), but this was not the case for diastolic BP (–0.51 mmHg (–1.96 
to 0.95) vs –1.10 mmHg (–1.78 to –0.41)). Blood pressure effects of calcium 
supplementation were particularly pronounced in four trials among Asian populations, 
comprising a total of 154 subjects with a habitual calcium intake of 400-550 mg/day. 
This discrepancy persisted after adjustment for age, gender, initial BP, calcium dose and 
habitual calcium intake, that is, BP estimates of -9.66/-4.62 mmHg in Asian subjects 
compared to -1.54/0.32 mmHg in blacks and -1.21/-0.78 mmHg in whites.  
 Multivariate, stratified meta-analysis (Table 2) with adjustment for subgroup 
differences in mean age, gender distribution, initial BP, initial calcium intake and calcium 
dose, yielded essentially similar results. BP response did not differ among subgroups, but 
again a tendency towards larger BP reductions was observed in populations with a low 
initial calcium intake (<800 mg/day) which could not be explained by differences in mean 
age, gender distribution, initial BP or calcium dose.   
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20 10 0 -10 -20 -30 
 
Figure 3 Blood pressure (BP) response to calcium supplementation in randomized 
controlled trials. BP effects in individual trials are depicted as open squares with 95% 
confidence intervals (CIs), for systolic BP (Forest plot A) and diastolic BP (Forest plot B), 
respectively. Pooled estimates with 95% CIs are depicted as diamonds. 
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Table 2 Blood pressure response to calcium supplementation in strata of subjects’ characteristics and calcium dose. 
 No. of strata 
(subjects) 
Systolic blood pressure1  Diastolic blood pressure1 
  Univariate model Multivariate model2  Univariate model Multivariate model2 
Age (years)       
<45 21 (1256) –1.17 (–2.71;0.36) –1.45 (–2.99;0.09)  –1.21 (–2.15;–0.28) –1.26 (–2.20;–0.33) 
45  29 (1236) –2.43 (–3.83;–1.03) –2.33 (–3.69;–0.96)  –0.81(–1.64;0.02) –0.80 (–1.62;0.02) 
  P = 0.24 P = 0.42  P = 0.53 P = 0.48 
Gender (males)       
50%  23 (1170) –2.08 (–3.63;–0.53) –2.20 (–3.68;–0.72)  –1.12 (–2.04;–0.21) –1.12 (–1.98;–0.26) 
>50%  27 (1322) –1.67 (–3.10;–0.24) –1.77 (–3.13;–0.42)  –0.88 (–1.73;–0.02) –0.84 (–1.65;–0.04) 
  P = 0.70 P = 0.67  P = 0.70 P = 0.65 
Initial blood pressure 
(mmHg) 
      
<140/90  27 (1728) –1.64 (–3.01;–0.27) –2.04 (–3.40;–0.68)  –1.02 (–1.85;–0.19) –1.04 (–1.86;–0.22) 
140/90  23 (764) –2.17 (–3.78;–0.55) –1.85 (–3.45;–0.32)  –0.95 (–1.89;–0.01) –0.89 (–1.79;0.01) 
  P = 0.62 P = 0.89  P = 0.91 P = 0.81 
Initial calcium intake 
(mg/day) 
      
<800  27 (1388) –2.68 (–4.07;–1.28) –2.63 (–4.03;–1.24)  –1.30 (–2.15;–0.46) –1.30 (–2.13;–0.47) 
≥800  23 (1104) –0.90 (–2.41;0.61) –1.07 (–2.62;0.48)  –0.63 (–1.53; 0.28) –0.53 (–1.44;0.38) 
  P = 0.089 P = 0.15  P = 0.28 P = 0.23 
Calcium dose (mg/day)       
1000  25 (1346) –2.13 (–3.62;–0.64) –2.17 (–3.59;–0.75)  –1.36 (–2.23;–0.49) –1.41 (–2.24;–0.59) 
>1000  25 (1146) –1.59 (–3.08;–0.11) –1.75 (–3.20;–0.31)  –0.61 (–1.49;0.26) –0.56 (–1.40;0.29) 
  P = 0.62 P = 0.69  P = 0.23 P = 0.16 
1 Mean BP effects with 95% confidence interval obtained from random-effects model. P-values are given for difference in BP response between  
strata. 2 Adjusted for age, gender distribution, initial calcium intake, calcium dose and initial BP. 
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Discussion 
 
This meta-analysis of 40 RCTs shows that calcium supplementation (~1 g/day) may 
significantly reduce systolic BP by 1.9 mmHg and diastolic BP by 1.0 mmHg. The BP 
effect tended to be more pronounced in populations with a habitually low calcium intake 
(2.6/1.3 mmHg). Blood pressure showed no further decrease when calcium doses 
exceeded 1 g/day. 
Compared to previous meta-analyses of calcium and BP, this study included six 
RCTs2, 16, 19, 22, 30, 37 that had not been analyzed previously. A random effects model was 
used to account for heterogeneity; using an advanced statistical approach.55 Power of 
this meta-analysis was sufficient to allow subgroup analyses to study modification of BP 
response to calcium supplementation. Our pooled BP estimate of –1.9/–1.0 mmHg was 
somewhat larger than in previous meta-analyses of calcium supplementation trials 
(ranging from –1.4 to –0.8 mmHg systolic and –0.8 to –0.2 mmHg diastolic).4-6 If only 
double-blind trials with high internal validity were included in meta-analysis, our pooled 
BP estimate was slightly attenuated to –1.7/–0.9 mmHg.  
It has been suggested supplemental calcium exerts a stronger effect on BP in 
calcium-deficient subjects.5, 11, 57 In our meta-analysis, BP response to calcium tended to 
be stronger in people with a low habitual calcium intake (–2.7/–1.3 mmHg) compared to 
people with a higher intake (–0.9/–0.6 mmHg). However, it should be noted that initial 
calcium intake was not reported in 16 trials, for which we imputed the mean intake of the 
population from which subjects were recruited. These findings should therefore be 
interpreted with caution. Previous meta-analyses showed stronger associations of calcium 
with BP in hypertensive subjects4, at high doses of calcium58 and for food-based 
increases in calcium intake.6 This could not be confirmed in our study, except for a 
potentially larger effect of calcium-enriched foods on systolic BP. Stratified analysis of 
dietary compared to supplemental calcium, however, included only five dietary 
intervention studies and may have lacked power. 
High intake of calcium is often accompanied by an increased intake of other 
nutrients, including saturated fat and sodium, which may elevate BP. In the Dietary 
Approaches to Stop Hypertension (DASH) trial the effect of dietary patterns on BP was 
assessed.59 The DASH combination diet, rich in fruits, vegetables and low-fat dairy 
products, reduced systolic and diastolic BP to a greater extent (–5.5/–3.0 mmHg) than 
the “fruits and vegetables diet” (–2.8/–1.1 mmHg). This may partly be attributable to 
extra dietary calcium from low-fat dairy products (1240 mg/day) in this US population 
with a daily calcium intake of only 400–500 mg.  
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Prospective cohort studies provide better insight in the long-term BP effect of 
calcium intake than trials, that are mostly of short duration. However, observational data 
must be interpreted with caution because of inaccuracies in the assessment of habitual 
calcium intake, potential confounding by other dietary and lifestyle factors, and the fact 
that the range of calcium intake within a single population may be too limited to 
demonstrate an effect on BP. In the Third National Health and Nutrition Examination 
Survey (NHANES III) a higher intake of calcium was associated with a reduced rate of 
rise in systolic BP with age, suggesting an effect of dietary calcium also on long-term BP 
control.60  
Minor reductions in population BP could have a substantial impact on 
cardiovascular disease in westernized societies. MacMahon et al showed that a prolonged 
difference in usual diastolic BP of only 5 mmHg is associated with at least 34% less 
stroke and 21% less coronary heart disease.61 This meta-analysis showed a small 
favorable effect of calcium supplementation on BP. This beneficial effect may be larger in 
populations with a habitually low calcium intake, for example in Asian subjects. We 
recommend that more research is carried out on the potential health benefits of 
increased calcium intake, especially in vulnerable subgroups. 
 
 
What is known about this topic 
 Epidemiological studies suggest that an adequate intake of calcium may prevent hypertension, 
but findings are inconsistent.3  
 Randomized controlled trials have shown a small effect of calcium supplementation  
on BP.4  
 There may be heterogeneity in BP response to calcium intake among individuals.11 
 
What this study adds   
 Meta-analysis of 40 randomized controlled trials showed that calcium supplementation  
(~1 g/day) significantly reduces systolic BP by 2 mmHg and diastolic BP by 1 mmHg. 
 BP response to calcium supplementation tended to be stronger in populations with a low 
habitual calcium intake (<800 mg/day) than in populations with an adequate intake. 
 BP response to calcium supplementation was not modified by age, gender and presence of 
hypertension.  
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In a randomized controlled study, we found no effect of a dairy drink containing 
additional amounts of potassium, calcium, magnesium, selenium and vitamins C and E on 
blood pressure (BP). The results of this study confirm the discrepancy between dietary 
intervention studies showing reasonable BP lowering effects and intervention studies with 
a combination of minerals or vitamins showing no effect. Future studies should focus on 
assessing the effect of subsets of combinations of minerals and vitamins in natural 
matrices to get a better understanding of the possible antagonistic action between some 
of these ingredients. 
 
The Dietary Approaches to Stop Hypertension (DASH) study showed an impressive 
reduction on BP.1 The effective components of this diet probably include minerals and 
vitamins. Several meta-analyses and intervention studies investigated the relationship 
between individual minerals and vitamins and their effect on BP. A meta-analysis showed 
a significant effect of potassium supplementation on systolic blood pressure (SBP) of -
3.11mm Hg and of diastolic blood pressure (DBP) of -1.97mm Hg.2 Studies on the effect 
of a combination of minerals3–6 and vitamins7 showed mixed results. The present study is, 
to the best of our knowledge, the first study investigating the effect of a combination of 
minerals and vitamins on BP.  
 We tested the BP lowering effect of skimmed milk with added vitamins and 
minerals (calcium 446 mg, magnesium 100 mg, selenium 40 mg, vitamin C 180 mg, 
vitamin E 30 mg and tocopherol equivalents and either of two levels of potassium (high-K 
combination 1500 mg/serving and low-K combination 750 mg/serving)) in an 8 week 
trial. Untreated subjects with elevated BP were enrolled. The placebo and the run-in 
product consisted of 250 g of water. By adding titaniumoxide, xanthan and pectin, the 
appearance of the placebo product was comparable to the other test products. No BP 
effects have been described for these additives. Products were provided in 
nontransparent cups and lids. Office BP was measured three times with an oscillometric 
automatic device (OMRON HEM-907) following an overnight fast and after 15 min of rest. 
The mean of the second and third measurement was used for statistics. Office BP was 
measured at 2 days at baseline (week 0) and at the end of the intervention (week 8), 
and once at week 2, week 4, and after 2 weeks of wash-out. Twenty-four hours 
ambulatory blood pressure (24 h ABP) was measured once at baseline and at week 8 
using an oscillometric automatic device (Spacelab monitor type 90217). Body weight and 
24 h urinary sodium and potassium excretion were measured at baseline and week 8. 
The primary outcome of this study was the reduction in SBP. Secondary outcomes 
included DBP and 24 h ABP. The target sample size of 40 subjects per treatment group 
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was estimated to provide 80% power and  = 0.05 (one-sided) to detect a reduction in 
SBP of 5 mmHg. Data are expressed as mean  SEM. Analyses were performed using 
analysis of variance. To compare differences between groups, the Tukey multiple 
comparison method was used. A total of 124 subjects completed the study. Data of nine 
subjects were excluded (use of medication interfering with BP (n = 5), the uptake of the 
product (n = 1), arrhythmia (n = 1) and other (n = 2)). Baseline characteristics (BP 
levels, body weight and urinary excretion levels) were comparable in each of the groups. 
After 8 weeks, office SBP decreased by 4.6 ± 1.4 (high-K combination), 4.5 ± 1.4 (low-K 
combination) and 5.1 ± 1.4mm Hg (placebo). These changes were not significantly 
different between the groups. The decrease in office DBP, pulse pressure (PP), 24 h SBP, 
24 h DBP and HR were not significantly different either (for more information about office 
DBP and PP data see Table 1). Office BP levels after 2 weeks of wash-out did not change 
significantly when compared to values at week 8. Body weight showed an increase in the 
intervention groups compared to baseline, while it showed a decrease in the placebo 
group. There was, however, no interaction between weight change and intervention 
group on BP changes. At the end of treatment, sodium excretion increased somewhat in 
the high-K combination group and urinary potassium excretion increased during 
treatment, depending on the potassium content in the product.  
 
Table 1 Office SBP, DBP and PP (mean ± SEM). 
 Placebo High-K combination Low-K combination 
Office SBP    
Week 0 143.1 ± 1.4 145.4 ± 1.8 144.2 ± 1.8 
Week 8 139.4 ± 1.8 141.5 ± 1.7 140.4 ± 1.7 
Office DBP    
Week 0 84.9 ± 1.2 85.4 ± 1.6 87.8 ± 1.2 
Week 8 83.0 ± 1.4 84.0 ± 1.3 86.9 ± 1.2 
PP    
Week 0 58.3 ± 1.4 60.0 ± 1.7 56.5 ± 1.5 
Week 8 56.4 ± 1.3 57.5 ± 1.6 53.5 ± 1.2 
Abbreviations: DBP, diastolic blood pressure; PP, pulse pressure; SBP, systolic blood pressure. 
 
The results found in the present study are in contrast with many studies addressing 
interventions with the individual components. One explanation for this may be that the 
amount of minerals and vitamins in the intervention products used in this study is 
smaller than the amounts usually tested.2,8–10 Studies exploring the effect of 
combinations of minerals or vitamins on BP, hypothesized that the reductions would be 
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greater than the effect reported in studies of each mineral/vitamin alone.3–7 However, 
although most of these studies have shown a decrease in BP, they did not find a clear 
additive or synergistic effect of the nutrients. Notably, in two studies, in which 
supplements of combinations of minerals were given to the subjects, the effect found was 
even lower than expected from one of the minerals (that is potassium).4,5 As an 
explanation for these unexpected findings, the possibility of a counteracting effect of the 
combination of minerals on the effect of potassium on BP was mentioned.5 This 
phenomenon might have influenced the results of our study as well.  
 The results of the present study are also in contrast with the substantial effects 
found in dietary intervention studies. Several aspects might explain this difference. First, 
studies replacing complete diets not only add potentially beneficial components, but 
reduce potential negative components in the diet as well. Second, there may be other 
components in foods ‘not known’ yet to be beneficial for BP, which are unchanged in 
supplementation trials, but are higher in studies replacing (part of) a diet. Finally, 
nutrients in dietary supplements/products may not reduce BP to the same extent as 
nutrients in food because of altered bioavailability. The dairy matrix used in this study 
may be not the optimal matrix for the nutrients to show their effect. 
 The question now is whether or not to continue exploring the efficacy of mineral 
and vitamin supplements/products on BP. In the PREMIER study, the effect of the DASH 
diet was explored when subjects purchased their own food. The effect found was much 
smaller than expected. One of the explanations mentioned was that subjects in real life 
do not fully comply to the guidelines.11 This illustrates that it is hard to change 
someone’s diet and difficult to extrapolate findings from well-controlled studies and 
motivated volunteers to the population at large. Therefore, supplements or products 
containing a combination of nutrients resulting in a reasonable BP reduction in 
combination with guidelines for a healthy diet could help many people with slightly 
elevated BP levels, and may have a substantial impact on the total number of 
cardiovascular disease in Westernized societies.12  
 In conclusion, we were not able to demonstrate a BP lowering effect of a vitamin 
and mineral combination drink. Future studies should focus on assessing the effect of 
subsets of combinations of minerals and vitamins in natural matrices to get a better 
understanding of the possible antagonistic action between some of these ingredients. 
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What is known about this topic 
 Several meta-analyses and intervention studies have shown a beneficial effect of individual 
minerals and vitamins on BP. 
 Studies exploring the effect of combinations of minerals on BP could not prove clear additive or 
synergistic effects. The same counts for studies exploring the effect of combinations of vitamins 
on BP whereas dietary intervention studies did find substantial BP lowering results, for 
example, the DASH diet. 
 The effect of a dairy product enriched in vitamins and minerals on BP has not been tested 
before. 
 
What this study adds 
 In this randomized double-blind placebo-controlled parallel study, we did not find a BP lowering 
effect of a dairy drink containing an additional amount of potassium, calcium, magnesium, 
selenium and the vitamins C and E.  
 The results of this study confirm the discrepancy in results between dietary intervention studies 
and intervention studies with a combination of minerals or vitamins and do not suggest an 
additive BP effect of combinations of vitamins and/or minerals. 
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Abstract 
 
Background: Dietary factors directly influence blood pressure (BP). The lactotripeptides 
(LTPs) IPP (isoleucine-proline-proline) and VPP (valine-proline-proline), formed by 
hydrolyzing dairy proteins, and potassium, a mineral mainly found in fruit, vegetables, 
and dairy products, are extensively studied for their BP-lowering effect. The efficacy of 
LTPs seems modest in whites compared with that in Asians. 
Objective: The objective was to study the effects of enzymatically produced LTPs alone or 
in combination with potassium on ambulatory BP in whites. 
Design: Two multicenter, placebo-controlled, randomized, crossover studies were 
conducted; each consisted of two 4-wk intervention periods separated by a 4-wk 
washout period. In study 1, 69 subjects received 200 g/d of a dairy drink with 5.8 mg 
IPP and 4.4 mg VPP or placebo. In study 2, 93 subjects received 100 g/d of a dairy drink 
with 2.7 mg IPP, 1.9 mg VPP, and 350 mg added potassium or placebo. The subjects 
were randomly assigned according to their daytime ambulatory BP. 
Results: Mean 24-h systolic and diastolic BP (baseline values - study 1: 137.1/81.6 
mmHg; study 2: 139.2/80.9 mmHg) remained similar with no significant differences 
between treatments in either study (P > 0.10). Office BP decreased over the course of 
both studies (systolic BP > 5 mmHg), but differences between interventions were not 
significant (P > 0.10). In both studies, nighttime BP dipped during all treatments (≥15%) 
but was statistically more significant with placebo (P < 0.05). Sodium excretion increased 
significantly after consumption of LTPs and potassium compared with after placebo 
intervention (P = 0.01), but not after consumption of LTPs alone. 
Conclusion: The data do not support a BP-lowering effect of LTPs in whites. 
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Introduction  
 
Elevated blood pressure (BP) is an important public health challenge because of its high 
prevalence worldwide1, poor treatment and control rate2, and consistent relation with the 
risk of cardiovascular disease.3 Health authorities recommend adoption of a healthy diet 
and lifestyle for persons with a high normal BP and for patients who require drug 
treatment.3,4 Dietary and lifestyle factors can directly influence BP, particularly a diet rich 
in fruit and vegetables and in low-fat dairy products, as was shown in the Dietary 
Approaches to Stop Hypertension (DASH) Study.5 Furthermore a considerable number of 
human studies have addressed the BP-lowering effect of individual nutrients. Peptides, 
particularly the milk-derived lactotripeptides (LTPs) IPP (isoleucine-proline-proline) and 
VPP (valine-proline-proline), and potassium, a mineral mainly found in fruit, vegetables, 
and dairy products, have been extensively studied for their BP-lowering effect.  
 Several meta-analyses of >30 intervention studies have shown significant BP-
lowering effects of potassium supplementation at relatively high doses.6-9 Most studies 
that examined the effect of IPP and VPP have also reported significant decreases in BP, 
although the reported magnitude of the effect varies considerably between data derived 
from Asian10-19 and white20-26 populations.  
 Two recent meta-analyses provided evidence of a significant effect of peptides on 
BP.27,28 The meta-analysis by Pripp28 included intervention studies on both IPP and VPP 
and other peptides derived from food proteins, and found a significant pooled effect on 
systolic BP (SBP) of -5.1 mmHg and on diastolic BP (DBP) of -2.4 mmHg. A second meta-
analysis by Xu et al.27, which only included IPP and VPP intervention studies, also found a 
significant effect on SBP of -4.8 mmHg and on DBP of -2.2 mmHg. Recently, several new 
IPP and VPP intervention studies were published, most of which found no significant BP-
lowering effect.20,22,25,26 These studies were not included in the meta-analyses; thus, it is 
likely that findings from these meta-analyses overestimated the true underlying effect.  
 LTPs can be produced by 2 processes: fermentation and enzymatic hydrolysis. In 
fermented milk, IPP, VPP, and many other dairy peptides are produced from milk casein 
by the complex proteolytic activity of lactic acid bacteria. Enzymatic LTPs are formed by 
enzymatic hydrolysis of dairy protein (milk casein) by a single protease. Enzymatic LTPs 
have a less complex peptide breakdown pattern than does fermented LTP.  
 To further investigate the BP-lowering effect of IPP and VPP, we studied the effect 
of enzymatic LTPs on BP in a white population and performed 2 multicenter, randomized, 
double-blind, placebo controlled, crossover studies with two 4-wk intervention periods 
separated by a 4-wk washout period. In total, 162 Scottish subjects not receiving 
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antihypertensive treatment were included. We used ambulatory BP as the primary 
outcome measure to improve the precision of the BP values and to be able to detect any 
possible transient effects. In study 1, the effect of 5.8 mg IPP and 4.4 mg VPP was 
tested. In study 2, the effect of 2.7 mg IPP, 1.9 mg VPP, and 350 mg added potassium - 
similar to the level in one serving of fruit, vegetables, or a dairy product - was tested. 
 
 
Materials and methods 
 
Subjects 
The studies were performed subsequently at 9 general practitioner sites located in 
Scotland. The Contract Research Organization (CRO; Quintiles Ltd, Bracknell, United 
Kingdom) was responsible for the management of both studies. The subjects were 
screened between November 2005 and April 2006. Subjects with untreated elevated BP 
were recruited in collaboration with general practitioners and qualified for inclusion in the 
studies if they were white and between 35 and 70 y of age. To minimize the risk of 
misclassification of a person’s BP, office BP (inclusion criteria: SBP > 135 mmHg) and 
mean daytime (0900–2100) ambulatory BP (inclusion criteria: SBP 130–160 mmHg, DBP 
<100 mmHg) were measured at prescreening and at screening. In both studies, subjects 
were excluded if they had a body mass index (in kg/m2) <18 or >32, used protein 
supplements during the study or <4 wk before the study, had a recorded history of 
cardiovascular disease or other medical conditions, or had lifestyle habits that could 
influence the primary outcome of the studies. 
 All participants received both written and oral information and gave their written 
consent. Written approval for the studies was obtained from the Multicentre Research 
Ethics Committee (study 1: Central Manchester Local Research Ethics Committee, South 
Manchester, United Kingdom; study 2: West Glasgow Research Ethics Committee, 
Glasgow, United Kingdom). The studies were executed in accordance with Good Clinical 
Practice policy, according to the principles of the Declaration of Helsinki, revision 2000. 
 
Design 
The 2 studies had a double-blind, multicenter, placebo controlled, randomized full-
crossover design and involved 2 treatments and two 4-wk intervention periods separated 
by a 4-wk washout period. Thus, each subject participated for 12 wk in the study. The 
studies were designed to compare the BP-lowering effect of a dairy product with LTPs 
and a dairy product with LTPs and enriched in potassium with that of a placebo product in 
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subjects with elevated BP. The recruited subjects were randomly assigned according to 
their daytime (0900–2100) ambulatory BP values, which were obtained at baseline. The 
subjects then consumed the active or placebo product for 4 wk. The treatments were 
crossed over after the washout and continued in the study for another 4 wk (Figure 1). 
 
Test products 
The test products were ready-to-drink yogurt drinks. The active products and placebo 
products used in the studies were similar in appearance, color, taste, and smell and were 
provided in nontransparent white cups that differed only in terms of the coding on the 
bottles. All products were provided by Unilever (Vlaardingen, Netherlands). The products 
were made from pasteurized semiskim milk that was acidified with a standard yogurt 
strain to produce a yogurt drink. The active substance was LTPs obtained by enzymatic 
hydrolysis of sodium caseinate. After hydrolysis, the powder was produced by spray-
drying. This powder was added to the yogurt. The extra protein content achieved by 
adding hydrolyzed casein in the active product was corrected for in the placebo product 
by adding whey-protein isolate. Pectin for stability and sugar, fruit puree, and flavoring 
for taste were added. The dairy products contained naturally present potassium (150 
mg/100 g). The active product used in study 2 was enriched with food-grade potassium 
gluconate, which provided 350 mg K. The nutritional composition of the products is 
shown in Table 1. In study 1, the subjects randomly received a daily dose of 200 g of 
dairy drink with 5.8 mg IPP and 4.4 mg VPP or placebo. In study 2, the subjects 
randomly received a daily dose of 100 g of dairy drink with 2.7 mg IPP and 1.9 mg VPP 
enriched with potassium (350 mg) or placebo. To assess compliance, the subjects were 
asked to return used and unused cups of the test products. The research staff and 
subjects remained blinded to the type of treatment during the study.  
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Table 1 Nutrient Composition of the test products per 100 g of Dairy Drink.1 
Study 12 Study 23 Product 
LTP  Placebo LTP + 
potassium  
Placebo 
Energy (kcal) 81 ( 162) 82 (164) 85 (85) 85 (85) 
Protein (g) 3.7 (7.4) 3.4 (6.8) 3.5 (3.5) 3.6 (3.6) 
Carbohydrates (g) 13.0 (26.0) 12.2 (24.4) 13.5 (13.5) 13.1 (13.1) 
Fat (g) 0.6 (1.2) 0.6 (1.2) 0.6 (0.6) 0.7 (0.7) 
Calcium (mg) 97 (194) 91 (182) 93 (93) 97 (97) 
Sodium (mg) 57 (114) 38 (76) 58 (58) 39 (39) 
Potassium (mg) 142 (284) 140 (280) 471 (471) 138 (138) 
Magnesium (mg) 9 (18) 9 (18) 9 (9) 10 (10) 
LTP     
IPP (mg) 2.9 (5.8)  --- 2.7 (2.7)   --- 
VPP (mg) 2.2 (4.4)    --- 1.9 (1.9)  --- 
1 Daily dose of the product is in parentheses. LTP, lactotripeptides; IPP, Isoleucine-Proline-Proline; 
VPP, Valine-Proline-Proline. 2 Treatment: 200 g of dairy drink/d. 3 Treatment: 100 g of dairy 
drink/d. 
 
Diet 
For the duration of the studies, the subjects were asked to maintain their normal diet and 
lifestyle, except that the subjects were instructed to not consume protein supplements. 
On the measurement days, the subjects were asked to refrain from strenuous exercise 
and to refrain from consuming specific fermented foods (eg, meat, fish and soy products, 
and foods containing licorice). The subjects were asked to consume fermented milk 
products and alcoholic beverages as accustomed to, but not to vary more than one 
volume unit between the visit days. Furthermore, the subjects were asked to fast and 
consume only water from 2200 onward on the evening before a visit day and were 
instructed to eat breakfast and consume the test products daily in the morning with 
breakfast and standardized between 2.5 and 3 h before the office BP measurement. On a 
visit day, no food or drink (except for water) was allowed after breakfast until after the 
office BP was measured. The subjects were asked to eat, on all subsequent visit days, 
exactly the same breakfast that they had consumed on the day of visit 1. Because of a 
possible BP effect of caffeine, each subject was asked to consume no more than one 
caffeinated beverage as part of his or her breakfast. 
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Blood pressure measurements 
At baseline and after both intervention periods, the subject’s 24-h ambulatory BP was 
measured (study 1: monitor A/A type Spacelabs 90217; Spacelabs Medical, Issaquah, 
WA; study 2: monitor A/A type TM-2430; A&D Company Ltd, Tokyo, Japan). The monitor 
was programmed to take readings on the nondominant arm every 20 min during the day 
and every hour during the night for a length of ≥25 h. The values obtained from the first 
hour were discarded. The subjects were instructed on how to operate the monitor and 
were asked to refrain from any strenuous activity. The subjects were asked to sit down if 
possible or stand still and relax their arms during the readings. Other than refraining 
from strenuous activity and avoiding the consumption of particular standardized food 
products, the subjects were instructed to maintain their usual lifestyle habits. The 
ambulatory BP measurement was automatically repeated if the measurement was not 
successful (eg, if the monitor malfunctioned or if the subject moved his or her arm during 
the assessment). It was preferable that all 24-h ambulatory BP measurements per 
subject were made on the same day of the week during the study. Daytime (0900–
2100), nighttime (0000–0600), and the first 2 h after consumption of the product 
ambulatory BP were derived from the 24-h ambulatory BP measurements. 
 At baseline, after both intervention periods and after the washout period, office BP 
was measured on the subject’s dominant arm on each visit. The subjects were asked to 
rest for 15 min; an automatic arm cuff (monitor A/A type Omron HEM 907; Omron 
Healthcare Europe BV, Hoofddorp, Netherlands) was fitted to obtain 6 successive 
measurements of office BP. When possible, the same monitor was used for each subject 
during the study. If an error occurred during any of the first 6 measurements of office 
BP, additional measurements were made. The mean of the last 4 successful 
measurements was calculated and used in the studies. For all subjects, measurements 
were made at a fixed time point during the day, preferably 2.5–3 h after consumption of 
the product. Measurements were performed between 0900 and 1300 on weekdays to 
reduce variability. 
 
Additional measurements 
Body weight was measured at baseline, after both intervention periods and after the 
washout period. The subjects were weighed after voiding and while not wearing shoes. 
Well-being was measured on a 5-point scale (1 = excellent and 5 = very poor) at 
baseline, after both the intervention periods and after the washout period. Safety 
indicators (measures of liver function, kidney function, and hematology) were analyzed in 
blood collected at baseline and after the last intervention period into a 4-mL EDTA 
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containing tube, an 8-mL clotting tube, and a 2-mL NaF containing tube. The subjects 
were asked to collect 24-h urine samples at baseline, after both intervention periods, and 
after the washout period. The urine was weighed, and the volume was measured. Urinary 
sodium, potassium, creatinine and, albumin concentrations were measured on a Roche 
Modular instrument (Hoffman La-Roche, Basel, Switzerland). The Roche ISE indirect 
method was used to measure sodium and potassium, the Roche Jaffe Kinetic Colormetric 
assay for creatinine, and the Roche BCG method for albumin.  
 All adverse events (AEs) experienced during the study were reported on a clinical 
report form. The intensity of the AE was graded on a 3-point scale (mild, moderate, or 
severe) and was reported in detail on the clinical report form. The relation of the adverse 
event to the treatment was also assessed by the investigator. 
 
Statistical analysis 
Raw data were collected by electronic data capture entry, and the resulting spreadsheets 
were archived at the Contract Research Organization; 100% of the inclusion and 
exclusion criteria and main outcome variables were verified, and 10% of all other data 
were verified. The treatment codes were broken after the blind data analysis.  
 Two statistical analyses were performed based on the intention-to-treat (ITT) 
population and on the per protocol population. The ITT population (primary population) 
consisted of all subjects who had been randomly assigned for treatment and had received 
at least one dose of the study product. Decisions about which subjects were to be 
excluded from the per protocol population were made during 2 data review meetings 
before deblinding of the data.  
 The values reported in text and tables are least-squares means ± SEMs based on 
the ITT population, except for baseline data, which are reported as means ± SD. Mixed 
linear models (analysis of covariance) were used to compare the differences between 
treatments. This procedure corrected for the imbalance between groups and missing 
values and was used to test the period effect and the carryover effect. The following 
variables were included in the models: treatment, period, and interaction. The following 
covariates were included as continuous variables and random effects and were left in the 
model if the variables were shown to have a significant effect: baseline BP value, age, 
sex, and weight change during the study. The absolute values for 24-h ambulatory BP 
and office SBP and DBP were statistically evaluated for differences between the active 
period and the placebo period within each subject.  
 Results of the power calculation showed that, for each crossover study, 48 
subjects should have been sufficient to detect a change in SBP of 3 mmHg with a power 
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of 0.9 and one-sided  = 0.05. The analyses were performed by using SAS software 
(version 9.1.3; SAS Institute, Cary, NC).  
 
 
Results 
 
Subjects and compliance 
A total of 263 subjects underwent screening for ambulatory BP, and 162 subjects were 
enrolled in the 2 studies: 69 subjects were randomly assigned to treatment in study 1 
and 93 to treatment in study 2. Study 1 was completed by 64 subjects (1 person was 
excluded because of an abnormal laboratory results, 4 persons withdrew consent, and 2 
persons were excluded because they could not comply with the visit schedule). Study 2 
was completed by 91 subjects (1 person was excluded because of lymphedema, and 1 
person was excluded because they did not tolerate the intervention product). The 
number of subjects screened and randomized overall and per study is shown in Figure 1. 
Treatment compliance was excellent. In both studies >95% of the drinks were consumed 
as indicated by the number of (empty) bottles returned. Scores for well-being were high 
at baseline and remained high throughout the studies (mean: < 2). Both Scottish study 
populations consisted of slightly overweight and older men and women with untreated 
elevated BP (Table 2). 
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Figure 1 Flow chart and design of the two double-blind, randomized, placebo-controlled 
cross-over studies in 162 Scottish subjects with untreated elevated blood pressure. LTP, 
lactotripeptides; BP, blood pressure. 
Recruitment and randomization according to daytime (0900-2100) 
ambulatory BP values 
N (screened) = 263, N (randomized) = 162 
Study 1: 14 mg LTP 
 
N (randomized) = 69  
Study 2: 7 mg LTP, 350 mg added 
potassium  
N (randomized) = 93 
Intervention  
N = 31 
Placebo 
N = 38 
Intervention  
N = 45 
Placebo 
N = 48 
Placebo  
N = 30 
Intervention  
N = 34 
Placebo  
N = 44  
Intervention  
N = 47 
Wash-out 
period 
4 weeks 
Second 
intervention 
period  
4 weeks  
First 
intervention 
period  
4 weeks  
Chapter 5 
Lactotripeptides and blood pressure 
 
 
93 
Table 2 Baseline characteristics of the participants in study 1 and study 2.1 
 Study 1  Study 2 
No. of subjects (male/female)   69 (45/24)   93 (47/46) 
Age (y)   61.7 ± 6.72   61.1 ± 7.0 
Weight (kg)   78.8 ± 14.1   78.7 ± 14.4 
Height (cm) 170.7 ± 8.8 170.4 ± 10.3 
BMI (kg/m2)   26.9 ± 3.2   26.9 ± 3.0 
Ambulatory blood pressure (mmHg) 
- 24-h SBP 
- 24-h DBP 
- HR (beats/min) 
 
137.1 ± 8.1 
  81.6 ± 6.6 
  75.0 ± 9.7 
 
139.2 ± 7.8 
  80.9 ± 6.4 
  73.1 ± 8.9 
Office blood pressure (mmHg) 
- SBP 
- DBP 
 
147.4 ± 9.0 
  89.0 ± 5.9 
 
144.9 ± 8.3 
   87.0 ± 6.4 
Urinary excretion (mmol/24h) 
- Sodium 
- Potassium 
 
131.8 ± 52.1 
  75.2 ± 27.9 
 
119.1 ± 47.7 
  67.3 ± 20.5 
1 BP, blood pressure; SBP, systolic blood pressure; DBP, diastolic blood pressure.  
2 Mean ± SD (all such values). 
 
Blood pressure results 
In study 1, no significant differences in 24-h SBP/DBP were found between treatments 
(LTPs compared with placebo) after 4 wk of intervention. Also, daytime SBP/DBP, 
nighttime DBP, and SBP/DBP 2 h after intake did not change significantly, except for 
nighttime SBP, for which the decrease was less pronounced after the LTP treatment than 
after placebo (Table 3). In study 2 also, 24-h SBP/DBP, daytime SBP/DBP, nighttime 
DBP, and SBP/DBP 2 h after intake did not change significantly between treatments (LTPs 
plus potassium compared with placebo) after 4 wk of intervention. Again, nighttime SBP 
decreased significantly less after the LTPs plus potassium treatment than after placebo 
(Table 4). In both studies, nighttime BP decreased by ≥15% after each treatment. In 
contrast with 24-h ambulatory BP, office BP decreased during both studies (SBP >5 
mmHg), regardless of the intervention. In both studies, heart rate did not change 
significantly during the intervention, and no significant differences were found between 
treatments (LTPs compared with placebo) after 4 wk of intervention. Also, no carryover 
effects were found for the primary outcome models with covariates, except for a 
significant carryover effect in study 1 for nighttime ambulatory DBP (P = 0.001). Similar 
results were obtained in both studies in the per protocol analysis and when the covariates 
were not included (data not shown). Post hoc analysis of daytime BP during the first 4, 8, 
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and 12 h after consumption of the enzymatic LTP-containing drink showed no immediate 
and/or transient BP-lowering effects (data not shown). 
 
Table 3 Study 1: Ambulatory blood pressure (BP), office BP, and heart rate after 4 wk of 
intervention with the placebo drink or the lactotripeptides (LTP) dairy drink.1 
 Placebo 
(n = 68 )  
LTP2 
(n = 65) 
Difference 
(95% CI) 
P value3 
24-h Ambulatory BP (mmHg) 
- SBP 
- DBP 
- Heart rate (beats/min) 
Daytime (0900-2100) BP (mmHg) 
- SBP 
- DBP 
Night-time (0000-0600) BP (mmHg) 
- SBP 
- DBP 
2-hour after intake (mmHg) 
- SBP 
- DBP 
Office BP (mmHg) 
- SBP 
- DBP 
 
135.8 ± 0.94 
  79.9 ± 0.6 
  74.6 ± 0.8 
 
141.0 ± 1.0 
  83.1 ± 0.6 
 
114.5 ± 1.2 
  67.0 ± 0.7 
 
137.6 ± 1.6 
  81.5 ± 1.2  
 
142.3 ± 1.0 
  86.2 ± 0.8 
 
136.4 ± 0.9 
  80.2 ± 0.6 
  75.0 ± 0.8 
 
141.2 ± 1.0 
  83.3 ± 0.6 
 
117.7 ± 1.2 
  68.3 ± 0.7 
 
138.1 ± 1.6 
  82.2 ± 1.2 
 
142.3 ± 1.0 
  85.7 ± 0.9 
 
0.6 (-1.4;2.7) 
0.3 (-0.9;1.5) 
0.4 (-1.4;2.2) 
 
0.2 (-2.2;2.6) 
0.2 (-1.2;1.6) 
 
3.2 (0.3;6.1) 
1.2 (-0.8;3.3) 
 
0.5 (-3.1;4.0) 
0.7 (-1.6;3.0) 
 
0.0 (-2.4;2.4) 
-0.6 (-1.9;0.7) 
 
0.55 
0.63 
0.68 
 
0.86 
0.75 
 
0.03 
0.23 
 
0.80 
0.54 
 
0.98 
0.37 
1 SBP, systolic blood pressure; DBP, diastolic blood pressure. 2 Isoleucine-Proline-Proline and 
Valine-Proline-Proline. 3 ANCOVA, with baseline BP, age, sex and weight change as covariates. P 
values Are 2-sided. 4 Least-squares mean ± SEM (all such values). 
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Table 4 Study 2: Ambulatory blood pressure (BP), office BP, and heart rate after 4 wk of 
intervention with the placebo drink or the lactotripeptides (LTP) + potassium dairy drink.1  
 Placebo 
(n = 92) 
LTP2 + 
potassium 
(n = 92) 
Difference 
(95% CI) 
 
P value3 
24-h Ambulatory BP (mmHg) 
- SBP 
- DBP 
- Heart rate (beats/min) 
Daytime (0900-2100) BP (mmHg) 
- SBP 
- DBP 
Night-time (0000-0600) BP mmHg) 
- SBP 
- DBP 
2-hour after intake (mmHg) 
- SBP 
- DBP 
Office BP (mmHg) 
- SBP 
- DBP 
 
138.0 ± 1.04 
  80.7 ± 0.6 
  73.7 ± 0.7 
 
141.3 ± 1.1 
  82.8 ± 0.6 
 
115.7 ± 1.5 
  67.6 ± 1.1 
 
138.5 ± 1.8 
  80.0 ± 1.6 
 
135.6 ± 0.8 
83.4 ± 0.7 
 
137.1 ± 1.0 
  80.8 ± 0.6 
  74.4 ± 0.7 
 
140.3 ± 1.1 
  83.0 ± 0.7 
 
119.8 ± 1.4 
  68.3 ± 1.1 
 
140.1 ± 1.7 
  83.3 ± 1.5 
 
134.7 ± 0.9 
82.3 ± 0.8 
 
-0.9 (-3.0;1.3) 
0.1 (-1.4;1.6) 
0.8 (-1.2;2.7) 
 
-1.0 (-3.5;1.5) 
0.3 (-1.4;1.9) 
 
4.1 (0.7;7.6) 
0.7 (-2.0;3.3) 
 
1.5 (-3.0;6.1) 
3.3 (-1.0;7.6) 
 
-1.0 (-3.4;1.5) 
-1.1 (-2.6;0.3) 
 
0.42 
0.89 
0.44 
 
0.43 
0.74 
 
0.02 
0.60 
 
0.50 
0.13 
 
0.43 
0.12 
1 SBP, systolic blood pressure; DBP, diastolic blood pressure. 2 Isoleucine-Proline-Proline and 
Valine-Proline-Proline. 3 ANCOVA, with baseline BP, age, sex and weight change as covariates. P 
values are 2-sided. 4 Least-squares mean ± SEM (all such values). 
 
Other outcomes 
Weight did not change significantly between the different treatment groups in the 2 
studies. Also, no significant changes in urinary albumin, creatinine, and potassium were 
found between the treatment periods in both studies; urinary sodium was significantly 
higher after the LTP plus potassium treatment than after placebo in study 2 (Table 5).  
 In study 1, 44 subjects experienced a total of 81 AEs, which were determined not 
to be related to treatment. Most of the AEs were mild, and all subjects recovered. The 3 
most frequent AEs were acute nasopharyngitis (n = 14), joint pain (n = 4), and dizziness 
and giddiness (n = 4). Two serious AEs (SAEs) were experienced, both of which lasted 
for 1 d and were determined not to be related to treatment; the subjects recovered from 
both SAEs. In study 2, 55 subjects experienced 101 AEs, which were determined not to 
be related to treatment. Most AEs were mild and all subjects recovered. The 4 most 
frequent AEs were hay fever (n = 8), head cold (n = 8), headaches (n = 7), and lower 
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back pain (n = 5). One SAE was experienced, which was mild; the subject recovered, 
and the SAE was determined not to be related to the study treatment. 
 
Table 5 Studies 1 and 2: urinary excretion of sodium and potassium (mmol/24-h) and 
the ratio of sodium to potassium at the end of the intervention periods. 
Urinary excretion  
(mmol/24 h) 
Placebo  LTP1 + 
Potassium 
Difference  
(95% CI)  
P-value2 
Study 1 
- Sodium  
- Potassium  
- Sodium:potassium 
 
122.1 ± 5.73 
  73.6 ± 2.7 
    1.8 ± 0.1 
 
132.0 ± 5.7 
  74.2 ± 2.7 
    1.9 ± 0.1 
 
9.9 (-5.4;25.2) 
0.5 (-6.7;7.8) 
0.1 (0.0;0.3) 
 
0.20 
0.88 
0.26 
Study 2  
- Sodium  
- Potassium  
- Sodium:potassium  
 
115.1 ± 5.8 
  75.4 ± 3.0 
    1.6 ± 0.1 
 
132.7± 5.6 
  78.5 ± 2.9 
    1.8 ± 0.1 
 
17.6 (3.6;31.5) 
3.1 (-5.3;11.4) 
0.2 (0.0;0.3) 
 
0.01 
0.47 
0.08 
1 LTP, lactotripeptides (Isoleucine-Proline-Proline and Valine-Proline-Proline). 2 ANCOVA, with 
baseline BP, age, sex, and weight change as covariates. P values are 2-sided. 3 Least-squares 
mean ± SEM (all such values). 
 
 
Discussion 
 
The results of the present 2 multicenter crossover studies showed no antihypertensive 
effect of daily consumption of a dairy drink with enzymatic LTPs (5.8 mg IPP and 4.4 mg 
VPP) or enzymatic LTPs (2.7 mg IPP and 1.9 mg VPP) plus potassium (350 mg added) in 
a population of 162 Scottish subjects. The lack of effect on 24-h ambulatory and office BP 
confirm that whites may not benefit from LTP treatment to the extent previously reported 
for Asians. Possible explanations for the discrepant findings include differences in diet, 
genetics, or physical background between Asians and whites, such as intakes of sodium 
and fermented products, LTP dose per kilogram body weight, and baseline BP values. 
 We found a significantly greater reduction in nighttime ambulatory SBP in the 
placebo group than in the active group in both studies (P < 0.05), but no effect was 
found in the studies of nighttime ambulatory DBP. Nighttime BP values might have been 
less reliable than daytime and 24-h BP values because fewer measurements of nighttime 
BP were made every hour (from 0000 to 0600); daytime BP was measured every 20 min 
during the day (from 0900 to 2100). Whether the decrease in nighttime BP has any 
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physiologic relevance with respect to endorgan damage is unclear: during LTP treatment 
in both studies, BP still decreased by ≥15%, which is considered to be a healthy 
pattern.29 This finding requires additional research focusing on LTPs and nighttime BP.  
 In study 2, the urinary excretion of sodium increased significantly with the LTPs 
plus potassium intervention compared with the placebo. Potassium excretion did not 
change significantly in any of the studies. Therefore, the 350-mg difference in potassium 
between the intervention and placebo groups was probably too small to reliably measure 
because other factors that can influence potassium excretion can have a larger effect. 
The increase in sodium excretion in study 2 might have been due to the potassium 
content of the intervention product, which triggered greater sodium excretion.30,31 
However, per the literature, a dose of 350 mg potassium might be too small to 
demonstrate a natriuretic effect.  
 A strength of the present studies was their randomized, double blind, placebo-
controlled design. We chose to measure ambulatory BP during the screening period and 
to use this value as the primary study outcome. Studies have shown that ambulatory BP 
more accurately reflects treatment-induced decreases in BP than does office BP, because 
of a higher reproducibility over time and an absent or negligible ‘‘white coat’’ or placebo 
effect.4 We observed in both studies a continuous decrease in office BP, regardless of the 
intervention. In contrast, 24-h ambulatory BP levels remained stable during the 
intervention periods. This finding supports the importance of using ambulatory BP to 
detect small changes in BP. Furthermore ambulatory BP has shown to be a better 
predictor of cardiovascular disease risk.4 Compliance with the test product was excellent, 
and dropout rates were low. High dropout rates are considered to be one of the major 
drawbacks of a crossover design. Also, baseline characteristics, including initial BP levels, 
were similar between the treatment groups, and body weight did not change during the 
intervention periods in either study. No carryover effects were observed in any of the 
models with covariates, except for a significant carryover effect in study 1 for nighttime 
ambulatory DBP (P = 0.001). 
 A limitation of the present studies was the relatively short intervention period (4 
wk). Although previous studies of LTPs observed BP changes after intervention periods as 
short as 1 or 2 wk, many showed significant effects on BP after 4- or 8-wk intervention 
periods. Furthermore, the doses of LTPs (2.7 mg IPP and 1.9 mg VPP/d) and potassium 
(350 mg added/d) in study 2 were chosen based on a hypothesized additive or 
synergistic effect of the combination of LTPs and potassium. However, on the basis of the 
results in study 1 (5.8 mg IPP and 4.4 mg VPP/d), it is unlikely that LTPs contributed to 
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an effect on BP in study 2. Therefore, the current design of study 2 may not have been 
sufficiently powered to detect BP changes due to a solely small increase in potassium 
intake (Table 4). A higher level of potassium, similar to 3 servings of good food sources 
of potassium (approximately 1 g/d) and proven to reduce BP in intervention studies32,33, 
would have been a more appropriate amount to test. 
 In conclusion, we were unable to show a BP-lowering effect in whites after daily 
consumption of enzymatic LTPs (5.8 mg IPP and 4.4 mg VPP) or enzymatic LTPs (2.7 mg 
IPP and 1.9 mg VPP) with an additional amount of potassium (350 mg) using ambulatory 
BP as the primary outcome. The data do not support a BP-lowering effect of LTPs in 
whites. 
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Abstract  
 
Data suggest that polyphenol-rich products may improve endothelial function and other 
cardiovascular health risk factors. Grape and wine contain high amounts of polyphenols, 
but effects of these polyphenols have hardly been investigated in isolation in randomized 
controlled studies. The objective of this study was to test the chronic effect of polyphenol 
rich solids either derived from a wine-grape mix or grape seed on flow-mediated dilation 
(FMD). Blood pressure (BP) and other vascular function measures, platelet function and 
blood lipids were secondary outcomes. 35 healthy males were randomized in a double-
blind, placebo-controlled crossover study, consisting of three 2-wk intervention periods 
separated by 1-wk washout periods. The test products, containing 800 mg of polyphenols, 
were consumed as capsules. At the end of each intervention period, effects were 
measured after consumption of a low fat breakfast (on average 751 kJ, 25% fat) and a 
high fat lunch (on average 3136 kJ, 78% fat). After the low fat breakfast the treatments 
did not significantly affect FMD. The absolute difference after wine-grape solids was -
0.4% (95% CI -1.8 to 0.9; P = 0.77) and after grape seed solids 0.2% (-1.2 to 1.5; P = 
0.94) compared to after the placebo treatment. FMD effects after the high fat lunch and 
effects on secondary outcomes showed also no consistent differences between grape 
solids and placebo treatment. In conclusion, consumption of grape polyphenols has no 
major impact on FMD in healthy men. Future studies should address whether grape 
polyphenols can improve FMD and other cardiovascular health risk factors in populations 
with increased cardiovascular risk. 
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Introduction 
 
Endothelial function has predictive value for future cardiovascular events.1-6 Non-invasive 
flow-mediated dilation (FMD) is a frequently used method to assess endothelial function 
in humans.7,8 FMD is the difference in brachial artery diameter measured by ultrasound 
before and after a period of induced ischemia of the forearm by inflation of a blood 
pressure (BP) cuff. FMD is expressed as the percentage increase in brachial artery 
diameter after release of the BP cuff. As the dilation is mediated by nitric oxide, FMD is 
thought to reflect the bioavailability of nitric oxide.7 
 Evidence for a role of dietary flavonoids in the prevention of cardiovascular 
diseases (CVD) from epidemiologic and intervention studies is increasing.9,10 
Consumption of red wine has been proposed as explanation of the “French paradox” of 
relatively low coronary heart disease mortality rates in France, despite high intake of 
saturated fat.10-12 This association has been attributed mainly to the high levels of grape 
polyphenols in the wine, although other wine constituents and ethanol could also have 
beneficial effects.13 In vitro data suggest that red wine and its constituents induce 
vasodilatation by increasing production of nitric oxide. Furthermore, although several 
studies investigated the acute effects on endothelial function of red wine and other grape 
products in humans14, evidence from randomized controlled intervention studies is still 
limited.9,10,15 In addition, most studies have been performed in participants with elevated 
CVD risk14,16-23, rather than in healthy participants and in the majority of studies the 
contribution of grape polyphenols to the observed effects has not been addressed.14 
 The objective of our study was to assess the effect of polyphenol rich grape solids 
on endothelial function and other cardiovascular health markers in healthy participants. 
To that end, we conducted a placebo-controlled, double-blind crossover study to measure 
whether daily intake of polyphenol rich solids either derived from a wine-grape mix or 
grape seed, provided at a dose of 800 mg of polyphenols, would affect responses on 
endothelial function and other CVD risk markers compared to placebo after 2 wk 
intervention. The wine-grape mix represents a product with a broad range of polyphenols 
(monomeric anthocyanins, catechins, flavonols, procyanidins and stillbenes and 
unidentified oligomers and polymers), while the grape seed primarily consists of 
monomeric catechins and unidentified oligomers and polymers.24 Both the red wine 
(ProvinolsTM) and the grape seed (LeucoselectTM) solids have been shown to affect 
vascular function in animals studies.25,26 We studied effects after a low fat breakfast and 
after a high fat lunch as it has been suggested that red wine might counteract endothelial 
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dysfunction caused by a vascular function stressor, such as cigarette smoking or a high-
fat meal.14,19,27-29 
 
 
Methods  
 
Participants 
35 Apparently healthy males, aged between 18 and 45 y were recruited. Participants 
were not included if they reported current or previous metabolic diseases, 
gastrointestinal disorders, or CVD, had a body mass index (in kg/m2) <18 or >32, had 
blood markers (WBC, RBC, haemoglobin, haematocrit and platelet count), plasma liver 
enzymes (ALAT, ASAT and -GT), BP (systolic BP ≥160 mmHg and/or diastolic BP ≥95 
mmHg), fasting blood lipids in serum (total cholesterol >8 mmol/L, total cholesterol/HDL 
cholesterol ratio >8 and triglycerides >4 mmol/L), urinary protein and glucose markers 
outside normal reference range and/or lifestyle habits that could influence the primary 
outcome of the studies. All participants received both written and oral information about 
the study and gave their written consent. The study took place from November-
December 2003 at Unilever Research and Development Vlaardingen, the Netherlands. 
The protocol was approved by the Medical Ethics Committee of Wageningen University, 
the Netherlands.  
 
Design and randomization procedure 
The study had a double-blind, placebo-controlled randomized full crossover design with a 
three days run-in period, 3 two wk intervention- and 2 one wk washout periods. 
Participants were randomly divided over the 3 treatment orders according to a complete 
balanced design.30 The 3 treatments consisted of two different grape solids and a 
placebo. Measurements were performed following the run-in period (baseline 
assessment), and at the end of each of the intervention periods. The effect of the 
treatment under basal conditions and after a fat-load was investigated by measurements 
after a low fat breakfast and 3 hours after a high fat lunch, and these responses were 
compared to the placebo response (Supplemental Figure 1). Staff and participants 
remained blinded toward the type of treatment during the study and data analysis. 
 
Test products 
The placebo and grape solids (wine-grape and grape seed) were consumed in 6 capsules 
per d each of 500 mg. The placebo capsules contained micro-crystalline cellulose. The 
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total polyphenol content of both grape solids in the 6 daily capsules was 800 mg, 
according to gallic acid equivalents; 1405 mg of the wine-grape solids contained 550 mg 
polyphenols of Provinols™ (Seppic, France), and 250 mg polyphenols of MegaNaturalTM 
Rubired grape juice (Polyphenolics, US); 2547 mg of the grape seed solids contained 800 
mg polyphenols of LeucoselectTM Phytosome (Indena, Italy). 
 Identification by HPLC analysis of monomeric polyphenols revealed that the 550 
mg of wine solids contained 18.8 mg anthocyanins, 6.9 mg phenolic acids, 4.0 mg 
catechins, 0.4 mg flavonols and 0.1 mg stilbenes and that 250 mg of grape juice 
contained 118.5 mg anthocyanins, 2.7 mg phenolic acids, 0.2 mg catechins, 0.5 mg 
flavonols and 0.1 mg stilbenes. However, the majority of polyphenols in these solids are 
oligomers and polymers that could not be identified by this analysis. According to 
analysis by Gabetta et al.31 the polyphenolic profile of the grape seed consists of 
approximately 15% (+)-catechin and (-)-epicatechin and 85% (-)-epicatechin 3-O-
gallate and unidentified oligomers and polymers.  
 During the 2-wk treatment periods, volunteers consumed daily three capsules 
with breakfast and three with dinner. On the test day after each treatment period, 
participants ingested three capsules with a low fat breakfast and three capsules with a 
high fat lunch. To assess compliance, participants were asked to register their intake of 
the capsules on each day in the intervention period.  
 
Background diet and test meals 
Volunteers were asked to refrain from vitamin supplementation as from the day of the 
screening till the end of the study. On the days prior to a test day standardized meals 
were provided to the participants. On the day prior to the test day participants were 
asked to avoid eating fruit, drinks high in fruit, apple-sauce and alcoholic drinks, 
chocolate and to limit their intake of tea to two cups. To assess compliance, participants 
were asked to record their food intake on the day prior to the first test day, and were 
requested to follow a similar dietary pattern on the day prior to the 3 remaining test 
days.  
 To start a test day in a fasting state, participants had to refrain from foods for 10 
hours and drinks for 8 hours, except (mineral) water. During the test days all foods and 
drinks were provided, including breakfast (water and max 2 sandwiches with low energy 
filling, 410-1092 kJ, fat 1-9 g, protein 2-15 g, carbohydrates 16-32 g per d), and all 
products were low in antioxidants, flavonoids, fat, glucose and caffeine. The high fat 
lunch was similar to the low fat breakfast, but consumed together with 143 mL liquid 
whipping cream (2385 kJ, fat 61 g, protein 3 g, carbohydrates 4 g). 
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Measurements  
BP was assessed at the left arm by a calibrated Omron IC device. The BP cuff around the 
left arm was three times inflated and BP values were recorded. FMD was assessed by 
echo-Doppler (Esaote, Genova, Italy) on each test day at baseline and 3 h after the fat 
challenge at the subject's right arm in recumbent position by using a 7.5MHz transducer 
and automatic tracking vessel wall movement software (Wall Track SystemTM). The 
brachial artery was imaged in the upper arm (about 5 cm above the antecubital crease) 
in B-mode. The baseline arterial diameter was measured in M-mode (motion-mode). 
Following this, a cuff placed around the upper arm was inflated to 200 mmHg for 4 
minutes. After deflation of the cuff the arterial diameter was measured at 20-second 
intervals for 5 minutes. FMD was defined as the maximal percentage diameter change of 
the post-occlusion arterial diameter measurement relative to the mean of the 
corresponding 3 baseline measurements. The device automatically calculated pulse wave 
transit time starting with the electrical signal reflecting the ventricular systole to the 
arterial wall movement of the brachial artery measured by the echo-transducer. The wall 
movement results from the pulse wave propagation initiated by each ventricular 
contraction, and is a measure of arterial stiffness. 
 As an explorative vascular function tool, the HDI/PulseWaveTM CR-2000 Research 
Cardio Vascular Profiling System (Hypertension Diagnostics, Minnesota, USA) was 
included in the study protocol, and used according to the indications of the supplier. The 
device generates a radial artery waveform by tonometry, and by using an algorithm, 
calculates the large (C1) and small (C2) artery elasticity index. C1 reflects capacitive 
arterial compliance and C2 oscillatory or reflective arterial compliance. Detailed 
information on measurement of platelet function and blood lipids is available at 
http://jn.nutrition.org. 
 
Additional measurements 
Body weight was measured without shoes and heavy clothing at each visit on an 
electronic device. Height was measured during screening using a wall-mounted 
stadiometer. Body mass index was computed based on these two measurements. All 
adverse events experienced during the study were reported and coded by the study 
physician. 
 
Statistical analysis 
Data collected on paper were 100% verified and all data were archived at Unilever 
Research and Development Vlaardingen, The Netherlands. Data were analyzed according 
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to the intention-to-treat principle. The values reported in text and tables are Least-
Squares Means (LSMeans)  SEMs, except for baseline data, which are reported as 
means  SD. Results of the power calculation showed that 35 participants would be 
sufficient to detect a clinically relevant FMD improvement of 2.5% (power of 0.8,  = 
0.05). Data were analyzed using an analysis of covariance (Proc Mixed, SAS software 
V9.1, Cary, NC USA) to compare the absolute differences after the intervention periods 
between the two treatments and placebo. The model terms were treatment, period and 
their interaction. Baseline values were used as covariables. For the FMD analyses 
baseline diameter of the brachial artery was also included in the model. To test the 
differences of both interventions with the placebo treatment a multiple comparison 
according to Dunnett was performed.  
 
 
Results  
 
Participants and compliance  
Of the 53 volunteers who responded to advertisements and underwent screening, 11 
were excluded based on their blood and urine results, and 7 were excluded by lottery. 
The remaining 35 participants were randomized and completed the study. Compliance of 
the test products was 86% as indicated by registration of test product consumption by 
participants. The participants were young healthy males with BMI, vascular function 
parameters and lipid levels in the normal range and not receiving medication that might 
affect outcome variables or bioavailability of the test products (Table 1). 
Chapter 6 
Grape polyphenols and endothelial function 
 
 
108 
Table 1 Baseline characteristics of the healthy male participants.1 
Characteristics  
Age (y) 31.4 ± 9.0 
Height (cm) 183.6 ± 7.2 
Weight (kg) 78.1 ± 10.5 
BMI (kg/m2) 23.2 ± 2.5 
FMD (%) 5.6 ± 3.6 
Brachial artery diameter (mm) 4.22 ± 0.54 
Systolic BP (mmHg) 
Diastolic BP (mmHg) 
Heart Rate (beats/min) 
123.0 ± 10.5 
72.6 ± 9.2 
62.7 ± 7.8 
Serum Total cholesterol (mmol/L) 
Serum HDL cholesterol (mmol/L) 
Serum LDL cholesterol (mmol/L) 
Serum Triglycerides (mmol/L) 
4.8 ± 1.1 
1.4 ± 0.3 
3.2 ± 1.0 
1.0 ± 0.4 
1 Values are means ± SD, n=35. 
 
Vascular function 
Neither FMD after low fat breakfast, nor FMD after high fat lunch were significantly 
affected by the treatments (Table 2). The mean difference in maximal response in 
diameter within 5 minutes of measurement after breakfast between the end of the 
intervention period and the end of the placebo period treatment was -0.4% (95% 
Confidence Interval (CI) -1.8; 0.9, P = 0.77) for the wine-grape solids and 0.2% (-1.2; 
1.5, P = 0.94) for the grape seed solids. After the high fat challenge, the mean 
differences in FMD vs. placebo were 0.7% (-0.6; 2.0, P = 0.49) after the wine-grape 
solids intervention and -0.2% (-1.5; 1.1, P = 0.94) after the grape seed solids 
intervention.  
 No significant effects on BP were found. The mean difference between wine-grape 
and placebo in systolic BP was -1.3 mmHg (-4.7; 2.2, P = 0.70) and for diastolic BP -1.6 
mmHg (-4.4; 1.3, P = 0.44). For grape seed differences were -0.6 mmHg (-4.0; 2.9, P = 
0.92) for systolic BP and -0.6 mmHg (-3.4; 2.2, P = 0.88) for diastolic BP. In addition no 
significant differences were found for heart rate, pulse wave transit time and large 
arterial elasticity and small arterial elasticity (Table 2). Results for all these vascular 
function measures were similar after the fat challenge (data not shown, except for FMD).   
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Table 2 Vascular function of men after 2-wk interventions with wine-grape solids, grape 
seed solids, and placebo.1 
Difference compared to placebo   
Placebo Wine-grape Grape seed 
FMDmax (%)  
after low fat breakfast 
after high fat lunch 
 
3.9 ± 0.5 
4.5 ± 0.5 
 
-0.4 (-1.8;0.9) 
0.7 (-0.6;2.0) 
 
0.2 (-1.2;1.5) 
-0.2 (-1.5;1.1) 
Systolic BP (mmHg) 
Diastolic BP (mmHg) 
Heart Rate (beats/min)  
118.6 ± 1.2 
70.8 ± 1.0 
61.4 ± 1.1 
-1.3 (-4.7;2.2) 
-1.6 (-4.4;1.3) 
1.2 (-1.9;4.3) 
-0.6 (-4.0;2.9) 
-0.6 (-3.4;2.2) 
0.0 (-3.1;3.1) 
Pulse wave transit time (ms) 
Large arterial elasticity (C1, mL/mmHgx10) 
Small arterial elasticity (C2, mL/mmHgx100) 
168.7 ± 2.9 
18.3 ± 0.7 
10.3 ± 0.3 
4.2 (-4.0;12.5) 
-0.1 (-1.5;1.2) 
0.5 (-0.3;1.3) 
0.8 (-7.4;9.1) 
-0.2 (-1.6;1.1) 
0.3 (-0.5;1.1) 
1 Values are LSmeans ± SEM or LSmeans (95% CI), n=35; Data were analyzed by ANCOVA with 
the baseline value as the covariable or for FMD, baseline FMD and baseline brachial artery diameter 
as covariables. 
 
Platelet function and blood lipids 
Measures of platelet function did not differ after the treatments compared to placebo 
although platelet activation in whole blood induced by a combination of collagen and 
epinephrine after the fat challenge tended to be enhanced due to the wine-grape 
treatment compared to placebo [14.5 s (1.3 to 27.6; P = 0.06)] (Supplemental Table 1). 
Platelet aggregation in platelet rich plasma induced by ADP (10 mol/L) after the fat 
challenge also tended to be reduced [-6% (-12.1 to 0.1; P < 0.10) after the wine-grape 
treatment compared to placebo (Supplemental Table 1).  
 After the wine-grape intervention, serum total cholesterol was lower after the low-
fat breakfast [-0.16 mmol/L (-0.31 to -0.01; P = 0.07)] and after the high-fat lunch [-
0.20 mmol/L (-0.33 to -0.07; P < 0.01)] compared to after the placebo treatment. The 
serum total cholesterol concentration did not differ after the grape seed and placebo 
treatments. Compared to the placebo treatment, serum triglycerides were reduced by the 
wine-grape treatment after the high fat lunch [-0.29 mmol/L (-0.54 to -0.04; P < 0.05)] 
and tended to be reduced by the grape seed treatment [-0.25 mmol/L (-0.51 to 0.00; P  
 0.1)]. Serum LDL- and HDL-cholesterol concentrations did not differ after the 
treatments compared to after placebo (Supplemental Table 2). 
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Other outcomes 
Body weights did not differ after the treatment periods compared to after placebo. 
Participants experienced a total of 39 adverse events, which were determined to be not 
related to any of the test products. Most of the adverse events were mild, and all 
participants recovered. The 4 most frequent events were acute nasopharingitis (n = 7), 
headache (n = 6), diarrhea (n = 4) and flatulence (n = 4). 
 
 
Discussion 
 
Possible protective effects of wine (constituents) on CVD risk factors have been 
suggested by in vitro, and animal studies15, whereas data from well-controlled human 
studies are scarce.9 The present hypothesis-testing study in 35 healthy males 
investigated the potential of the polyphenolic part of two different grape solids in a 
randomized, double-blind, placebo-controlled cross-over setting. We found no significant 
differences in FMD, and other vascular function markers after grape solids treatment 
compared to after placebo treatment, despite the large range of indicators assessed 
(FMD, BP, heart rate, pulse wave transit time, large and small arterial elasticity) and the 
considerable high polyphenol content of the solids. 
 The strength of this study is its randomized double-blind placebo-controlled 
design. In addition, all participants completed the study and compliance to the test 
capsules was high. Furthermore, unlike most other studies in this field, encapsulation of 
the solids ensured blinding of the test products. To reduce variation we measured FMD 
on all test days in each participant on the same day of the week at the same time point 
and by the same observer. We only included men in this study to decrease variation in 
FMD measurements due to hormonal fluctuations in women.32 Effects of the grape solids 
on FMD and other outcomes were measured after a low fat breakfast and after a high fat 
lunch as it has been suggested that a high fat meal or other vascular function stressors, 
such as smoking, may acutely impair FMD and that this impairment may be prevented by 
intake of red wine constituents.14,19,27-29 For this proof of principle study we selected 
extracts with a high polyphenols content (approximately 80% of the dry weight) and with 
a large range of polyphenols subtypes. The polyphenol dose (800 mg polyphenols per d), 
was similar to the dose tested in other intervention studies addressing the chronic effects 
(2-8 wks) of the polyphenolic fraction of grape consumption on endothelial function 
and/or BP.23,33-37 
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 The study design also had its limitations. The intervention period was relatively 
short, but we expected to show benefits of polyphenols within 2 weeks, because previous 
studies investigated acute and several weeks effects on FMD with positive 
outcomes.16,28,29,33-35,37,38 The wash-out period was 1 wk, which was considered more 
than sufficient to prevent carry-over effects, because polyphenols are rapidly metabolized 
and their maximum plasma concentrations are usually reached within hours.39 
Furthermore, only participants without elevated CVD risk factors were included, whereas 
in most other studies investigating the effects of grape polyphenols on vascular function, 
the focus was on participants with elevated CVD risk.14 Indeed, our study population 
appeared to be largely insensitive to the fat challenge, indicating a balanced and healthy 
vascular function. Consequently, grape solids may still protect vascular function in 
participants at increased risk for CVD. In addition, our study may have not been 
optimally designed to answer the secondary objectives. The trends we found on platelet 
function were not consistent across the different methods we applied. This may reflect 
differences in sensitivity of the applied methods towards specific platelet activation 
pathways.40 More consistent seem the total cholesterol-lowering effects after wine-grape 
treatment in this normolipidemic population. Some human studies also found beneficial 
effects of grape products on lipid profile, however evidence is not consistent.10,13 
Moreover, triglycerides were significantly lower after the high fat challenge for the wine-
grape treatment compared to placebo treatment and tended to be lower after grape seed 
consumption. This effect may be explained by inhibition of chylomicron secretion from 
intestinal cells by the grape polyphenols.41 It should be noted that the observed benefits 
could well be chance findings and require confirmation in a separate study, including 
multiple blood sampling in the postprandial phase. We investigated effects on blood lipids 
as secondary outcome with the same wine-grape treatment in 30 hypertensive 
participants and were not able to confirm the lipid lowering effects (unpublished data). To 
directly test effects on blood lipids, it would require a cross-over study with about 60 
subjects to detect differences of a similar magnitude as observed here.  
 In conclusion, this randomized controlled study does not support that grape 
polyphenolic compounds have important potential to improve endothelial function and 
related cardiovascular health markers in a healthy population. Future studies should 
focus on the potential of grape polyphenols for improving endothelial function and 
cardiovascular health in participants with an elevated cardiovascular risk profile with 
interventions of sufficient duration to accurately allow assessment of longer term effects.  
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Online Supplemental Material 
 
Blood platelet and blood lipids measurements 
Blood was collected 1.75 h after the low fat breakfast and 3.75 h after the high fat lunch. 
Platelet activation was determined in citrated blood using several experimental 
approaches. First, it was measured in whole blood to ensure a physiological environment 
as close as possible using the Platelet Function Analyser (PFA 100). PFA-100 represents 
the different processes that are involved in thrombus formation with increased PFA-100 
values indicating a less thrombotic state of the blood. Whole blood is aspirated through a 
collagen plus epinephrine or collagen plus ADP coated filter that induces platelet 
activation leading to thrombus formation and occlusion of the filter. The time required to 
occlude the filter reflects the capacity of blood platelets to contribute to thrombus 
formation. Additionally, platelet aggregation in an optical aggregometer was measured in 
platelet-rich plasma derived from citrated blood using a centrifugation step, according to 
the method of Born (Born, 1967). The platelet count was adjusted to 200,000 
platelets/µL. After a resting period of 30 min at room temperature, the suspension was 
used for experiments. Platelets were activated separately by two concentrations of 
adenosine diphosphate (ADP; 5 and 10 µM) or collagen. Total cholesterol, LDL, HDL and 
triglycerides were measured by means of a Hitachi 912 auto analyzer using the 
enzymatic colorimetric test CHOD-PAP (Roche, cat. no. 1489232), the homogenous 
enzymatic colorimetric test “LDL cholesterol plus 2nd generation” (Roche cat. no. 
04714423190), the “HDL cholesterol plus 3rd generation” (Roche, cat. no. 04713109 
190), and the enzymatic colorimetric test GPO-PAP (Roche, cat. no. 1488872), 
respectively.  
 All measurements were performed in each participant on the same day of the 
week at the same time of the day by the same observer. 
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Supplemental Table 1 Platelet function of men after 2-wk interventions with wine-
grape solids, grape seed solids, and placebo.1 
Difference compared to placebo   
Placebo Wine-grape  Grape seed 
PFA2 100 epinephrine coated cartridge (s) 
after low fat breakfast 
after high fat lunch 
PFA 100 ADP3 coated cartridge (s) 
after low fat breakfast 
after high fat lunch 
Aggregometry ADP 10 mol/L-induced (%)4 
after low fat breakfast 
after high fat lunch 
Aggregometry Collagen-induced (%) 
after low fat breakfast 
after high fat lunch 
 
145.4 ± 7.3 
138.9 ± 6.3 
 
80.4 ± 1.6 
77.9 ± 1.9 
 
71.3 ± 2.4 
72.9 ± 2.5 
 
73.6 ± 3.1 
70.2 ± 4.2 
 
7.8 (-5.0;20.6) 
14.5 (1.3;27.6) 
 
0.4 (-3.5;4.3) 
2.1 (-2.5;6.8) 
 
1.0 (-4.5;6.5)    
-6.0 (-12.1;0.1)   
 
-2.6 (-9.3;4.0)    
-5.9 (-15.5;3.7) 
 
6.5 (-6.4;19.3) 
7.5 (-5.8;20.7) 
 
0.9 (-3.0;4.7) 
0.5 (-4.2;5.1) 
 
1.2 (-4.5;6.8)      
-4.2 (-10.2;1.7)    
 
-2.0 (-8.8;4.7) 
-4.5 (-13.9;4.9) 
1 Values are LSmeans ± SEM or LSmeans (95% CI), n=35; Data were analyzed by ANCOVA with 
the baseline value as the covariable. 2 PFA, Blood platelet function. 3 ADP, Adenosine diphosphate.  
4 Aggregometry ADP 5 mol/L-induced (%), was also measured, but is not reported. 
 
Supplemental Table 2 Lipid levels of men after 2-wk interventions with wine-grape 
solids, grape seed solids, and placebo.1 
Difference compared to placebo   
Placebo Wine-grape Grape seed 
Total cholesterol (mmol/L) 
after low fat breakfast 
after high fat lunch 
LDL-C (mmol/L) 
after low fat breakfast 
after high fat lunch 
HDL-C (mmol/L) 
after low fat breakfast 
after high fat lunch 
Triglycerides (mmol/L) 
after low fat breakfast 
after high fat lunch 
 
4.66 ± 0.07 
4.78 ± 0.07 
 
3.07 ± 0.06 
3.02 ± 0.06 
 
1.35 ± 0.03 
1.31 ± 0.03 
 
1.06 ± 0.08 
1.91 ± 0.15 
 
-0.16 (-0.31 ; -0.01) 
-0.20 (-0.33 ; -0.07)§ 
 
-0.12 (-0.27 ; 0.04) 
-0.11 (-0.25 ; 0.02) 
 
-0.00 (-0.05 ; 0.05) 
-0.01 (-0.06 ; 0.05) 
 
-0.13 (-0.33 ; 0.06)   
-0.29 (-0.54 ; -0.04)# 
 
-0.10 (-0.25 ; 0.06) 
-0.08 (-0.21 ; 0.06) 
 
-0.07 (-0.23; 0.08) 
-0.03 (-0.17 ; 0.10) 
 
0.03 (-0.02 ; 0.08) 
0.02 (-0.04 ; 0.08) 
 
-0.13 (-0.33 ; 0.06) 
-0.25 (-0.51 ; 0.01) 
1 Values are LSmeans ± SEM or LSmeans (95% CI), n=35; Data were analyzed by ANCOVA with 
the baseline value as the covariable; # P < 0.05; § P < 0.01; 2-sided P values for the difference 
from placebo (Dunnett test). 
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Supplemental Figure 1 Flowchart and design of the randomized controlled cross-over 
study in 35 healthy men. 
 
 
 
 
Information meeting (n = 100) 
 
Completed screening questionnaire (n = 83) 
 
Invited for screening (n = 60) 
 
Completed screening  (n = 53) 
Not meeting inclusion criteria (n = 19) 
Refused to participate (n = 4) 
Participants eligible for the study (n = 42), of which  
(n = 7) were excluded from the study by lot. 
 
Participants randomized (n = 35) 
Excluded based on blood and urine 
results (n = 19) 
Wash-out 
period 
1 week 
Intervention 
period  
2 weeks  
Wine-grape solids, grape seed solids or placebo  
(n = 35) 
Wash-out 
period 
1 week 
Intervention 
period  
2 weeks  
Intervention 
period  
2 weeks  
Run-in period  
3 days 
Wine-grape solids, grape seed solids or placebo  
(n = 35) 
 
Wine-grape solids, grape seed solids or placebo  
(n = 35) 
 
 
 
 
Test day 1-4:  
 
after run-in period and  
after each intervention period 
 
Arrival at test facility: 
Test day 1: breakfast 
Test day 2-4: 3 capsules of test 
product with breakfast 
 
One hour after arrival: 
Start 1st measurements 
 
Three hours after arrival: 
Test day 1: high fat lunch 
Test day 2-4: 3 capsules of test 
product with high fat lunch 
 
Six hours after arrival: 
Start 2nd measurements 
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Abstract 
 
Background: The effect of folic acid on endothelial function, a prognostic factor for 
cardiovascular diseases, is not well established. We calculated this effect in a meta-
analysis of randomized, double-blind, placebo-controlled trials in humans.  
Objective: The objective of the study was to quantify the effect of folic acid on 
endothelial function, as measured with the use of flow-mediated dilatation (FMD). 
Design: We conducted a meta-analysis of randomized, double-blind, placebo-controlled 
folic acid trials evaluating endothelial function. Trials were identified through MEDLINE 
(1966–15 Sept 2005), by hand-searching of references, and by contact with investigators 
for unpublished results. Two of us (AdB and RD) independently extracted trial data. A 
pooled estimate was calculated by using random-effects meta-analysis. Previously 
defined stratified analyses were conducted to explore the influence of study 
characteristics.  
Results: Of 163 identified studies, 14 met inclusion criteria and provided data on 732 
persons. Evidence for publication bias was not obvious. In the overall pooled estimate, 
folic acid improved FMD by 1.08 (95% CI: 0.57, 1.59; P = 0.0005) percentage points 
over placebo. Of the study characteristics, only folic acid dose significantly influenced the 
outcome. Post hoc analysis, which should be interpreted with caution, seemed to indicate 
a dose-response effect: the change in FMD was -0.07 (95% CI: -0.37, 0.22) percentage 
points at doses between 400 and 800 g/d, 1.37 (95% CI: 1.12, 1.54) percentage points 
at doses of 5000 g/d, and 2.04 (95% CI: 1.43, 2.65) percentage points at doses of 10 
000 g/d.  
Conclusion: This study indicates that high doses of folic acid improve endothelial 
function, which could potentially reduce the risk of cardiovascular disease.  
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Introduction 
 
A large amount of epidemiologic evidence links elevated homocysteine concentrations to 
an increased risk of cardiovascular disease (CVD).1,2 This linkage has initiated the 
execution of secondary prevention trials testing whether homocysteine lowering therapy 
reduces the risk of recurrent CVD events.3 Because the B vitamin folic acid and, to a 
lesser extent, vitamin B-6 and vitamin B-12 lower homocysteine concentrations4, they 
are used in such trials. Many of these trials are ongoing, and data from 4 of them have 
been published, showing disappointing results.5-8 A combined analysis of these 4 trials 
lacked the power to detect significant differences. However, the CIs around the summary 
risk estimates of these 4 trials were compatible with a 10% lower risk of ischemic heart 
disease and a 20% lower risk of stroke associated with a 25% lower homocysteine 
concentration.9 Furthermore, we should also bear in mind that these secondary 
prevention trials typically look at risk reduction after short-term treatment in high-risk 
subjects, and thus these results should not be generalized to the overall population. 
Indeed, a beneficial effect of folic acid fortification on stroke mortality in the United 
States and Canada was recently reported.10  
 Although folic acid may not be able to reverse advanced atherosclerosis in CVD 
patients, it may affect the early stages of the CVD process, such as endothelial 
dysfunction.11 This possibility has not been investigated in a systematic way. Endothelial 
function can be measured by the degree of flow-mediated dilatation (FMD).12 FMD 
represents the ability of the brachial artery to dilate in response to ischemia-induced 
hyperemia in the forearm, and as such it reflects the bioavailability of the endogenous 
vasodilator nitric oxide (NO). In the present study, we systematically evaluated the effect 
of folic acid (with or without vitamin B-6, vitamin B-12, or both) on FMD in humans by 
performing a meta-analysis of randomized, placebo controlled clinical trials. 
 
 
Study methods 
 
Strategy to search randomized trials  
The Quality of Reporting of Meta-analyses standards13 were followed during all phases of 
the design and implementation of the present analysis. Included studies were 
randomized clinical trials that measured vascular reactivity by using the percentage of 
FMD (%FMD) after folic acid supplementation without a vascular challenge (such as a 
methionine or fat load). Trials were identified by searching the MEDLINE database from 
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1966 to 15 September 2005 with the use of the search terms homocysteine OR folate OR 
folic acid OR vitamin B-12 OR cobalamin OR vitamin B-6 OR B-6 and flow mediated OR 
flow-mediated OR endothelium-dependent OR vasomotor OR vasoacti* OR “blood flow” 
OR brachial* OR intima OR vasodilat* OR dilat* OR circulation OR endothel* OR 
distensibility OR microcirculat* OR micro-circulation OR vascular resistance OR wave OR 
plethysmography OR “blood supply” OR claudication OR cold hands.  
 We limited the search to clinical trials conducted in humans aged 19 y and 
published in the English language. Furthermore, we hand-searched the reference lists of 
the articles obtained through MEDLINE and of conference abstract books for additional 
studies. 
 
Trial review 
A flow chart of the selection of the included trials is given in Figure 1. The MEDLINE 
search identified 158 studies. The abstracts of these studies were screened 
independently by 2 of us (AdB and RD). After the exclusion of 127 studies, the remaining 
31 studies were assessed more specifically, including a review of their reference lists. 
This resulted in the identification of 4 additional studies for inclusion.14-17 Finally, 1 other 
trial was identified in a conference abstract book, for a total of 36 studies. Two of us 
(AdB and RD) independently evaluated these studies in detail - reviewing the complete 
publication, if available - which left 13 published trials18-30 and 1 then-unpublished trial 
(M Olthof, personal communication, 22 November 2005; now:31) that met the inclusion 
criteria. The inclusion and exclusion decisions were unanimous. 
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Figure 1 Flow diagram of showing the process (and the reasons) of selecting and 
excluding studies for this meta-analysis. 
 
Data extraction 
For each of the 14 studies meeting the inclusion criteria, data on study design, 
population, sample size and number of dropouts, intervention type, dose, and duration 
were independently extracted (by AdB and RD). Standard forms in EXCEL were used to 
calculate the net change in %FMD after folic acid supplementation compared with that 
after administration of placebo and also to calculate the SE of this change (see Statistical 
analysis). Study quality was also independently assessed (by AdB and RD) according to 
the criteria for quality assessment of randomized clinical trials developed by Delphi 
consensus.32 The 9 criteria were treatment allocation (randomized = 1 point), similarity 
of groups at baseline with respect to the most important prognostic indicators (1 point), 
eligibility criteria (specified = 1 point), blinding (treatment allocation blinded = 1 point, 
outcome assessment blinded = 1 point, care provided blinded = 1 point, and patients 
blinded = 1 point), measures of variability presented for FMD measurement (yes = 1 
point), and intention-to-treat analysis (yes = 1 point; studies with no drop-outs received 
1 point for this criterion). Thus, the highest score a trial could get was 9 points. 
 We assessed the validity of data extraction by comparing the independently 
abstracted results for concordance. Discussion and review of the original manuscript 
resolved any discrepancies between the results abstracted by the 2 independent 
investigators.  
Potentially relevant studies  
identified and screened ( n= 158) Excluded: 127 
 82 no folic acid intervention 
 30 no endothelial function 
 8   patient group  
 3   co-intervention with other ingredients 
 1   no control group 
 1   description of a trial 
 1   no intervention 
 1   duplicate 
Excluded: 22  
 8 not randomized 
 1 vascular function not measured 
 5 vascular function not measured with FMD  
 1 no placebo  
 2 duplicates 
 1 FMD after fat load 
 1 infusion of folates  
 3 wash-out < 4 weeks Studies included in meta-analysis 
(n = 14) 
Studies retrieved for more  
detailed evaluation 
31 from first selection 
4 extra by scanning reference lists  
1 from abstract book 
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Exposure and outcome variables 
 
Supplementation with folic acid, vitamin B-6, and vitamin B-12  
As exposure variable, we used the dose of folic acid and vitamin B-6 or vitamin B-12 (or 
both) rather than the plasma concentration of these B vitamins or of homocysteine. We 
did this because the absence of a gold standard method makes it very difficult to 
compare plasma concentrations between studies, and thus there are great variations 
between different laboratories.33,34 In addition, circulating concentrations of B vitamins 
are known to vary and therefore are not very stable markers for actual intake.35-37 
 
Flow-mediated dilatation 
As outcome variable, we used the net change in FMD. In most of the articles, FMD was 
presented as the %FMD, which is calculated by the following equation:  
 
%FMD = [(maximum diameter - baseline diameter)/ 
       baseline diameter] x 100%   (1) 
 
For consistency, we have used that formulation throughout as the unit of FMD 
measurement. 
 
 
Statistical analysis 
 
Net change in flow-mediated dilatation 
Our primary outcome was the net change in FMD due to folic acid (with or without 
vitamin B-6 and vitamin B-12) treatment - ie, %FMD after folic acid - %FMD after 
placebo. For the 6 included crossover trials, %FMD at the end of the control period was 
subtracted from vascular reactivity at the end of the treatment period. For parallel design 
trials, the %FMD change from baseline to study end in the control group was subtracted 
from the %FMD change from baseline to study end in the treatment group. 
 
Standard error of the net change in flow-mediated dilatation 
For the crossover trials, the SE of the net change in %FMD was derived from the P 
value18,19, from the SD20, or directly from the author of one of the studies.31 Two 
crossover trials did not report %FMD but reported the baseline diameter (in mm) and the 
increase (in m) after occlusion.24,26 For these studies we estimated the %FMD for the 
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end of the control period and the end of the treatment period. Then we calculated the 
variance in these %FMD values by using the following equation: 
 
VarianceFMD =  
[varianceincrease + FMD2 x variancebaseline diameter – 2 x FMD x covariancebaseline diameter 
increase]/(baseline diameter2)         (2) 
 
An estimate of the covariance between the baseline diameter and the increase after 
occlusion for these calculations was obtained from unpublished FMD data (ie -16, based 
on 316 data points; R Draijer, personal communication, 16 November 2005). The SE at 
the end of the control period (SEC) and the SE at the end of the treatment period (SET) 
were calculated by taking the square root of the estimated variance in %FMD at the end 
of the control period and at the end of the treatment period. The pooled SE of the net 
difference was then calculated according to the equation of Follmann et al.38: 
 
SE of the net difference = 
√[(SET2 + SEC2) - 2(r)(SET)(SEC)]         (3) 
 
where r is the within-subject correlation in %FMD between the treatment and control 
period, which is estimated to be 0.5.  
 For the 8 included parallel designs, the SE of the net change in %FMD was 
estimated with the P value for 2 studies.23,30 Six of the parallel trials provided either the 
SE27 or the SD17, 21, 22, 29, 30 at baseline and at the end of the study for the control and 
treatment groups. Respective SEs were calculated by using the following equation17, 21, 22, 
29, 30:  
 
SE = SD/√(n)           (4) 
 
The SEs were used to calculate the SE for the change within the treatment group (SETG) 
and within the control group (SECG), again with the method of Follmann et al.38 For 
example, for the treatment group, we used the following equation: 
 
SETG = √[(SETbaseline2 + SETend of study2) - 2(r)(SETbaseline)(SETend of study)]    (5) 
 
where r was estimated to be 0.5. Finally, the SE of the net change was calculated by 
using the following equation: 
Chapter 7 
Folic acid and endothelial function 
 
 
126 
SE of the net change = √[(SETG2 + SECG2)        (6) 
 
One parallel trial28 did not report %FMD values, but reported the baseline diameter (in 
mm) and the increase (in m) after occlusion. The %FMD values and respective SEs were 
calculated as described above for the crossover trials. We used these values and 
equations 5 and 6 to calculate the SE of the net change. Data for the calculation of the 
change in %FMD and the SE of this change were not missing from any trial.  
 Because this meta-analysis brings together studies that are diverse both clinically 
(eg, dose and type of subjects) and methodologically (eg, design and quality), 
heterogeneity in their results is expected. We calculated that the proportion of total 
variation between studies due to heterogeneity rather than to chance was 26%.39 
Although a value >50% is considered to represent substantial heterogeneity, we used a 
random-effects model (SAS PROC MIXED) with inverse variance weighting for each 
trial.40 In this way, we addressed the question “What is the average effect of folic acid 
supplementation on %FMD?” rather than using a fixed-effects model that addresses the 
question “What is the best estimate of the effect of folic acid on %FMD?” In addition, a 
random effects model results in a more conservative estimate of statistical significance 
than does a fixed-effects model. 
 We performed defined stratified meta-analyses to roughly explore the potential 
effect of study design (crossover or parallel), mean population age (55 or 55 y old), 
general health (healthy or at greater risk of CVD), folic acid dose (400–800, 5000, or 10 
000 g/d), duration of treatment (8 or 8 wk), additional vitamin B-6 or vitamin B-12 or 
both (no or yes), and study quality (7 or 7 Delphi criteria). 
 To assess publication bias, a funnel plot of the treatment effect versus 1/SE2 was 
visually inspected as described earlier.41 In addition, the symmetry of the funnel plot was 
judged by regressing the standard normal deviate (ie, effect of folic acid supplementation 
on %FMD/SE of this effect) against the estimate precision (1/SE) (standard normal 
deviate =  +  x precision). A symmetrical funnel plot should give a regression equation 
in which  is close to 0 and  indicates the size and direction of effect.41 
 We used SAS software (version 8.2; SAS Institute, Cary, NC) for the statistical 
analyses. The effect of folic acid on %FMD was reported with the use of 95% CIs. Two-
sided P values   0.05 were considered significant. 
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Results 
 
Trial characteristics 
Of the 14 trials meeting inclusion criteria, 1 trial29 had 2 separate intervention groups, 
and thus 15 intervention groups are presented in Table 1. Six of these trials had a 
crossover design, and 8 had a parallel design. In total, this meta-analysis was based on 
732 persons treated with folic acid (with or without vitamin B-6 or vitamin B-12 or both) 
or placebo for a median of 8 wk, with a median study size of 34 participants. Most trials 
included middle-aged male subjects: the mean age in the individual studies ranged from 
29.3 to 69.1 y (overall median: 55.8 y), and the median percentage of males was 86%. 
Seven intervention groups were composed of populations with CVD or high cholesterol 
concentrations, 5 groups were generally healthy, and 3 were healthy but with slightly 
elevated plasma homocysteine concentrations. The median folic acid dose was 5000g/d 
(range: 400–10 000 g/d). In 5 studies, additional vitamin B-6 and vitamin B-12 were 
supplied. All studies that supplied information on the plasma homocysteine concentration 
showed a drop in this concentration after intervention. The lowest Delphi score was 7 
points; 5 trials had that score. Three trials fulfilled all 9 Delphi criteria. 
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Table 1 Characteristics of the 15 intervention groups (14 trials) included in the meta-analysis.1  
  Subjects2       tHcy    
Reference Design Folic acid 
group 
 
Control 
group 
 Age Male  General health Folic acid 
dose 
Vitamin 
B-6 
dose  
Vitamin 
B-12 
dose 
Placebo 
group 
Folic acid 
group 
Duration  Drop-out Delphi 
criteria 
met3 
  n n y %  µg/d mg/d µg/d µmol/L µmol/L wk % n 
Bellamy, 199919  CO 18 19 NA NA 
Healthy, tHcy>13 
µmol/L 
5000 - - 
 
~11 
 
~7 
6 10 7 
Woo, 199920 CO 17 17 54 88 Healthy 10.000 - - 9.5  2.54 8.1  3.05 8 0 9 
Title, 200021 P 25 25 58.9 80 CAD 5000 - - 11.8 10.9 16 0 9 
Chambers, 200022 P 59 30 56 100 CAD 5000 - 1000 14.9  6.5 9.3  1.95 8 0 7 
Thambyrajah, 200123 P 43 43 63 87 CAD 5000 - - 12.3 9.35 12 4.4 7 
Pullin, 200124 CO 106 106 39 42 Healthy 400  - - 10.9  6.9 8.5  3.16 16 15.9 8 
Van Dijk, 200125 P 63 67 45.3 51 Healthy 5000 250 - 
12.3  5.5 7.5  1.96 
 
52 6.5 8 
Doshi, 200126 CO 48 48 57 88 CAD 5000 - - 10.8  2.4 9.3  2.45 6 3.8 7 
Sydow, 200327 P 8 8 69.1 78 PAOD 10.000 20 200 NA NA 8 11 8 
Doshi, 200228 P 16 17 55.5 91 CAD 5000 - - 10.8  2.1 8.3  1.35 6 0 7 
Hirsch, 200229 7 P 9 11 29.3 100 Healthy 600 2 800 ~9 ~8 8 0 8 
Hirsch, 200229 P 9 11 29.3 100 
Healthy, tHcy  15 
µmol/L 
600 2  800  ~22 ~10 8 0 8 
Woodman, 200418 CO 26 26 49 69 
Healthy, mean tHcy 
15.6 µmol/L 
5000 - - 
~12.8 ~8.4 
 
8 0 9 
Lekakis, 2004 30 P 17 17 56.5 85 
HCHOL, 50% with 
CAD, all taking statins 
5000 - - 
NA NA 
4 0 8 
Olthof, 2006 31 CO 39 39 59 58  Healthy  800 - - 9.9 1.6 8.0 1.35 6 2.5 8 
1 tHcy, total homocysteine; CO, crossover; NA, not available; P, parallel; CAD, coronary artery disease; PAOD, peripheral arterial occlusive disease;  
HCHOL, hypercholesterolemia. 2 Subjects who completed the trial. 3 Total Delphi criteria = 9. 4 x ± SD (all such values). 5 Significantly different from 
tHcy value in placebo group, P < 0.05. The tHcy concentration was estimated from data given in the referenced article. 6 Significance level of difference 
not available. 7 Half of the study population had high concentrations of homocysteine. 
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Effect of folic acid on flow-mediated dilatation 
The individual trial results and the pooled estimate are shown in Figure 2. In the overall 
pooled estimate, compared with placebo, folic acid improved FMD with 1.08%FMD (95% 
CI: 0.57, 1.59; P = 0.0005). There was no effect of design, mean age of the study 
population, study duration, or the addition of vitamin B-6 or vitamin B-12 on the 
estimated change in %FMD due to folic acid (Table 2). However, there was a tendency 
that subjects at greater risk of CVD had a larger improvement in %FMD, and studies that 
met a higher number of Delphi criteria had a smaller improvement in %FMD. The dose of 
folic acid was clearly important. The trials using a lower dose - ie, <5000 g - did not 
show a beneficial effect of folic acid on FMD (-0.07%FMD; 95% CI: -0.37, 0.22%FMD), 
whereas the studies with a dose ≥5000 g/d did (1.42%FMD; 95% CI: 1.25, 
1.58%FMD). In a post hoc analysis, a dose-response effect became apparent when we 
created 3 strata: a low-dose stratum with folic acid doses between 400 and 800 g/d (4 
intervention groups), an intermediate stratum with studies using a folic acid dose of 
5000g/d (9 intervention groups), and a high-dose stratum with studies using a folic acid 
dose of 10 000g/d (2 intervention groups). At folic acid intakes 800 g/d, FMD did not 
change [-0.07%FMD (95% CI: -0.37, 0.22%FMD)]; at 5000 g/d, it improved 
[1.37%FMD (1.12, 1.54%FMD)]; and, at 10 000 g/d, it improved further [2.04%FMD 
(1.43, 2.65%FMD)]. 
 Evaluation of the funnel plot showed little evidence for publication bias (Figure 3). 
In addition, the funnel plot was quite symmetric, as  = -0.05 and  = 1.09.42 
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1.08 (95% CI: 0.57, 1.59)
Folic acid dose: 10.000 µg/d
Folic acid dose: 5000 µg/d
Folic acid 
dose:
400 to 800 
µg/d
Change in %FMD in response to folic acid supplementation
 
Figure 2 Change (and 95% CIs) in the percentage flow-mediated dilatation (%FMD) due 
to folic acid supplementation per included intervention group and the overall estimated 
change (and 95% CI). Half of the participants in the study by Hirsch et al. had high 
concentrations of homocysteine. 
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Table 2 Effect of folic acid supplementation on flow-mediated dilation stratified by 
previously defined study characteristics. 
Characteristic  Intervention 
groups  
Effect (95% CI) P1 
  n   
Design    
 Cross-over 6 0.99 (0.38;1.59) 0.6 
 Parallel 9 1.21 (0.50;1.92)  
Mean Age (y)2    
 <56 7 1.01 (0.28;1.73) 0.8 
 ≥56 8 1.13 (0.53;1.74)  
Health    
 Generally healthy 8 0.84 (0.22;1.46) 0.3 
 Chronic condition 7 1.34 (0.71;1.98)  
Folic acid dose (µg/d)    
<5000  4 -0.07 (-0.37;0.22) 0.0001  
≥5000 11 1.42 (1.26;1.58)  
Study duration (wk)    
<8  5 1.16 (0.49;1.84) 0.7  
≥8  10 1.01 (0.37;1.65)  
Addition of other B-vitamins    
No vitamin B-6 and/or B-12 10 1.11 (0.60;1.62) 0.8  
Vitamin B-6, B-12, or both 5 0.93 (-0.25;2.12)  
Study quality    
 Delphi <8 5 1.34 (0.73;1.94) 0.2 
 Delphi ≥8 10 0.81 (0.20;1.43)  
1 Difference between strata. 2 One trial19 did not provide data on this variable. We set the mean 
age in this trial at 56 y, which was the median age for all trials. 
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Figure 3 Funnel plot of trial weight against change in percentage of flow-mediated 
dilatation (%FMD) in the 14 intervention trials included in the meta-analysis. The vertical 
line indicates a mean change in all studies. 
 
 
Discussion 
 
This meta-analysis of randomized, double-blind, placebo controlled clinical trials showed 
that supplementation with high doses of folic acid for 4 wk improves FMD assessment of 
endothelial function. The result of a meta-analysis depends on the studies included. In 
the present review, we used a broad specified search and also contacted investigators for 
unpublished results to prevent any possible publication bias. In addition, we avoided the 
inclusion of studies on the basis of their outcome by defining inclusion and exclusion 
criteria. The use of these criteria led to 14 eligible trials. The number of studies is not 
large, but our methods ensured that the trials had a high internal validity and were 
reasonably comparable. To account for any heterogeneity, we used a random-effects 
model, and we assessed characteristics, as described in Table 1. To ensure comparability 
of the trials, we had to exclude some trials42-51 even though they were randomized, 
double-blind, placebo-controlled trials; were not conducted in a specific patient 
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population; and assessed the effect of folic acid on endothelial function. All but one50 of 
these studies support the findings of our meta-analysis.  
 Although several review articles have indicated that folic acid could beneficially 
affect endothelial function as measured with FMD11,52, a comprehensive meta-analysis 
that takes into account both within- and between-study variability was lacking. Thus, our 
analysis is the first that provides a quantitative estimate of the improvement in FMD after 
folic acid supplementation, in which the overall effect showed a favorable change of 
1.08%FMD. A (statistically nonsignificant) larger improvement was seen in subjects at a 
higher risk of CVD (1.34%FMD) than in healthy subjects (0.84%FMD). Because the 
average FMD value in populations at greater risk of CVD was 3.6%FMD and that in 
healthy populations was 5.6%FMD, our findings indicate potential significant 
improvements of 37% in subjects at CVD risk and 9% in healthy populations. 
 An important question is the extent to which FMD can be used as a predictor of 
long-term CVD risk? It is clear that FMD is a predictor of this risk in a selected group of 
patients, such as those with coronary heart disease, heart failure, and hypertension.53-57 
However, the extent to which FMD can be used to predict the risk of CVD in the general 
population is less clear. Nevertheless, preliminary epidemiologic data showed a modest, 
positive correlation between FMD and the Framingham Study risk score in a general 
population sample of 1016 elderly persons.58 
 The FMD value indicates the bioavailability of endothelium derived NO, which is 
essential to cardiovascular health.59 High homocysteine concentrations are postulated to 
reduce NO availability in several ways. Indeed, homocysteine may induce the formation 
of free radicals, as shown by in vitro studies.60,61 A certain proportion of these free 
radicals can be neutralized by NO, but other free radicals may directly damage 
endothelial cells60, and both processes would lead to a smaller amount of available NO. 
Oxidative stress may also increase as homocysteine inhibits glutathione peroxidase61,62, a 
potent cellular defense mechanism against free radicals. Homocysteine can also reduce 
NO availability by forming S-nitrosohomocysteine complexes.63,64 Finally, homocysteine 
may induce the formation of asymetric dymethyl arginine, which is a competitive 
inhibitor of enzymatic nitric oxide synthase (eNOS).65,66 Therefore, we postulate that folic 
acid administration beneficially affects FMD by lowering the plasma homocysteine 
concentration.  
 It is conceivable that folic acid could also improve the FMD value independently of 
homocysteine lowering. This possibility is supported by 3 mechanisms that would result 
in a greater availability of NO: 1) folic acid may act as an antioxidant48; 2) it may 
regenerate the cofactor for eNOS 49, 54; and 3) it may directly stimulate eNOS.67 Two 
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indications from the present study support an independent effect of folic acid. First, post 
hoc analysis hinted toward a favorable effect with higher doses of folic acid (>5000 
g/d). A folic acid dose of 400 to 800 g/d is typically required to achieve an almost-
maximal homocysteine lowering effect over an 8-wk period4, but the present analysis 
showed that such large homocysteine reductions apparently do not result in enhanced 
%FMD.24,29,31 In contrast, this observation is based on only 3 studies involving a small 
number (ie, 185) of subjects. In addition, one of these studies may have been performed 
against the background of folic acid fortification29, although the amount of folic acid 
provided by the supplements will have been much higher than that provided by the 
fortification program. Finally, all 3 studies involved healthy young (mean age: 31 y) 
persons, who probably have the least to gain from supplementation with folic acid. Thus, 
before we discard a beneficial effect of low doses of folic acid on FMD, we would like to 
see large studies in healthy older persons or subjects with (reversible) vascular 
dysfunction (eg, overweight or smoking). Second, the combination of folic acid 
supplementation with vitamin B-12 results in an additional 7% reduction in homocysteine 
(4), yet our analysis indicates no additional benefit with vitamin B-12 and vitamin B-6. In 
addition, because the study duration had no significant effect on our study outcome, our 
result would point to an acute effect of folic acid. Taken together, the findings of the 
studies considered in this meta-analysis suggest that the effect of folic acid is largely 
independent of a homocysteine-lowering effect. Yet, we must be careful with this 
interpretation because of the small number of studies in the low and high-dose strata. 
Therefore, it would be worthwhile to investigate acute effects of several doses (low and 
high) of folic acid or dietary folate or both on FMD values in subjects with suboptimal 
folate status. 
 In conclusion, this meta-analysis indicates that a high dose of folic acid can 
improve endothelial function as measured with FMD after 4 wk of supplementation, and 
this effect would seem to be independent of a reduction in homocysteine. Restored 
endothelial function in subjects with CVD may, in the short term, not prevent another 
CVD event, as can be deduced from published secondary prevention trials.5-8 However, 
an optimized FMD may be crucial to prevent a first-ever CVD event. 
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Blood pressure is an important risk factor for cardiovascular diseases (CVD). There is a 
graded increase in risk of CVD across the entire blood pressure range. The majority of 
people in Western populations have above optimal blood pressure levels. Modest 
reductions in blood pressure on the population level have a major impact on CVD 
incidence. Favorable lifestyle changes can play an important role on the individual as well 
as on the population level to improve blood pressure and reduce the burden of CVD 
(Chapter 1).  
 The studies in this thesis addressed two general aims. The first aim was to assess 
the importance of a selected number of minerals for population blood pressure levels. 
The second aim was to investigate the effect on blood pressure and endothelial function 
of other food components that have recently attracted much attention in the scientific 
literature. In this last chapter the main findings are summarized and interpreted, 
followed by a discussion on methodological aspects of the studies, interpretation of the 
findings and relevance for public health. Finally, suggestions for future research and 
strategies to improve current potassium and calcium intakes in populations are given. 
 
 
Main findings 
 
An overview summarizing the studies in this thesis is presented in Table 1. The first 3 
chapters (Chapter 2-4) address the potential public health impact of minerals for 
population blood pressure levels. The results of a review of national surveys (Chapter 2) 
showed that current potassium intakes in countries are suboptimal (range: 1.7 – 3.7 
gram per day). Increasing intake (to 4.7 gram per day) was estimated to result in 
reductions in population blood pressure of 2-3 mmHg in Western countries. The size of 
this estimated effect on population blood pressure is comparable to that which can be 
achieved with a reduction in salt intake (from 9 to 5 gram per day). In a meta-analysis of 
40 randomized controlled studies the effect of calcium supplementation on blood 
pressure overall and in population subgroups was assessed. The results of this analysis 
indicated statistically significant reductions of 2 mmHg for systolic blood pressure and 1 
mmHg for diastolic blood pressure per ~1200 mg per day of additional calcium intake. 
Blood pressure response to calcium supplementation tended to be stronger in populations 
with a low habitual calcium intake (<800 mg/day) (Chapter 3). In an 8-week 
randomized placebo controlled parallel study in 124 subjects, the effect on blood 
pressure of daily consumption of a skimmed milk enriched in potassium (either 1500 mg 
or 750 mg), combined with relatively low doses of calcium (446 mg), magnesium (100 
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mg), selenium (40 mg), vitamin C (180 mg), vitamin E (30 mg tocopherol equivalents) 
was studied. In this study we observed no significant effects on blood pressure (Chapter 
4).  
 The last 3 chapters address the potential blood pressure lowering effect of other 
food components that have recently attracted much attention in scientific research for 
their possible effects on blood pressure and endothelial function (Chapter 5-7). Two 4-
week randomized controlled cross-over studies, including 162 Scottish subjects in total 
with untreated elevated blood pressure, were performed to examine blood pressure 
response to intake of lactotripeptides in a European population (Chapter 5). No 
antihypertensive effect of daily consumption of a dairy drink with enzymatic 
lactotripeptides (5.8 mg Isoleucine-Proline-Proline (IPP) and 4.4 mg Valine-Proline-
Proline (VPP) per day) or enzymatic lactotripeptides (2.7 mg IPP and 1.9 mg VPP) plus 
350 mg added potassium per day was found. In a 4-week randomized placebo-controlled 
cross-over study in 35 healthy male subjects the effect of two different grape solids 
(wine-grape mix and grape seed), each containing 800 mg of polyphenols, on endothelial 
function and blood pressure were investigated. No improvements in flow-mediated 
dilation and/or blood pressure were observed (Chapter 6). Finally, the effect of folic acid 
on endothelial function was assessed based on a meta-analysis of 14 randomized 
controlled studies (Chapter 7). The results of this analysis showed that supplementation 
with folic acid (median dose 5000 g per day) significantly improved flow-mediated 
dilatation by 8%. This effect was only found in studies administrating a high folic acid 
dose (≥5000 g per day).  
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Table 1 Overview of research findings of the studies presented in this thesis. 
Type of research Exposure Main findings 
Chapter 2 What is the impact of increased potassium intake on population blood pressure? 
Systematic review of 
21 national surveys 
Potassium  Increasing current suboptimal potassium intakes (range 
1.7-3.7 g per day) may result in a population BP reduction 
of 2-3 mmHg 
Chapter 3 What is the effect of increased calcium intake on blood pressure, overall and in 
population subgroups? 
Meta-analysis of 40 
randomized controlled 
studies 
Calcium  Calcium supplementation (mean: 1200 mg per day) 
significantly reduces systolic BP by 2 mmHg, and diastolic 
BP by 1 mmHg, with a tendency towards a larger effect in 
populations with low calcium intakes (<800 mg per day) 
Chapter 4 Does potassium combined with other micronutrients at low doses have beneficial 
effects on blood pressure? 
Randomized 
controlled study in 
124 Dutch subjects 
with elevated BP 
Minerals and 
vitamins 
enriched 
milk 
After 8 weeks daily consumption of a skimmed milk with 
potassium (either 1500 mg or 750 mg) in combination 
with other minerals and vitamins at low dose, no 
significant BP reductions were observed compared to a 
water placebo 
Chapter 5 Do lactotripeptides improve blood pressure in a European population? 
Two randomized 
controlled studies in 
162 Scottish subjects 
with elevated BP 
Lactotri-
peptides 
After 4 weeks daily consumption of a yogurt drink with 
lactotripeptides (study 1: 5.8 mg IPP and 4.4 mg VPP; 
study 2:2.7 mg IPP and 1.9 mg VPP plus 350 mg added 
potassium), no significant BP reductions were observed 
compared to a yogurt placebo 
Chapter 6 Does the polyphenolic fraction of grape extracts improve endothelial function and blood 
pressure? 
Randomized 
controlled study in 35 
healthy males 
Grape 
polyphenols 
After 2 weeks daily consumption of 2 grape solids (wine-
grape mix and grape seed capsules), at a level of 800 mg 
polyphenols per day, no significant improvements in 
endothelial function or BP were observed compared to 
placebo capsules 
Chapter 7 Does folic acid improve endothelial function? 
Meta-analysis of 14 
randomized controlled 
studies 
Folic acid In studies applying high doses of folic acid (≥5000 g per 
day), endothelial function as measured by flow-mediated 
dilation was improved by 8%  
BP, blood pressure ; IPP, Isoleucine-Proline-Proline ; VPP, Valine-Proline-Proline. 
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Methodological considerations 
 
This paragraph addresses a number of the methodological aspects of the studies 
presented in this thesis that are relevant for the validity of our findings. These aspects 
are discussed separately for the systematic reviews and intervention studies.  
 
Systematic reviews 
For both meta-analyses in this thesis (Chapter 3 and Chapter 7) the Quality of 
Reporting of Meta-analyses (QUORUM)1 guidelines were followed. A priori eligibility 
criteria were defined and only randomized placebo controlled studies were included in the 
meta-analyses. Because the validity of a meta-analysis depends not only on the quality 
of the data, but also on the comparability of data from the included studies2, a statistical 
approach was used to analyze the data that accounted for both within- and between-
study variability.3 Funnel plots were constructed to examine the possibility of publication 
bias. In the folic acid meta-analysis there was little evidence for publication bias. In our 
calcium meta-analysis a non-parametric ‘trim and fill’ method revealed that small trials 
reporting large blood pressure reductions were overrepresented. To account for the 
possible bias toward overestimation we adjusted our effect estimate for putative missing 
data. For all studies included in the meta-analyses changes in blood pressure or flow-
mediated dilation in the intervention group were extracted from changes in the placebo 
group the yield the net change resulting from the intervention.  
 Well-performed meta-analyses provide a more precise estimate of a treatment 
effect, but they also have some potential pitfalls that can compromise validity.4, 5 An 
important methodological aspect of meta-analyses is heterogeneity across studies. 
Heterogeneity may result from differences in study characteristics as well as from 
differences in populations studied across studies.6  
 In our meta-analysis of folic acid and endothelial function, we included 14 
randomized controlled studies with very different types of populations (e.g. healthy 
subjects and CVD patients) and study characteristics (e.g. dose of folic acid, with or 
without other B-vitamins). We explored why effects differed across studies in this meta-
analysis, but because of the limited number of studies in each subgroup and the fact that 
we did not control for confounders, the results should be interpreted cautiously. An 
improvement in flow-mediated dilation was only found for intakes of folic acid higher 
than ≥5000 g per day (P = 0.0001). It should be mentioned that studies in CVD 
patients used high doses of folic acid (5000 or 10.000 µg per day), whereas studies 
performed in healthy populations used high doses of folic acid (5000 or 10.000 µg per 
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day) as well as much lower doses of folic acid (400–800 µg per day). Therefore, it is not 
clear whether folic acid dose and/or type of population were responsible for this observed 
difference. Furthermore, it remains possible that in high risk populations lower doses of 
folic acid can result in reductions in flow-mediated dilation, but this could not be 
addressed in our meta-analysis. Another aspect relates to the fact that folic acid 
supplementation was combined with other B-vitamins (vitamin B6 or vitamin B12 or both) 
in several studies. Therefore, it could be argued that the effects observed in our meta-
analysis are not completely attributable to folic acid alone. However, this was not 
confirmed by stratified analysis (P for difference 0.8).  
 The large number of studies, 40 in total, in our meta-analysis on calcium and 
blood pressure allowed testing of the a priori hypothesis of differential effects in 
population subgroups.5 In these stratified analyses, we used a multivariable model to 
adjust for potential confounders. Though, an important limitation is that these subgroup 
analyses were performed using aggregated rather than original data. This could have 
blurred the between-group differences in blood pressure response to calcium 
supplementation. Furthermore, findings from multiple subgroup analyses should be 
interpreted with caution since these are observational by nature and not based on 
randomized comparisons. For a better insight in differences in effects between population 
subgroups, data should be assembled for each participant within the separate studies.7  
  
To estimate the impact of increasing potassium intakes to recommended levels on 
population blood pressure (Chapter 2) we relied on available data from national surveys, 
intervention and observational studies. No direct estimations of blood pressure effects for 
changes in potassium intake were made. Nevertheless, the dietary potassium intakes in 
our review are based on data from representative national surveys in >1000 participants 
using dietary assessment methods that reasonably well estimate dietary potassium 
intakes.8-13 Furthermore, our estimated effect of increasing potassium intake on blood 
pressure is based on data from the INTERSALT study and supported by data from several 
other observational studies14-17 and well-controlled intervention studies.18-21 Therefore, 
we believe our estimates are reliable.  
  
Intervention studies 
The 4 intervention studies in this thesis were double-blind randomized placebo-controlled 
studies with low drop out rates. Compliance varied between 86-99% in these studies. In 
each study changes in blood pressure and flow-mediated dilation in the intervention 
group were extracted from changes in the placebo group to yield the net change 
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resulting from the intervention. A number of limitations, however, also need to be 
addressed. Our cross-over studies (Chapter 5 and 6), were of relatively short duration 
(2-4 weeks). Nevertheless, in other studies with similar duration, blood pressure lowering 
effects of lactotripeptides22 and improvements in endothelial function for grape 
polyphenols23 were found. Extending the intervention periods, particularly for studies 
with cross-over designs, might also have negative consequences, e.g. increase in 
variation in outcome due to seasonal variations, lower compliance and higher drop-out 
rates.  
Doses of potassium in our intervention studies were relatively low, since we  
preferred a diet-based approach and expected an additive or maybe even a synergistic 
effect of potassium in combination with other micronutrients (Chapter 4) or 
lactotripeptides (Chapter 5) on blood pressure. However, the choice of these levels 
where somewhat arbitrary, and it can be debated whether higher doses would have been 
better. In our intervention study addressing the effect of combinations of minerals and 
vitamins participants consumed skimmed milk enriched in potassium at (either 1500 or 
750 mg per day), in combination with relatively low levels of other minerals and vitamins 
(calcium 446 mg, magnesium 100 mg, selenium 40 mg, vitamin C 180 mg and vitamin E 
30 mg tocopherol equivalents per day). In comparison, the amounts of the 
micronutrients tested in intervention studies addressing the effect of the individual 
micronutrients on blood pressure were much higher; median daily doses of 2933 mg for 
potassium, 500-2000 mg for calcium, 374 mg for magnesium, and 500 mg for vitamin 
C.21, 24-26 In addition, our study was powered to find a reduction in systolic blood pressure 
of 5 mmHg. Considering the relevance for public health of small reductions in blood 
pressure, nutritional intervention studies of this type should aim more at detecting 
modest effects in the order of 2-3 mmHg. The confidence intervals of the changes 
observed in our study are still compatible with a possible 2-3 mmHg reduction in systolic 
blood pressure. For potassium combined with lactotripeptides (Chapter 5), we also 
hypothesized an additive effect. However, recent studies suggest that the lactotripeptides 
do not lower blood pressure.27-31 As a result, the additional dose of 350 mg potassium in 
this study was too low for finding a significant blood pressure effect. 
  Concerning the study on grape polyphenols, it should be mentioned that the 
number of subjects (Chapter 6) was relatively small i.e. 35 normotensive men (mean 
systolic blood pressure 123 mmHg). The primary outcome in this study was endothelial 
function and not blood pressure. Therefore this study can not be taken as definitive 
evidence that grape polyphenols have no antihypertensive effect.  
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An important methodological issue in blood pressure research is statistical power; blood 
pressure shows large fluctuations within and between days32, and diet has relatively 
modest effects on blood pressure. In our four intervention studies (Chapter 4-6), we 
used several approaches to reduce variation and increase accuracy of blood pressure. 
First, participants were randomly allocated to treatment.33 Secondly, average blood 
pressure values were determined based on multiple standardized measurements of blood 
pressure on several days in an attempt to get a better estimate of each subject’s true 
blood pressure at the time of measurement. Thirdly, in our analyses we adjusted for 
baseline blood pressure by means of Analysis of Covariance (ANCOVA)33, except for the 
micronutrient intervention study. For this study we used ANOVA analysis. Furthermore, in 
the 2 lactotripeptide studies (Chapter 5) we used ambulatory blood pressure during 
screening and as the primary outcome. Several studies have shown that ambulatory 
blood pressure is a better predictor of CVD risk, and correlates more closely to 
hypertension-related organ damage.32 In addition, studies show that ambulatory blood 
pressure has a much better reproducibility than office blood pressure.32  
 
 
Interpretation of findings 
 
This section describes the studies in this thesis in light of the scientific evidence in this 
area. We separately discuss the studies addressing the effect of minerals and the studies 
addressing the effect of other food components. 
 
Minerals 
Meta-analyses of >30 intervention studies showed that increasing potassium intake 
lowers blood pressure. In these studies an increase in potassium intake of ~2-3 gram per 
day resulted in a decrease in systolic blood pressure of ~3-4 mmHg.18-21 A review of the 
scientific literature by the US Institute of Medicine showed that an adequate potassium 
intake, defined at 4.7 gram per day, blunts the age-related rise in blood pressure, 
reduces the adverse effects of high sodium chloride intake on blood pressure, reduces 
the risk of recurrent kidney stones, and possibly decreases bone loss.8 The review in 
Chapter 2 of this thesis assesses the impact of improving current potassium intakes on 
population blood pressure levels. Our findings show that improving current nation-wide 
potassium intake has the potential to result in reductions in systolic blood pressure of 2-3 
mmHg at the population level, which is comparable to the estimated effects for reduced 
sodium intake.34, 35 A number of independent organizations and authoritative bodies 
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support the link between increased potassium intake and the beneficial effect on blood 
pressure and/or CVD risk36-39, and several recent publications highlighted a critical role 
for potassium in relation to blood pressure and CVD40-42, but to the best of our knowledge 
no other studies assessed the impact of suboptimal potassium intake levels on population 
blood pressure levels in different countries.  
Comparison of our data on potassium intakes obtained from national surveys with 
other data sources, such as 24-hour urinary potassium excretion data from INTERSALT 
(1982-1985)43 and INTERMAP (1990-1997)44 suggests that potassium intakes in 
populations may have increased over time. The recently reported potassium intake data 
based on the EPIC study45 suggest that intakes for most countries are similar to those 
based on national surveys. This comparison should be done with caution, because of 
essential differences in methodology of assessing potassium intake (urinary excretion 
versus dietary assessment) and in sampling of subjects (representative versus not 
representative for total population). Nevertheless, these different types of data together, 
are consistent in pointing to lower potassium intake levels in populations than the 
recommended intake as set by the Institute of Medicine.8 
 
The meta-analysis in Chapter 3 addresses the effect of calcium supplementation on 
blood pressure. Previous meta-analyses of intervention studies24, 46, 47 showed reductions 
of 0.9-1.4 mmHg for systolic blood pressure and 0.2-0.8 mmHg for diastolic blood 
pressure after calcium supplementation. In these meta-analyses heterogeneity between 
studies was observed, but the effect in population subgroups was only partly addressed. 
In our meta-analysis of 40 randomized controlled studies, we tried to explain this 
heterogeneity and addressed the impact of calcium supplementation on blood pressure in 
various population subgroups based on pre-defined subgroup analyses (Chapter 3). Our 
results confirm a blood pressure lowering effect of 2 mmHg for systolic blood pressure 
and 1 mmHg for diastolic blood pressure after a mean increase in calcium intake of ~1.2 
gram per day, in addition to intake from the diet. The effects in our updated meta-
analysis were somewhat larger than the effects observed in previous meta-analysis.24, 46, 
47 The meta-analysis by Griffith et al. showed a reduction in systolic blood pressure of 1.4 
mmHg and 0.8 mmHg for diastolic blood pressure.24 Several methodological aspects 
might explain this difference in estimated effects between our meta-analysis and the 
meta-analysis by Griffith et al. For example, our exclusion criteria were stricter, 
especially with regard to co-intervention of calcium with other nutrients or as part of a 
dietary intervention, but also for other inclusion criteria, such as studies performed in 
populations with renal disease or hyperparathyroidism. In addition, we included 6 studies 
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that were not included in previous meta-analyses. Other methodological and statistical 
aspects that might explain differences in estimated effect are selection of blood pressure 
outcome to use in the meta-analysis when more than one different measurement method 
is reported for an individual study; the way data from studies with more than one 
intervention group were included in the meta-analysis; and the approach used to 
estimate the variance of the blood pressure change in the individual studies. 
Our subgroup analyses showed that the blood pressure level of populations with 
lower calcium intakes (≤800 mg per day) may particularly benefit from an increased 
intake of calcium. This was not addressed in previous meta-analyses estimating the 
effect of calcium supplementation in the general population.24, 46, 47 Several intervention 
studies in children and pregnant women, both population subgroups with increased 
calcium requirements48, support our findings and also observed larger blood pressure 
reductions after calcium supplementation in individuals with lower initial calcium 
intakes.49-52  
 
In our 8-week randomized controlled trial in 124 Dutch subjects we observed no 
significant blood pressure lowering effect of potassium (either 1500 mg or 750 mg per 
day) combined with these specific other micronutrients at low dose (calcium 446 mg, 
magnesium 100 mg, selenium 40 mg, vitamin C 180 mg, vitamin E 30 mg tocopherol 
equivalents per day) in a dairy matrix (Chapter 4). No other intervention studies have 
investigated the effect of intake of multiple minerals combined with vitamins on blood 
pressure. Few studies investigated the effect of multiple minerals on blood pressure.53-57 
In 2 large scale studies (study 1: 125 subjects with untreated mild or borderline 
hypertension; study 2: 321 normotensive women with low habitual intakes) conducted 
by Sacks et al.55, 56 with long duration (16 weeks and 6 months) no indications for 
additive effects of combinations of potassium, calcium and magnesium supplements were 
found. Two relatively small studies (study 1:  53 normotensive female students on a low 
calcium diet; study 2: 38 participants) with shorter intervention periods (4 and 6 weeks), 
suggested possible blood pressure reductions of combinations of potassium, calcium and 
magnesium in a dairy matrix (see Introduction, Chapter 1).54, 57 In our study we could 
not confirm a significant blood pressure lowering effect of a combination of 
micronutrients in a dairy matrix. We considered several explanations why studies 
investigating combinations of micronutrients did not show strong suggestions for a blood 
pressure lowering effect. As explained the levels of micronutrients in our and other 
studies on combinations of minerals were much lower compared to the levels tested in 
studies addressing the effect of individual minerals on blood pressure (median daily dose 
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for potassium: 2933 mg, for calcium range 500-2000 mg, for magnesium 374 mg, for 
vitamin C:500 mg).21, 24-26 The differences in mineral content between the DASH diet and 
its control diet was also much larger (4415 versus 1752 mg for potassium, 1265 versus 
443 mg for calcium, and 480 versus 176 mg for magnesium).58 Another explanation for 
the small or absent effects that we observed might be that calcium and magnesium or 
other micronutrients interfere with the blood pressure lowering effects of potassium. This 
has also been suggested by Sacks et al.56 Recent studies indicate that potassium 
bicarbonate, in contrast to potassium chloride, reduces urinary calcium excretion.59-61 In 
the DASH combination diet, excretion of urinary calcium was not increased, despite the 
large increase in calcium intake in this diet, and the “Fruits and vegetables diet” induced 
a reduction in urinary calcium.62 This might also explain why the small studies 
investigating the effect of combinations of minerals in a natural matrix did find 
indications for blood pressure lowering effects54, 57, whereas the studies performed with 
mineral supplements, using potassium chloride, did not.55, 56  However, this cannot 
explain why we did not observe blood pressure lowering effects in our study, as we used 
potassium lactate, which is a bicarbonate precursor.  
 
In summary, our findings add to other evidence in underscoring the importance of 
increasing current potassium intakes for improving population blood pressure levels. 
Furthermore our data confirm a modest effect of increasing calcium intake on blood 
pressure levels in the general population, and show that this effect might have a larger 
impact in populations with low habitual calcium intakes. This hypothesis is supported by 
findings from other studies in population subgroups with increased calcium requirements, 
e.g. children and pregnant women. The intervention study in this thesis on blood 
pressure effects of potassium combined with other minerals and vitamins at low doses 
does not provide evidence for additive effects of these micronutrients. This is in line with 
a limited number of other blood pressure studies addressing combinations of minerals at 
low doses.  
 
Other food components 
The results of our two randomized controlled studies, which involved a total of 162 
Scottish subjects, do not suggest a blood pressure lowering effect of lactotripeptides 
(Chapter 5). Dairy peptides, and particularly lactotripeptides, have been tested in many 
intervention studies for their possible blood pressure lowering effect. Most studies were 
performed in Japan.63-67 Studies from Finland have also found blood pressure lowering 
effects, but these were smaller than in Japan.68-71 Recently, several well-designed and 
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large scale intervention studies on lactotripeptides and blood pressure in other European 
populations have been published.27-31 These data do not suggest beneficial effects on 
blood pressure of these peptides, which is in line with the results from our studies. The 
combined IPP and VPP intake tested in our studies (study 1: 10.2 mg per day and study 
2: 4.6 mg per day) was comparable or higher than in most of the Japanese and Finnish 
studies (3-5 mg per day).72 Of note is that lactotripeptides, which are assumed to be 
the active ingredients, can be generated by different processes. In most of the recent 
studies27, 31, including our own studies, the lactotripeptides were obtained via enzymatic 
hydrolysis. On the contrary, in most Japanese and Finnish studies fermented 
lactotripeptides were used, either in the form of fermented milk or fermented powdered 
milk.31 One could argue that fermented lactotripeptides have different blood pressure 
lowering properties, because they contain in addition to IPP and VPP a significant amount 
of other peptides, which may also affect blood pressure.31 Engberink et al.28 investigated 
fermented powdered lactotripeptides, enzymatic lactotripeptides, and also synthetic 
lactotripeptides in an intervention study, in 135 Dutch subjects with elevated blood 
pressure, but did not confirm this hypothesis. The fermented powdered lactotripeptides 
tested in this study were gained from dried fermented milk after removing micro-
organisms, casein and lactic acid. Fermented milk, however, was not tested in this study 
and contains in addition to lactotripeptides uncleaved protein, lactic acid, micro-
organisms and minerals like potassium, calcium and magnesium. Therefore, it can not be 
excluded that other compounds in fermented milk might be responsible for the blood 
pressure lowering effects observed in Japanese and Finnish studies.   
 There are also several methodological shortcomings in the Japanese and Finnish 
studies that might explain the differences in effect sizes found between the recent 
lactotripeptide studies and the studies performed in Asian and Finnish populations. In a 
number of these intervention studies placebo effects were not taken properly into 
account and in other studies initial blood pressure levels tended to be higher in the 
intervention group than in the control group.72 Furthermore, differences in genetic 
background and habitual diet might explain (part of) the heterogeneity.73  
 
Two different polyphenol-rich solids in capsules, derived from a wine-grape mix or grape 
seed, were examined for their effect on flow-mediated dilation and compared to placebo 
capsules in a randomized crossover study (Chapter 6). No significant effects on 
endothelial function and blood pressure were observed. The total daily dose of grape 
polyphenols for both interventions was 800 mg, according to gallic acid equivalents, 
which is considerable and higher than the total polyphenol content in a glass of 100% 
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fruit juice (0.4-3.8 mg/ml) or a glass of red wine (2.2 - 3.5 mg/ml).74, 75 The amount of 
polyphenols tested in our intervention study was comparable to that in the 4 other small 
intervention studies (15-40 participants) addressing the chronic effects (2-8 weeks) of 
the polyphenolic fraction of grape consumption (759-1664 mg polyphenols per day) on 
endothelial function and/or blood pressure.76-79 Some of these studies suggested 
improvements in endothelial function or blood pressure, but the quality of these studies 
was relatively poor; only 2 studies included a control group (see Introduction, Chapter 
1).  
Polyphenols, and particularly flavonoids, are increasingly being investigated in 
intervention studies for their effects on CVD risk factors.80 Evidence for efficacy in 
humans varies between the different polyphenol subclasses. For some flavonoids 
sources, e.g. cocoa, effects on blood pressure and endothelial function are promising, but 
results are still based on a limited number of mainly small intervention studies.80 It is 
important to note that research on polyphenols is complex. Not only because of the huge 
number of different polyphenols81, but also for other reasons; the bioavailability of 
polyphenols is limited, polyphenols are extensively metabolized, and the polyphenol 
content of foods is dependent on many factors, including genetics, environmental and 
agronomic factors and processing techniques.82, 83 In addition, most intervention studies 
on CVD risk factors focused on polyphenol-rich foods. As a result it is unclear whether 
observed effects are fully attributable to the polyphenols.80, 81  
 
In Chapter 7 the evidence for effects of folic acid on endothelial function as measured by 
flow-mediated dilation was reviewed in a meta-analysis of randomized controlled studies. 
Results indicate an improvement in endothelial function after consumption of folic acid, 
but only at high doses (≥5000 g per day). Also, effects seemed to be larger in 
populations with CVD compared to healthy populations. Another recent meta-analysis, 
only including studies with high doses of folic acid (≥5000 g per day), concluded that 
folic acid reduced systolic blood pressure by 2 mmHg, but not diastolic blood pressure, 
and increased flow-mediated dilation by 1.61%.84 The majority of studies included in this 
meta-analysis were conducted in patients. Thus, available results suggest that folic acid 
can improve endothelial function when applied at high doses in patients, but effects at 
lower doses in the general population are not supported by current evidence.  
 It is important to mention here that several large-scale randomized controlled 
intervention studies, mainly secondary prevention studies, have tested effects of folic 
acid supplementation on CVD mortality and morbidity. These trials were set up because 
folic acid reduces plasma homocysteine levels and observational data showed a link 
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between elevated blood homocysteine and risk of CVD. Results of these intervention 
studies did not confirm a reduction in CVD mortality and/or morbidity after folic acid 
supplementation.85, 86 The fact that many conditions and CVD risk factors, e.g. diabetes 
and smoking, are associated with increased homocysteine levels, and the discrepancy 
between the epidemiological data and results of intervention studies and suggest that 
homocysteine levels are a marker rather than a cause of CVD.86 These data also indicate 
that if folic acid would have some effect on flow-mediated dilation, the relevance of 
increased folic acid intake for long-term CVD outcome is limited.  
 
In conclusion, in line with other recent studies, our data confirm that the lactotripeptides 
IPP and VPP do not exert a beneficial effect on blood pressure in European populations. A 
blood pressure lowering effect for fermented milk products and in Asian populations 
cannot be excluded based on the data available, although we consider it unlikely. Only a 
few intervention studies in humans have addressed the effect of grape polyphenols on 
blood pressure and/or endothelial function. Based on these and our own data, we 
conclude that evidence on vascular health benefits is insufficient. Two meta-analyses, 
including our own, suggest that folic acid may have beneficial effects on endothelial 
function, but only at high doses (≥5000 g per day). This evidence is based on a limited 
number of studies with substantial heterogeneity regarding study and population 
characteristics between the included studies.  
 
 
Relevance for public health 
 
Several aspects need to be considered when estimating the potential health impact of 
dietary changes in free-living populations based on effects measured in controlled 
intervention studies. These include differences in compliance, and uncertainties about the 
extent to which effects observed in short-term studies under experimental conditions and 
with different subjects can be translated to longer term effects in the general population. 
Participants in intervention studies are more motivated towards dietary changes than 
people in the general population. Furthermore, effects observed in most intervention 
studies are based on relatively short duration (weeks). It is conceivable that adherence 
to diets after longer follow-up periods will reduce. In addition, blood pressure effects of 
dietary changes tend to be stronger in (pre)hypertensives compared to normotensives.20, 
87-89 In intervention studies, participants are often selected on basis of elevated blood 
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pressure levels. As a result, the effects on blood pressure in the free-living population will 
likely be smaller compared to the effects observed in intervention studies. 
 Regardless of this possible overestimation of the true potential to affect blood 
pressure in intervention studies, the majority of people in populations in Western 
countries have high-normal blood pressure, and even small reductions in blood pressure 
on a population level will have a large public health impact.90-94 For instance, a 
population-wide reduction in systolic blood pressure of 2 mmHg is estimated to reduce 
stroke mortality by ~10% and mortality from ischemic heart disease or other vascular 
causes by ~7%.95 Thus, even though favorable effects of dietary interventions on a 
population level might be smaller than effects found in intervention studies, these small 
changes on population blood pressure level are still highly relevant. 
 
Minerals 
We estimated that a nation-wide increase in potassium intakes (to 4.7 gram per day) has 
the potential to reduce systolic blood pressure by about 2-3 mmHg in Western 
populations (Chapter 2). Intervention studies showed larger effects of increased 
potassium intake on blood pressure in subjects with a high salt intake20, 21, which is the 
case in current societies.96 Furthermore, the sodium to potassium intake ratio may be 
more strongly related to blood pressure43 and CVD risk42 than sodium and potassium 
alone. Therefore, a strategy combining an increase in potassium intake with reductions in 
sodium intake could be a more powerful strategy to reduce population blood pressure 
levels than salt reduction alone. Next to favorable effects of increasing potassium intake, 
potential adverse effects should also be considered. In the general  population dietary 
potassium intake above recommended levels does not lead to a potential risk for adverse 
health effects as excess potassium is readily excreted in the urine.97, 98 Some specific 
subgroups, such as people with severely impaired kidney function and patients on certain 
type of blood pressure lowering medication should avoid high potassium intake.99-101 In 
practice, most of these patients are under medical supervision and follow specific 
guidelines to control mineral intake.8, 98 
 
The results of our meta-analysis (Chapter 3) suggest that not only potassium, but also 
adequate calcium intake is relevant for population blood pressure levels. Increasing 
calcium intakes might be especially relevant for populations in which calcium intake is 
relatively low, as is indicated by our subgroup analysis. Regarding the source of calcium, 
data do not suggest a clear difference in efficacy between dietary and supplemental 
calcium sources for lowering blood pressure.24 Public health guidelines could consider the 
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evidence for the blood pressure lowering potential of adequate calcium intakes when 
setting future recommended intakes for calcium. Current recommended intakes for 
calcium in adults are largely based on its favorable effects on bone health102, and vary 
from 800-1000 mg per day.103, 104 Calcium intakes in Europe are not optimal, especially 
females frequently consume less than the recommended intakes.104 A report from the 
World Health Organization shows that calcium is one of the nutrients of greatest concern 
for public health, and that intakes in developing countries are even lower than in 
Europe.102 High calcium intakes of 2500 mg from both diet and supplements were found 
to be well tolerated in many studies of long duration, and there does not seem to be 
reason to restrict calcium intake because of adverse effects 102, 105, 106  
 
Data from studies with combined potassium, calcium, and magnesium intake, including 
our own study (Chapter 4) do not support an additive effect on blood pressure. 
However, only a limited number of studies addressed the combined effect of these 
minerals, and the doses of the individual minerals in these studies were relatively low 
compared to those in studies addressing the effect of individual minerals. Furthermore, 
our study was not designed to detect relatively small reductions in systolic blood 
pressure, i.e. 2-3 mmHg, that are still relevant for public health. 
 
Other food components 
Current evidence, based on a large number of studies, does not support a 
antihypertensive effect of the lactotripeptides IPP and VPP (Chapter 5). However, a 
beneficial effect of fermented milk and in Asian populations cannot be excluded. For 
assessing the potential health impact of dietary effects on endothelial function, additional 
prospective studies should address the importance of endothelial function for predicting 
CVD risk. Without such data, effects on endothelial function as observed in intervention 
studies cannot be translated to relevance for public health. Regarding grape polyphenols 
and blood pressure, well-controlled intervention studies are scanty and findings cannot 
yet be translated into public health practice.  In our meta-analysis on folic acid and 
endothelial function, we concluded that folic acid at high doses (≥5000 mg per day) may 
improve endothelial function. However, this finding is of limited value for public health. 
Apart from our considerations regarding endothelial function as a risk marker for CVD, 
the evidence was based on a limited number of studies, largely performed in patients, 
and at doses of folic acid intake that cannot be attained by every-day diets. Furthermore, 
results from recent intervention studies do not suggest that supplementation of folic acid 
and other B-vitamins has much relevance for reducing CVD risk.85, 86  
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Future research directions 
 
The present thesis provides several directions for further research. Some 
recommendations for establishing the relevance of minerals, polyphenols and for 
improving blood pressure at the population level are given below. 
 
Research may focus on both the practical aspects and feasibility of increasing the intake 
of potassium on a large, population-based scale, as well as assess the impact on 
population blood pressure under long-term, every-day conditions.  
 Furthermore, randomized controlled intervention studies of reduced sodium plus 
increased potassium intake compared to reduced sodium intake alone, are warranted. 
Such studies should provide additional evidence for the potential of a reduction in sodium 
intake combined with an increased potassium intake for population blood pressure levels.  
Intervention studies in various population subgroups49-52, including our own meta-
analysis, suggest that calcium supplementation might be especially relevant for blood 
pressure in population subgroups with low habitual calcium intakes.49-52 To test this 
hypothesis, a randomized placebo controlled intervention study could be performed in 
which the effect of increasing calcium intake on blood pressure in participants on a low 
calcium diet is compared with the effect on a normal or high calcium diet.  
More insight in bioavailability and metabolism is needed to address which of the 
many individual polyphenols and/or combinations of polyphenols, are most promising for 
further study in the field of vascular function.  
 
In meta-analyses, the options for addressing heterogeneity and investigating differences 
between different subgroups are often limited due to restrictions in the availability of the 
data from the individual studies. To allow systematic evaluation of subgroups, guidelines 
for reporting stratified data in future intervention studies would be useful.  
 An increasing number of studies, including two studies in this thesis, address 
endothelial function as primary outcome. Whether endothelial function predicts 
hypertension or CVD is not yet known. Therefore, additional prospective cohort studies in 
the general population should address the relevance of endothelial function as a reliable 
risk indicator for CVD (risk factors). 
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Strategies to improve mineral intake in populations 
 
While adequate intakes of potassium and calcium are potentially important for population 
blood pressure levels, as supported by our and several other studies, many more studies 
have demonstrated the efficacy of decreasing sodium intakes. Since current intakes of 
sodium are too high and potassium and sodium together play an important role in 
regulating blood pressure and CVD risk34, 43, 107, public health strategies should aim at 
adequate potassium and calcium intakes, combined with reductions in sodium intake. 
This paragraph discusses current guidelines and strategies in the area of mineral intakes 
and population blood pressure, and provides suggestions for governmental and food 
industry actions to improve current intakes in populations. 
 
Current guidelines and strategies 
Many guidelines and publications have addressed the importance of reducing salt intakes 
worldwide and in some countries strategies and programs to reduce salt intake have 
been implemented. However, even in countries in which salt intake has been reduced 
over the past years, the actual intake is still higher than recommended.108, 109 Research 
from the World Health Organization has shown that salt reduction strategies can be 
implemented at low cost and result in large reductions in mortality.110  
 A number of independent organizations and authoritative bodies also acknowledge 
that increasing potassium intake lowers blood pressure and reduces the risk of stroke.32, 
36, 111 In the United States of America and Canada a review by the  US Institute of 
Medicine showed that an adequate potassium intake, defined as 4.7 gram per day, blunts 
the age-related rise in blood pressure, reduces the adverse effects of high sodium 
chloride intake on blood pressure, reduces the risk of recurrent kidney stones, and 
possibly decreases bone loss.8 In addition, several recent publications have highlighted a 
critical role for potassium in relation to blood pressure and CVD risk.40-42 Current 
recommendations for calcium are primarily directed towards the prevention of 
osteoporosis.102 
 
Suggestions for improvement of current strategies 
Improving compliance to general dietary guidelines which recommend an increased 
intake of fruit and vegetables and low-fat dairy products would be an effective way to 
increase intake of both potassium and calcium. Both nutrients are abundantly available in 
these foods, but education programs aimed to optimize dietary intakes take a relatively 
long time to be effective. For example, in the United Kingdom (UK), despite many efforts 
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to promote the simple, clear, positive, quantified and food-based “five a day” campaign, 
there has been little improvement in fruit and vegetable intake.112, 113 These data are in 
line with general findings in Europe showing that nutrition policies are in place, but 
strong support for the implementation and evaluation of those policies is lacking.114 
 In order to successfully improve dietary mineral intakes, two complementary 
approaches can be considered for which collaboration between governmental bodies and 
the private sector is crucial. First, the availability, affordability and accessibility of foods 
with a healthy mineral composition could be increased to encourage individuals to 
improve their mineral intakes.114 Preferably, these changes need to affect the whole food 
range, from cheap to more expensive foods and not only in supermarkets, but also in 
restaurants.109, 114 Secondly, dietary modifications that do not depend on individual 
choice might be implemented by modifying the food supply.112 To improve the potassium 
and calcium content in foods, several options are available. One option is to use more 
potassium-rich and calcium-rich foods in processed foods. Other options are to restore 
losses in healthy minerals during food processing and/or to (partly) replace regular 
sodium chloride salt by potassium chloride mineral salts. In terms of health this last 
option will provide a double benefit. Implementation of these changes in the food 
environment combined with improvements in the mineral composition of foods that are 
habitually consumed can have a substantial impact on longer-term overall healthier 
mineral intake in the population.  
 
 
 
To summarize, the main conclusions of this thesis are:  
1. Adequate potassium and calcium intakes may play an important role in the 
prevention and control of hypertension at the population level. 
2. Evidence for blood pressure lowering effects of lactotripeptides and for 
improvements in endothelial function by grape polyphenols and folic acid is 
limited. 
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Box 
What was already known 
 A healthy diet can substantially lower BP. Small reductions in BP on the population level have a large impact on CVD morbidity and mortality. 
 Minerals play an important role in BP regulation. Decreasing sodium intake and increasing potassium intake, and to a lesser extent increasing calcium intake can 
reduce BP. An additive or synergistic effect of minerals has been tested in a few studies, with conflicting results. 
 Lactotripeptides may lower BP, but evidence is mainly based on studies performed in Japan and Finland. Grape polyphenols have been suggested to improve BP 
and endothelial function, but evidence from randomized controlled studies is limited. The effect of folic acid on endothelial function is studied in several 
intervention studies, but effects over a wide dose range, including lower dose levels, have not been systematically reviewed. 
What this thesis adds 
 Current potassium intakes in countries are below the recommended level. A nation-wide increase in potassium intake can result in substantial reductions in BP 
levels in Western populations. 
 We confirmed a BP lowering effect of calcium intake that may be especially relevant for populations with low habitual intakes. 
 We could not establish a BP lowering effect of potassium combined with other micronutrients at low doses in Dutch subjects with untreated elevated BP levels. 
 Lactotripeptides did not lower BP in Scottish subjects with untreated elevated BP. 
 Grape polyphenols had no effect on endothelial function and BP in healthy male Dutch subjects. 
 Folic acid could improve endothelial function, but only at high doses, that can not be attained by every-day diets. 
Public Health implications 
 Public health measures to encourage potassium intake (preferably from foods) are warranted, next to reductions in sodium intake. In populations or population 
subgroups with low calcium intakes, BP may benefit from increased calcium intake.  
 Fruit, vegetables and low-fat dairy are good sources of potassium and calcium. Consequently, increased intakes of these minerals can be achieved by strategies 
improving compliance to existing dietary guidelines. In addition, the government and food industry should act in concert to improve mineral intakes in 
populations, thereby reducing the prevalence of hypertension and burden of CVD. 
BP, blood pressure.
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Blood pressure levels show a graded independent relationship with risk of cardiovascular 
diseases (CVD). The majority of people in Western populations have blood pressure 
levels above optimal (i.e. ≥120/80 mmHg) and modest reductions in blood pressure on 
the population level can substantially reduce CVD incidence. Established lifestyle changes 
that lower blood pressure include weight loss, increased physical activity, moderation of 
alcohol intake, increased dietary potassium intake and reduced dietary sodium intake. 
Blood pressure is regulated by several physiological mechanisms, which also involve 
endothelial function.  
 
The studies in this thesis have been initiated to investigate the effect of micronutrients 
and other bio-active food components on blood pressure and endothelial function, with 
two main objectives:  
1. To assess the potential impact of selected minerals intake on population blood 
pressure levels. 
2. To investigate the effects of ‘emerging’ food components on blood pressure and 
endothelial function. 
 
Impact of minerals on population blood pressure 
Three studies described in this thesis assess the effects of mineral intakes on population 
blood pressure levels. The first two chapters (Chapter 2 and 3) focus on potassium and 
calcium and the third (Chapter 4) on milk enriched with a combination of minerals and 
vitamins. 
A systematic review of national dietary surveys estimates the potential impact of 
increasing potassium intake on population blood pressure (Chapter 2). Several meta-
analyses of intervention studies have shown that potassium supplementation of 2–3 
grams per day reduced systolic blood pressure by 3-4 mmHg, but the potential impact of 
improving potassium intakes on population blood pressure levels has not been estimated 
in previous studies. Our review of data from 21 countries shows that current potassium 
intakes are lower (range: 1.7–3.7 gram per day) than the current recommendation of 4.7 
gram per day. We estimated that increasing intake to this level has the potential to 
reduce population systolic blood pressure by 2-3 mmHg in Western countries. The size of 
this projected effect is comparable to that which can be achieved with a reduction in salt 
intake from current intakes of about 9 gram per day to the recommended level of 5 gram 
per day.  
Chapter 3 describes a meta-analysis of intervention studies on calcium 
supplementation and blood pressure. Previous meta-analyses of such intervention studies 
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showed reductions of 0.9-1.4 mmHg for systolic blood pressure, and 0.2-0.8 mmHg for 
diastolic blood pressure with calcium supplementation. These analyses only partly 
addressed the importance of increasing calcium intake in different population subgroups. 
We included 40 randomized controlled intervention studies, and investigated the 
importance of calcium supplementation on blood pressure for different population 
subgroups. Our analysis showed that calcium supplementation (mean dose 1200 mg per 
day) for at least two weeks significantly reduced systolic blood pressure by 1.9 mmHg 
and diastolic blood pressure by 1.0 mmHg. In addition, the data suggest that response of 
blood pressure to calcium supplementation tends to be stronger in populations with 
habitual calcium intakes <800 mg per day than in populations with intakes ≥800 mg per 
day.  
 The blood pressure effects of individual minerals have repeatedly been studied, 
but only a limited number of studies investigated the effects of combinations of minerals 
on blood pressure. Our 8-week double-blind randomized placebo controlled parallel study 
in 124 Dutch subjects examines the effect on blood pressure of a combination of minerals 
and vitamins in a dairy matrix (Chapter 4). Participants daily consumed either one of 
two types of skimmed milk enriched in potassium (either 1500 mg or 750 mg), combined 
with calcium (446 mg), magnesium (100 mg), selenium (40 mg), vitamin C (180 mg) 
and vitamin E (30 mg tocopherol equivalents) or placebo (water). Reductions in office 
systolic blood pressure after 8 weeks intervention were not significantly different 
between groups (P = 0.94). However, our study was not sufficiently powered to detect 
reductions in systolic blood pressure of 2-3 mmHg or less that can be considered relevant 
at the population level. 
 
Other food components and blood pressure (related) effects 
Three studies in this thesis address other food components that recently received much 
attention for their possible beneficial effects on blood pressure and/or endothelial 
function (Chapter 5, 6 and 7).  
Chapter 5 presents the effect of lactotripeptides on blood pressure based on the 
results of two double-blind, randomized, placebo controlled, cross-over studies. Other 
intervention studies, mainly studies performed in Japanese and Finnish populations, 
showed promising blood pressure lowering effects of dairy peptides, in particular for the 
lactotripeptides Isoleucine-Proline-Proline (IPP) and Valine-Proline-Proline (VPP). 
However, more recent studies in non-Finnish European populations found no significant 
blood pressure lowering effects of lactotripeptides. In our two 4-week intervention 
studies, we investigated the effect on blood pressure of lactotripeptides (mainly IPP and 
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VPP) obtained by enzymatic hydrolysis (study 1: 10.2 mg per day; study 2: 4.6 mg plus 
350 mg per day added potassium) in the form of a yoghurt drink in 162 Scottish 
subjects. No antihypertensive effects of the lactotripeptides were found; the mean 
difference in 24-h ambulatory systolic blood pressure response between intervention and 
placebo were 0.6 mmHg (P = 0.55) in study 1 and -0.9 mmHg (P = 0.42) in study 2.  
Chapter 6 addresses the effect of the polyphenolic fraction of two different solid 
grape extracts on endothelial function and blood pressure, in a randomized double-blind 
placebo controlled crossover study. Experimental data have suggested that red wine and 
its constituents can induce vasodilatation by increasing production of nitric oxide, but 
evidence from controlled human intervention studies is still limited. Earlier studies mostly 
addressed acute effects on endothelial function after administration of red wine, and 
were performed in patients with CVD, rather than in healthy subjects. In our study in 35 
healthy male subjects, with 2-week intervention periods we tested the effects on 
endothelial function and blood pressure of two polyphenol-rich solids at a dose of 800 mg 
of polyphenols per day. One solid extract was derived from a wine-grape mix, 
representing a broad range of polyphenols (monomeric anthocyanins, catechins, 
flavonols, procyanidins and stillbenes and unidentified oligomers and polymers). The 
grape seed primarily consists of monomeric catechins and unidentified oligomers and 
polymers. Compared to placebo, both the wine-grape mix and grape seed extract did not 
significantly affect endothelial function as measured with flow-mediated dilation (-0.4%; 
P=0.77 and 0.2%; P=0.94, respectively) or office blood pressure (systolic blood 
pressure: -1.3 mmHg; P=0.70 and -0.6 mmHg; P=0.92, respectively).  
Chapter 7 presents a meta-analysis of intervention studies on folic acid and 
endothelial function. Our combined estimate of 14 randomized, placebo-controlled 
intervention studies indicated that folic acid supplementation at a median dose of 5000 
g per day for at least 4 weeks significantly improved flow mediated dilatation by 1.1% 
over placebo. However, effects were confined to higher doses of folic acid (≥5000 g per 
day). In addition, results indicated a larger effect in populations with CVD than in healthy 
populations. 
 
Conclusions 
With regard to dietary minerals, we conclude that increasing the intake of potassium, 
which is generally below the recommended level in Western countries, and calcium, 
especially in populations with intakes <800 mg per day, has the potential to improve 
population blood pressure levels. Future population-based intervention studies should 
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bear out the blood pressure lowering potential of potassium, preferably in combination 
with sodium reductions. 
 Our well-controlled studies refute that lactotripeptides in the form of isolated IPP 
and VPP can lower blood pressure. Although we consider it unlikely, beneficial blood 
pressure effects of fermented milk and of lactotripeptides in Japanese and Finnish 
populations can not yet be fully ruled out. We were not able to detect any effect of grape 
polyphenols on blood pressure or endothelial function. More insight in bioavailability and 
metabolism of polyphenols is needed to address which specific species or combinations of 
the many polyphenols in foods are most promising for further studies. Folic acid can 
improve endothelial function at high doses (≥5000 g per day), but we consider this of 
limited value for public health as such intakes are far beyond what can be attained by 
diet.  
  For improving blood pressure at the population level, adherence to dietary 
guidelines is primarily recommended to achieve more optimal intakes of potassium and 
calcium from fruits, vegetables, and low-fat dairy products. In addition, the government 
and food industry should act in concert to improve mineral intakes in populations, 
thereby reducing the prevalence of hypertension and burden of CVD. 
 
The main conclusions of this thesis are:  
1. Adequate potassium and calcium intakes may play an important role in the 
prevention and control of hypertension at the population level. 
2. Evidence for blood pressure lowering effects of lactotripeptides and for 
improvements in endothelial function by grape polyphenols and folic acid is 
limited.
   
   
 
 
 
 
Samenvatting
Samenvatting 
 
 
176 
Bloeddruk is rechtevenredig en onafhankelijk gerelateerd aan het risico op hart- en 
vaatziekten. De bloeddruk van de meeste mensen in Westerse landen is hoger dan 
optimaal (≥120/80 mmHg). Kleine verlagingen van de bloeddruk in de bevolking kan de 
incidentie van hart- en vaatziekten aanzienlijk verminderen. Leefstijlveranderingen met 
een bewezen bloeddrukverlagend effect zijn onder andere gewichtsverlies, meer 
bewegen, verminderen van de alcoholconsumptie, een hogere kaliuminname en een 
lagere natriuminname. Bloeddruk wordt gereguleerd door verschillende fysiologische 
mechanismen, onder andere door de functie van het endotheel (de binnenbekleding van 
de bloedvaten).  
  
In dit proefschrift hebben we het effect van micronutriënten en andere 
voedingscomponenten op de bloeddruk en de functie van het endotheel onderzocht, met 
twee belangrijke doelstellingen:  
1. Het schatten van de invloed van de inname aan mineralen op de bloeddruk in de 
bevolking. 
2. Het onderzoeken of een aantal andere ‘veelbelovende’ voedingscomponenten een 
gunstig effect op de bloeddruk en endotheelfunctie hebben. 
 
Mineralen en bloeddruk in de bevolking 
In de hoofdstukken 2, 3 en 4 van dit proefschrift onderzoeken we hoe belangrijk de 
inname aan mineralen is voor de bloeddruk in de bevolking. Hoofdstuk 2 en 3 richten 
zich op kalium en calcium. Hoofdstuk 4 richt zich op melk verrijkt met een combinatie 
van mineralen en vitamines.  
De mogelijke effecten van een hogere kaliuminname op de bloeddruk in de 
bevolking worden berekend in een systematisch overzichtsartikel van nationale 
voedselconsumptiegegevens (Hoofdstuk 2). Verschillende eerdere meta-analyses van 
interventie-onderzoeken laten zien dat het verhogen van de kaliuminname met 2-3 gram 
per dag de systolische bloeddruk (bovendruk) met 3-4 mmHg kan verlagen. Eerdere 
onderzoeken hebben echter niet onderzocht wat het mogelijke effect is van het verhogen 
van de kaliuminname op de bloeddruk in de bevolking. Uit ons review, waarin we 
voedingsgegevens van 21 landen hebben meegenomen, blijkt dat de huidige inname aan 
kalium (range: 1,7-3,7 gram per dag) lager is dan de aanbeveling van 4,7 gram per dag. 
We schatten dat het verhogen van de kaliuminname tot het aanbevolen niveau leidt tot 
een verlaging van de systolische bloeddruk in de populatie met 2-3 mmHg in Westerse 
landen. Dit effect is vergelijkbaar met het effect dat bereikt kan worden met een 
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verlaging van de huidige consumptie van zout (natrium chloride) van 9 gram naar het 
aanbevolen niveau van 5 gram per dag.  
Hoofdstuk 3 beschrijft het effect van het verhogen van de calciuminname op de 
bloeddruk. Dit is gedaan middels een meta-analyse van interventie-onderzoeken. 
Eerdere meta-analyses laten een verlaging zien van de systolische bloeddruk met 0,9-1,4 
mmHg en van de diastolische bloeddruk (=onderdruk) met 0,2-0,8 mmHg. In deze 
analyses is de grootte van het effect in verschillende groepen in de bevolking slechts 
beperkt onderzocht. In onze meta-analyse, gebaseerd op 40 gerandomiseerde en 
gecontroleerde interventie onderzoeken, onderzochten we het effect van het verhogen 
van de calciuminname voor verschillende groepen in de bevolking. De resultaten laten 
zien dat het verhogen van de calciuminname (gemiddelde dosering 1200 mg per dag), 
voor minimaal twee weken, leidt tot een significante verlaging van de systolische 
bloeddruk met 1,9 mmHg, en van de diastolische bloeddruk met 1,0 mmHg. Tevens 
suggereren onze data een sterkere relatie tussen het verhogen van de calciuminname en 
bloeddruk in populaties met een calciuminname <800 mg per dag vergeleken met 
populaties met een inname ≥800 mg per dag.  
 De bloeddrukverlagende effecten van individuele mineralen zijn veelvuldig 
onderzocht. Over het bloeddrukeffect van een combinatie van mineralen is echter weinig 
bekend. We hebben een dubbel-blinde gerandomiseerde en placebo-gecontroleerde 
parallelle studie in 124 Nederlandse proefpersonen uitgevoerd. In deze studie hebben we 
het effect van magere melk verrijkt met een combinatie van mineralen en vitaminen op 
de bloeddruk bestudeerd (Hoofdstuk 4). Proefpersonen consumeerden dagelijks één 
van de twee soorten magere melk verrijkt in micronutriënten of een placebo (water). De 
melkproducten bevatten kalium (1500 mg of 750 mg), calcium (446 mg), magnesium 
(100 mg), selenium (40 mg), vitamine C (180 mg) en vitamine E (30 mg tocoferol 
equivalenten). De dalingen in systolische bloeddruk na een interventieperiode van 8 
weken waren niet verschillend tussen de groepen (P = 0,94). Onze studie was echter niet 
opgezet om relatief kleine effecten op systolische bloeddruk (2-3 mmHg) aan te tonen, 
hoewel deze wel relevant zijn op bevolkingsniveau.  
 
Andere voedingscomponenten en bloeddruk (gerelateerde) effecten 
In de hoofdstukken 5, 6 en 7 onderzoeken we het effect van voedingscomponenten die 
in de belangstelling staan omdat ze een mogelijk gunstig effect op bloeddruk en/of 
endotheelfunctie hebben. 
Hoofdstuk 5 behandelt het effect van lactotripeptiden op de bloeddruk, 
gebaseerd op de resultaten van twee dubbel-blinde, gerandomiseerde en placebo-
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gecontroleerde cross-over onderzoeken. Andere interventie onderzoeken, voornamelijk 
gebaseerd op onderzoeken in Japanse en Finse populaties, hebben veelbelovende 
bloeddrukverlagende effecten van zuivelpeptiden gevonden, in het bijzonder voor de 
lactotripeptiden Isoleucine-Proline-Proline (IPP) en Valine-Proline-Proline (VPP). 
Recentere onderzoeken in niet-Finse Europese populaties konden echter geen significante 
bloeddrukverlagende effecten van lactotripeptiden aantonen. In onze twee 
gecontroleerde onderzoeken met 4-weekse interventieperiodes hebben in totaal 162 
Schotse proefpersonen deelgenomen. In deze studies onderzochten we het effect van 
lactotripeptiden, voornamelijk IPP en VPP, verkregen door enzymatisch hydrolyse, op de 
bloeddruk. De proefpersonen consumeerden de lactotripeptiden in de vorm van een 
yoghurt drankje. De dagelijkse dosering lactotripeptiden was 10,2 mg in onderzoek 1 en 
4,6 mg en 350 mg toegevoegd kalium in onderzoek 2. We vonden geen 
bloeddrukverlagende effecten van de lactotripeptiden. Het gemiddelde verschil in 24-uurs 
ambulante systolische bloeddruk tussen de actieve behandeling en placebo was 0,6 
mmHg (P = 0,55) in het eerste onderzoek, en -0,9 mmHg (P = 0,42) in het tweede 
onderzoek.  
Hoofdstuk 6 beschrijft het effect van twee verschillende polyfenolrijke 
druivenextracten op endotheelfunctie en bloeddruk. Dit is gebaseerd op een dubbel-
blinde, gerandomiseerde en placebo gecontroleerde cross-over studie. Experimentele 
data lieten zien dat (bestanddelen van) rode wijn vaatverwijding kunnen induceren door 
het verhogen van de productie van stikstofmonoxide in het endotheel. Voor het optreden 
van dit effect bij mensen is echter weinig bewijs uit gecontroleerde interventie-
onderzoeken. De meeste onderzoeken onderzochten acute effecten van rode wijn 
consumptie op endotheelfunctie. Bovendien zijn deze onderzoeken veelal uitgevoerd in 
patiënten met hart- en vaatziekten en niet in gezonde deelnemers. In onze studie, met 
interventieperiodes van 2 weken, in 35 gezonde mannen, onderzochten we de langere-
termijneffecten op endotheelfunctie en bloeddruk van twee polyfenolrijke extracten (800 
mg polyfenolen per dag). Eén van de extracten was afkomstig van een wijn-druivenmix 
en bestaat uit veel verschillende soorten polyfenolen (monomere anthocyanines, 
catechines, flavonolen, procyanidines en stillbenen en ongeïdentificeerde oligomeren en 
polymeren). Het andere extract was afkomstig van druivenpitten, en bestaat 
voornamelijk uit monomere catechines en ongeïdentificeerde oligomeren en polymeren. 
We vonden geen significante effecten van zowel het wijn-druivenmixextract als het 
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druivenpitextract op flow-gemedieerde dilatatie (respectievelijk -0,4%; P = 0,77 en 0,2; 
P = 0,94) of bloeddruk (systolische bloeddruk respectievelijk: -1,3 mmHg; P = 0,70 en -
0,6 mmHg; P = 0,92) vergeleken met placebocapsules.  
Hoofdstuk 7 beschrijft een meta-analyse naar het effect van foliumzuur op 
endotheelfunctie. Onze gecombineerde schatting laat zien dat foliumzuursuppletie, bij 
een hoge mediane dosering van 5000 g per dag, voor tenminste 4 weken, significant 
flow-gemedieerde dilatatie verbetert met 1,1% ten opzichte van placebo. Deze schatting 
is gebaseerd op 14 gerandomiseerde, placebo-gecontroleerde interventie-onderzoeken. 
De significante verbeteringen werden alleen bij de hogere doseringen van foliumzuur 
(≥5000 g per dag) gevonden. Tevens suggereren de resultaten een groter effect in 
populaties met hart- en vaatziekten dan in gezonde populaties. 
 
Conclusies 
Het verhogen van de kaliuminname in Westerse landen, welke in het algemeen lager is 
dan de aanbevolen hoeveelheid, en de calciuminname, met name in populaties met een 
lage inname, kan de bloeddruk in de bevolking verbeteren. In onze goed gecontroleerde 
onderzoeken vinden we geen bloeddrukverlagende effecten van lactotripeptiden in de 
vorm van geïsoleerd IPP en VPP. Hoewel we het onwaarschijnlijk achten, kunnen 
bloeddrukverlagende effecten van gefermenteerde melk en van lactotripeptiden in 
Japanse en Finse populaties niet volledig worden uitgesloten. Wij vinden geen effect van 
druivenpolyfenolen op de bloeddruk en endotheelfunctie. Meer inzicht in de bio-
beschikbaarheid en het metabolisme van polyfenolen is nodig om vast te stellen welke 
specifieke soorten polyfenolen of combinaties van de verschillende polyfenolen in voeding 
veelbelovend zijn voor toekomstig onderzoek. Foliumzuur kan endotheelfunctie 
verbeteren bij hoge doseringen (≥5000 g per dag), maar deze bevinding is van 
beperkte waarde voor de volksgezondheid, omdat deze inname niet bereikt kan worden 
met een normale voeding.  
  De beste manier om de bloeddruk in de bevolking te verbeteren is door een 
betere naleving van de huidige voedingsrichtlijnen. Een verbetering in de inname van 
kalium en calcium kan bereikt worden door een hogere consumptie van fruit, groenten en 
magere zuivel. Daarnaast kan de overheid en de voedingsmiddelenindustrie 
samenwerken om de inname van mineralen in de bevolking te verbeteren en daarmee de 
                                   
flow-gemedieerde dilatatie is een techniek waarmee de stroomsnelheid van het bloed gemeten 
wordt. Het meet de elasticiteit van het endotheel, de bekleding van de vaatwand. 
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prevalentie van hypertensie en ziektelast ten gevolge van hart- en vaatziekten te 
verminderen. 
 
De belangrijkste conclusies van dit proefschrift zijn:  
1. Een adequate inname van kalium en calcium kan een belangrijke bijdrage leveren 
aan de preventie en het onder controle houden van hoge bloeddruk in de 
bevolking. 
2. Het bewijs voor een bloeddrukverlagend effect van lactotripeptiden en voor het 
verbeteren van endotheelfunctie met druivenpolyfenolen en foliumzuur is beperkt. 
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Het voelt erg fijn en het is bijna niet te geloven dat ik eindelijk kan beginnen aan het 
schrijven van het leukste en allerlaatste stuk voor mijn proefschrift: het Dankwoord.  
 
Ook al heb ik er zelf, vooral op het laatst, erg hard aan gewerkt om dit boekje af te 
krijgen, er zijn veel mensen zonder wie het nooit gelukt zou zijn. Deze mensen wil ik 
graag bedanken.  
 
Allereerst mijn 2 co-promotoren en promotor. Bedankt voor jullie vertrouwen in mij om 
deze unieke samenwerking aan te gaan!  
 Marianne, in 2002 leerden we elkaar kennen toen je mijn begeleidster was tijdens 
mijn afstudeervak. Daarna hebben we contact gehouden en samengewerkt. Toen ik je in 
2008 voorzichtig polste of het misschien mogelijk was voor mij om een promotie-
onderzoek te doen was je meteen enthousiast. Zonder al jouw hulp, kritische 
commentaar en positieve instelling, had ik dit proefschrift zeker niet in deze staat kunnen 
afronden.  
 Peter, je bent een erg fijne collega en je hebt me aangemoedigd dit promotie-
onderzoek te gaan doen. Ik kon altijd bij je terecht, niet alleen voor alledaagse vragen, 
maar zeker ook voor inhoudelijk commentaar.  
 Frans, als promotor was jij degene die hielp het onderzoek in perspectief te 
plaatsen en kritische vragen te stellen. De bijeenkomsten in Wageningen heb ik altijd als 
heel prettig ervaren.  
  
Daarnaast zijn er vele (ex) Unilever collega’s die ik graag wil bedanken. Allereerst mijn 
directe collega’s van de voormalige Vascular Function Skillbase, de Cardiovascular Health 
Skillbase en het Blood Pressure Team, nu genoemd het Physiology expertise team en het 
Genesis Cardiovascular Health team. Een aantal van jullie wil ik graag in het bijzonder 
noemen. Richard, bedankt voor jouw hulp en uitleg. Fijn dat ik een publicatie mocht 
schrijven over de druivenpolyfenolen studie. Kim, jouw kennis over interventie studies 
heeft me erg geholpen om me snel thuis te voelen op dit gebied. Arno, het harde werken 
aan ons kalium artikel is niet voor niets geweest. Angelika, bedankt dat ik de foliumzuur 
meta-analyse als hoofdstuk in dit proefschrift mocht opnemen. Christine en Thea, 
bedankt voor jullie vertrouwen in mij. Destijds was ik echt een ‘groentje’ in het team en 
de enige die niet gepromoveerd was. Ondanks dat gaven jullie mij meteen mijn eigen 
verantwoordelijkheden. De sfeer in de vascular function skillbase en het bloeddruk team 
heb ik altijd als erg prettig ervaren. Joris en Gerda, dankzij jullie kon ik bij Unilever mijn 
afstudeervak gaan doen. Wendy, jij hebt me erg geholpen het formeel mogelijk te maken 
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een promotie-onderzoek te gaan doen. Sheila, ook jou wil ik graag bedanken voor je 
support en de vrijheid die ik kreeg om naast het gewone werk tijd aan mijn promotie-
onderzoek te besteden. Henk, bedankt voor al je statistische ondersteuning, niets was 
teveel zelfs niet toen je al met pensioen was. Ze zullen je nog missen bij Unilever! Ook 
Veronique en Arne, bedankt voor de statistische analyses. Alle mensen van Clinicals 
bedankt voor jullie hulp bij het beantwoorden van de vele vragen over de 
druivenpolyfenolen studie. Sue and Maeve, thank you for checking the English grammar. 
Ans, jij ging mij voor, bedankt voor al je tips. Reggy en Karin, als afdelingshoofden 
hebben ook jullie mij geholpen dit traject mogelijk te maken. Nora, bedankt voor de 
secretariële ondersteuning. 
 
Dan wil ik ook graag een aantal mensen buiten Unilever bedanken. Allereerst natuurlijk 
alle deelnemers aan de 4 interventie studies beschreven in dit proefschrift. Verder ook 
alle mensen van NutriScience, in het bijzonder Inge Verkooijen en Frans Thomassen voor 
de uitvoering van de mineralen en vitaminen studie. I also would like to thank Quintiles, 
and especially Sian Perrington, for the excellent conduction of the lactotripeptide 
intervention studies. Lidia Arends, bedankt voor het geven van advies over de stuurfile 
voor mijn meta-analyse. Mariëlle Engberink, bedankt voor de fijne samenwerking en 
jouw tips bij het inleveren van de leesversie. Lucie Viet, bedankt voor het delen van de 
gegevens over de bloeddruk verdeling in de Nederlandse bevolking. Bedankt Boy 
Houben, Martinette Streppel, Diederick Grobbee en Maurice Zeegers voor het 
meeschrijven als co-auteurs. 
 
Graag wil ik Dr. Stephan Bakker, Prof. Peter de Leeuw en Prof. Edith Feskens bedanken 
voor het plaatsnemen in mijn promotiecommissie. I also would like to express my 
gratitude to Prof. Lawrence Appel. It is a great privilege for me that you are willing to 
travel to Wageningen and participate in my thesis committee. 
 
Dan natuurlijk mijn paranimfen: Pascalle en Anouk, echt super leuk dat jullie mijn 
paranimfen willen zijn! Al vanaf het begin van onze studie zijn we goede vriendinnen. 
Sinds die tijd hebben we veel samen meegemaakt; bestuur Di-Et-Tri, stage Finland, 
bezoek Amerika, commissies, jaarlijkse kerstetentjes en nog veel meer. Ik vind het altijd 
erg gezellig om jullie weer te zien en hoop dat het contact nog lang zo leuk mag blijven! 
 
Verder wil ik mijn andere vriend(inn)en en familie bedanken voor alle belangstelling de 
afgelopen tijd… 
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Pap en Mam, bedankt voor alles! Jullie hebben me altijd gesteund, maar tegelijkertijd 
ook heel vrij gelaten. Ik kan altijd bij jullie terecht, niets is te gek en ik geniet er enorm 
van om met jullie samen te zijn. Ik hoop dat we nog heel lang samen veel plezier en 
goede gesprekken zullen hebben en er voor elkaar kunnen zijn. 
 
Jos en Rob, alledrie zijn we eigenlijk heel anders, maar toch ook weer hebben we veel 
gemeen en staan we altijd voor elkaar klaar! Jos, bedankt ook voor de fijne tijd toen we 
met z’n drieën in één huis woonden. Rob, ik ben er trots op hoe je het allemaal aanpakt 
met je eigen bedrijf. Karin en Jerney, mijn broertjes hebben het getroffen met jullie. Ik 
vind het erg gezellig als jullie erbij zijn! 
 
Wim en Wil, Erik en Marieke, bedankt voor jullie interesse en natuurlijk voor de mooie 
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